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I.  Abdominal challenges
The abdominal cavity is enclosed by abdominal muscles, ventrally and laterally, and by 
the vertebral column dorsally. Situated in between thorax and pelvis, it contains many 
structures and a number of organs, most of them belonging to the gastrointestinal tract 
and urinary system. This thesis focuses on emergencies of the abdomen, including those 
of traumatic as well as non-traumatic etiology.
One of these ‘abdominal challenges’ is instigated by the intestinal pathogen Clos-
tridium difficile. The resulting C. difficile infection (CDI) is an emerging disease and the 
leading cause of nosocomial diarrhea in both North America and Europe. With 3 million 
new cases every year, and affecting up to 10% of all hospitalized patients in the United 
States, it is an infection of pandemic proportions.1-3 The colitis that can follow the colo-
nization by C. difficile varies in severity. The most severe is, the fulminant version of C. 
difficile colitis (fCDC), a disease that often constitutes a surgical emergency.
While C. difficile colitis (CDC) is especially targeting the older population; traumatic 
abdominal emergencies primarily affect the younger population. Trauma is the leading 
cause of death worldwide for people under 45 years of age.4 In the United States 32.3 
million people are treated in the Emergency Department for traumatic injuries each 
year, of whom 2.5 million are being hospitalized. Annually, the injury-related death rate 
is around 180.000, and medical costs are estimated to be close to $465 billion.4-7 Trauma 
to the abdomen occurs in about 13% of trauma patients and can result in devastating 
injuries that carry high morbidity and mortality.6 
Although one could argue that fCDC and abdominal trauma are two distinct diseases, 
we would suggest that there are major similarities in the host response and possible 
results. In both entities acute phase response proteins (cytokines) are immediately se-
creted, leading to a typically exaggerated Systemic Inflammatory Response Syndrome 
(SIRS).8, 9 The common final pathway in patients who receive inadequate or delayed 
treatment or in those who – despite appropriate treatment – cannot tolerate the insult, 
is Multiple Organ Dysfunction Syndrome (MODS). Mortality rates range from 30% to 
over 90%. Whether an infection is present or not, the patients’ systemic response to this 
amount of abdominal insult is very similar.10-15 In other words, these two very different 
entities (a traumatic injury vs. an intestinal infection) do actually overlap in the systemic 
response they provoke (Figure 1).11, 12, 14 Subsequently, treatment strategies may be over-
lapping as well.16 Therefore, the overall focus of this thesis will be on the initial treatment 
of two types of insults causing injury to the abdomen and its tissues; the Clostridium 
difficile infection and different types of blunt abdominal trauma. 
16 Chapter 1
II.  Clostridium difficile colitis 
(will be partially published in the MGH Board Review of Critical Care Medicine)
a. Clostridium difficile 
A Clostridium difficile infection (CDI) is defined by the following: (1) the presence of 
related symptoms (most often diarrhea, defined as 3 or more unformed stools in 24 or 
fewer consecutive hours); (2) either a positive enzyme immunoassay (EIA), detecting the 
glutamate dehydrogenase (GDH) antigen (an essential enzyme produced by all C. dif-
ficile isolates) and toxins A and B, or colonoscopic / histopathologic findings confirming 
pseudomembranous colitis.17
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The incidence of C. difficile infections in the U.S. increased significantly over the past 
10 years, from 5.6 per 1000 discharges in 2001 to 12.8 per 1000 in 2012.1, 2 Additionally, 
annual healthcare expenditures attributable to nosocomial CDIs range from $1-3 billion, 
and the average hospital length of stay is prolonged by 3-6 days.18-21 It was shown that 
of all hospital stays with CDI in U.S. hospitals, the overall mortality rate was 9.1% (3.7% 
when CDI was the principal diagnosis, and 11.7% when it was a secondary diagnosis), 
compared to 1.9% for all other stays. 1-3 The mortality rate in patients with the most 
severe version of CDI, fCDC, ranges from 30-80%.3, 22, 23 The most important risk fac-
tors for developing CDI are: an advanced age (higher age-adjusted rate of CDI among 
persons older than 65 years), previous exposure to antibiotics (frequently clindamycin, 
fluoroquinolones, penicillins, and cephalosporins), and hospitalization (cumulative daily 
risk of exposure to C. difficile spores in the healthcare setting).17, 24-28 Other risk factors, 
although some remain controversial, are: severe underlying disease, chemotherapy, im-
munosuppression, gastrointestinal surgery (manipulation of the gastrointestinal tract), 
and the use of acid-suppressing medications (histamine-2-blockers and proton pump 
inhibitors).17 
Pathogenesis
C. difficile is an anaerobic gram-positive, spore-forming, toxin-producing bacillus that 
is transmitted via person-to person spread through the fecal-oral route. It can exist in 
both spore and vegetative forms. When living outside the colon, it survives in spore 
form (spores are resistant to heat, acid and antibiotics), and may convert to a fully func-
tional vegetative, toxin-producing form when present in the colon. In this form C. difficile 
becomes susceptible to antimicrobial agents. So there are patients (about 20% of all 
hospitalized adults) that are carriers of C. difficile, but are asymptomatic. They carry the 
bacillus with them and can contaminate other people.29-31
Once a C. difficile strain starts releasing exotoxins, it becomes pathogenic. Two po-
tent exotoxins that mediate colitis and diarrhea are toxin A (enterotoxin) and toxin B 
(cytotoxin). Toxin A is a chemo-attractant for neutrophils and causes inflammation as 
well as fluid secretion of the colonic mucosa, while both toxins A (TcdA) and B (TcdB) 
activate inflammatory cytokine release from monocytes.25, 32-34 Toxin B is essential for the 
virulence of C. difficile, and is approximately ten times more potent than toxin A on a 
molar basis for mediating colonic mucosal damage. Both toxins adhere to receptors on 
the human colonocyte brush border and cause necrosis and shedding of these cells into 
the lumen. The C. difficile toxins target Rho family proteins, a group of low molecular 
weight GTP-binding proteins that regulate actin filaments in all cells. Once Rho proteins 
are inactivated by C. difficile toxins, actin filaments disintegrate and the damaged cell 
cannot function anymore. This condition ultimately leads to increased capillary perme-
18 Chapter 1
ability and peristalsis. The inflammation may result in toxic megacolon and perforation in 
fulminant cases.33 Systemic symptoms are often caused by toxin-induced inflammatory 
mediators released into the colon (tumor necrosis factor a, interleukin-8, macrophage 
inflammatory protein-2, and substance P).35
Since the beginning of this century there have been many C. difficile outbreaks, of 
which the majority was caused by a newly discovered, hypervirulent strain, NAP1/BI/027. 
This strain is resistant to fluoroquinolones, has hypersporulation capacity, and produces 
an additional ‘binary’ toxin (CDT).24, 36-38 This binary actin-ADP-ribosylating toxin CDT (C. 
difficile transferase) is not present in other strains, and seems to be associated with more 
severe disease and community-acquired CDI.35, 39
Clinical findings and diagnosis
Clinical findings almost always include diarrhea (typically with characteristic odor), and 
possibly but less common: fever, nausea, malaise, dehydration, leukocytosis with left 
shift, as well as abdominal distention and diffuse abdominal tenderness on physical 
exam.25, 28, 34
For years the type of diagnostic test that was used to detect the CDI, was the toxin 
A/B enzyme immunoassay. Although fast and inexpensive, the sensitivity was debatable 
and the standard was changed in 2012. The currently used test is a membrane EIA that 
detects the glutamate dehydrogenase (GDH) antigen (an essential enzyme produced by 
all C. difficile isolates) and toxins A and B. In specimens with discordant GDH antigen and 
toxin results, an additional polymerase chain reaction (PCR) test for toxigenic C. difficile 
is performed.17, 26, 27, 40
An abdominal CT scan may be used to differentiate between CDC and other causes of 
colitis, and to determine the extent of the disease.41 However, to diagnose regular CDI, 
e.g. when awaiting the results of the EIA, an abdominal CT has poor sensitivity (52%), 
and should not be used for this purpose.28, 42, 43 
Sometimes endoscopy is used to diagnose patients with CDC, but due to a risk for 
colonic perforation, it is recommended to only use it in patients with presumably severe 
CDC in which emergent therapeutic interventions are warranted, and results of regular 
diagnostic test are taking too long.28, 44 The most important finding (only in patients with 
fCDC) will be the presence of pseudomembranes. C. difficile toxins are causing a disrup-
tion of the cytoskeleton, resulting in ulcerations of the intestinal mucosa. Because of 
this ulcer formation, a mix of mucus, inflammatory cells and serum proteins are released; 
this results in yellow/white plaques on the mucosal surface, the so called ’pseudomem-










The treatment of C. difficile is most often completely medical. However, when CDI pro-
gresses to a severe colitis, there are surgical options that can be considered. First of all 
there are some general principles that need to be followed, including ending any usage 
of antimicrobial agents as soon as possible, since this enables the infection to exist. Infec-
tion control policies such as contact precautions and increased hand hygiene should be 
implemented, and the use of anti-peristaltic agents should be avoided. Anti-peristaltic 
agents (such as narcotics or anti-cholinergics) are a risk factor since they decrease the 
peristalsis, which is reducing the bacterial clearance and causes colonic dilation.17, 25, 26
Metronidazole is the most important antibiotic in the initial phase of CDI. In an initial 
episode of a mild-to-moderate CDI, metronidazole is being prescribed, while vanco-
mycin could be used as an alternative. For an initial episode of a severe CDI or severe, 
complicated CDI (progressing towards fCDC), vancomycin is the preferred drug.45 A re-
currence is managed the same as an initial episode, although it needs to be mentioned 
that metronidazole can cause cumulative neurotoxicity, and should not be used beyond 
the first recurrence of CDI or for long-term chronic therapy.17, 46, 47 Fidaxomicin is a new 
drug that was approved by the FDA in 2011. It has been shown to be as effective as 
vancomycin but it is more expensive.48, 49
Another option in CDI treatment, and especially in recurrences, is fecal bacteriother-
apy (intestinal microbiota transplantation; IMT). With IMT, intestinal microorganisms of 
healthy donor stool are being infused into the intestine of a sick patient to restore their 
microbiota.50,51 
In patients that progress towards fCDC, as will be described below, and that fail medi-
cal therapy, the current surgical standard of care is a total abdominal colectomy (TAC). 
During this procedure the entire colon (except from the rectum) is being removed and 
an ileostomy is created. 
b. Fulminant Clostridium difficile colitis
Fulminant Clostridium difficile colitis (fCDC) is defined as CDC with significant systemic 
toxic effects and shock, resulting in: the need for ICU admission, requirement of a col-
ectomy, or death.23 Around 3-5% of patients will progress to the fulminant disease.3, 52-54 
The clinical picture includes symptoms such as diarrhea (either severe or diminished 
due to ileus and colonic dilation), severe abdominal pain, fever, hypotension (need 
for vasopressors), tachycardia, severe leukocytosis with left shift, evidence of shock 
(decreased mental status, new organ failure, lactic acidosis), and an acute abdomen on 
physical exam. In the most severe cases a toxic megacolon (colonic dilation combined 
with severe systemic toxicity) and colonic perforation can be seen.23, 33, 55 As mentioned 
before, next to antibiotic therapy and supportive care, some of these patients will need 
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surgery, especially when their clinical status fails to improve and toxic megacolon or 
colonic perforation is being suspected.17, 26, 54 
III. Abdominal trauma
Abdominal trauma and intra-abdominal injuries can be caused by either a blunt or pen-
etrating mechanism. About 80% of abdominal trauma is caused by a blunt mechanism 
(rapid deceleration), such as a motor vehicle collision or fall, while the remaining 20% of 
patients sustain a penetrating injury (direct trauma), such as a gunshot wound or stab 
wound. 56, 57
Injuries to each of the organs are comprehensively graded by severity in the organ 
injury scales (OIS) of the American Association for the Surgery of Trauma (AAST), and are 
all based on the magnitude of anatomic disruption.58 Many studies have been published 
on the management of intra-abdominal injuries, which can be both operative and non-
operative (NOM). The focus of treatment is gradually shifting though, from operative 
management to a more conservative, sometimes completely non-operative, treatment 
in certain types of injuries. Non-operative management is considered to have many 
advantages such as lower hospital costs, a shorter hospital length of stay, avoidance 
of nontherapeutic celiotomies (with their associated cost and morbidity), consequently 
fewer intra-abdominal complications, and reduced transfusion rates.59 A significant gap 
in the literature needs to be filled though, before conservative management can be 
adopted in all types and grades of injuries, since data on those patients that are severely 
injured are missing; previous studies mainly focused on low-grade injuries, which have 
a high incidence. The chapters on abdominal trauma in this dissertation focus on the 
specifics around non-operative management in patients with high-grade blunt kidney- 
and liver injuries, as well as different types of management in severe injuries, both blunt 
and penetrating, to the pancreatoduodenal complex. 
a. The kidneys
Injuries to the genitourinary (GU) system occur in 10% of patients suffering traumatic 
injuries that require hospital admission. Renal trauma is the most common injury within 
the GU tract, with an incidence of 1-5% of all traumas, in 80% due to a blunt mecha-
nism.60, 61 Severity of the injuries is being classified using the kidney OIS (see Table 1).62 
Management ranges from renal exploration with the main indication being continuous 
hemodynamic instability of renal origin, to non-operative management in stable patients. 
Conservative management consists of close observation, bed rest, serial abdominal ex-
ams and hematocrit checks, hydration, and antibiotics.61, 63-69 In some cases angiographic 
embolization will be used.70, 71 Multiple studies in the literature have proven that NOM is 
a safe option in low-grade blunt injuries66, 72, 73, however evidence about the role of NOM 








also involve the collecting system, the chance that complications occur is increased, and 
often such complications are significant and require further management.78, 79 Because 
the published evidence is lacking appropriate sample size to present valid recommenda-
tions regarding both treatment and possible complications of such severe renal injuries, 
we designed a study that would be able to make those recommendations. 
b. The liver
The liver is the most commonly injured abdominal organ in blunt trauma, while it is the 
second most commonly injured organ in patients with penetrating abdominal trauma.6, 
80 The OIS for liver injuries (Table 2), divides the injuries in low (I, II, and III) and high (IV 
and V) grades.81
In patients with blunt liver trauma a shift from operative to non-operative manage-
ment occurred over the past three decades; currently more than 80% of cases are being 
managed without an operation.80, 82, 83 Reasons that explain the success of conservative 
management in the liver, foremost in hemodynamically stable patients, are versatile. It 
is now known that bleeding stops spontaneously after liver injuries in more than 50% of 
cases, while healing of the liver, even when severely injured, occurs much faster than in 
other organs. Additionally, there have been huge improvements in imaging, such as CT 
scanning and FAST exam (Focused Assessment with Sonography for Trauma), as well as 
advances in critical care monitoring. Conservative management involves monitored care, 
serial abdominal exams, hemoglobin assessment, and potentially angiographic embo-
lization when vascular extravasation is seen.84-86 Ongoing transfusion requirements and 
hemodynamic instability suggest continued bleeding, which is the main indication for 
Table 1. Kidney injury scale
Grade* Type of injury Description of injury AIS-90
I Contusion Microscopic or gross hematuria, urologic studies normal 2
Hematoma Subcapsular, nonexpanding without parenchymal laceration 2
II Hematoma Nonexpanding perirenal hematoma confirmed to renal 
retroperitoneum
2
Laceration <1.0 cm parenchymal depth of renal cortex without urinary 
extravasation
2
III Laceration <1.0 cm parenchymal depth of renal cortex without collecting 
system rupture or urinary extravasation
3
IV Laceration Parenchymal laceration extending through renal cortex, 
medulla, and collecting system
4
Vascular Main renal artery or vein injury with contained hemorrhage 4
V Laceration Completely shattered kidney 5
Vascular Avulsion of renal hilum which devascularizes kidney 5
*Advance one grade for bilateral injuries up to grade III
From Moore et al. 62
22 Chapter 1
operative intervention. When it comes to high grade blunt liver injuries though, limited 
evidence is available. There is an overwhelming amount of studies showing successful 
NOM in low grade injuries80, 82, 83, 87, and even grade IV injuries88-91, as well as extensive 
overviews of operative management of high grade injuries92, 93 However, there are very 
few papers written focusing on NOM in grade IV and V injuries, which are essentially 
devastating liver injuries. 
c. The pancreatoduodenal complex
In about 3 to 5 per cent of all traumatic abdominal injuries, the pancreas and duodenum 
are involved, in 75% caused by a penetrating mechanism.94-96 Combined injuries have a 
high morbidity and mortality, and due to its retroperitoneal locations in the abdomen, 
it can be challenging to properly diagnose injuries to the pancreatoduodenal complex, 
especially with a blunt mechanism.97-100 Both injuries to the pancreas and duodenum are 
categorized according to the AAST OIS (Tables 3 and 4), again dividing injuries into low 
(I,II,III), and high (IV and V) grades.101 Low grade blunt injuries can be managed without 
an operation, with gastrointestinal decompression, nutritional support, and careful 
monitoring and follow-up.100, 102 However, in high grade blunt injuries, and all penetrat-
ing injuries operative intervention is required. Often those are common interventions 
such as debridement of devitalized tissue, local repair of lacerations, drainage, and for 
duodenal injuries resection and primary anastomosis.103-108 The most severe injuries 
either combined or to the pancreatic head, are managed with resection, namely a pan-
Table 2. Liver injury scale (1994 revision)
Grade* Type of injury Description of injury AIS-90
I Hematoma Subcapsular, <10% surface area 2
Laceration Capsular tear, <1 cm parenchymal depth 2
II Hematoma Subcapsular, 10% to 50% surface area 2
Laceration Capsular tear, 1-3 cm parenchymal depth, <10 cm in length 2
III Hematoma Subcapsular, >50% surface area of ruptured subcapsular or 
parenchymal hematoma; intraparenchymal hematoma >10 cm 
or expanding
3
Laceration >3 cm parenchymal depth 3
IV Laceration Parenchymal disruption involving 25% to 75% hepatic lobe or 
1-3 Couinaud’s segments
4
V Laceration Parenchymal disruption involving >75% of hepatic lobe or >3 
Couinaud’s segments within a single lobe
5
Vascular Juxtahepatic venous injuries; ie, retrohepatic vena cava/central 
major hepatic veins
5
VI Vascular Hepatic avulsion 6
*Advance one grade for multiple injuries up to grade III








creatoduodenectomy (PDT). This PDT however, is an extremely rare procedure in trauma 
(performed in 1-5% of all combined injuries) , since the incidence of severe combined 
injuries is very low.94, 95, 97, 98, 109 It is not surprising that large series describing this rare and 
difficult procedure are scarce in the literature, resulting in many questions about specific 
indications and outcomes that still need to be answered.110 
OUTLINE OF THE THESIS
This is chapter 1, the general introduction and outline of the thesis. As mentioned 
earlier, this dissertation consists of two parts: trauma and non-trauma challenges in 
the abdomen. After an elaborate explanation of both trauma related and non-trauma 
related abdominal emergencies, we continue in the succeeding chapters with Part 1, 
Table 4. Duodenum injury scale 
Grade* Type of injury Description of injury AIS-90
I Hematoma Involving single portion of duodenum 2
Laceration Partial thickness, no perforation 3
II Hematoma Involving more than one portion 2
Laceration Disruption <50% of circumference 4
III Laceration Disruption 50-75% of circumference of D2;
Disruption 50-100% of circumference of D1,D3,D4
4
4
IV Laceration Disruption >75% of circumference of D2
Involving ampulla or distal common bile duct
5
5
V Laceration Massive disruption of duodenopancreatic complex 5
Vascular Devascularization of duodenum 5
*Advance one grade for multiple injuries up to grade III. D1-first position of duodenum; D2-second 
portion of duodenum; D3-third portion of duodenum; D4-fourth portion of duodenum
From Moore et al. 101
Table 3. Pancreas injury scale
Grade* Type of injury Description of injury AIS-90
I Hematoma Minor contusion without duct injury 2
Laceration Superficial laceration without duct injury 2
II Hematoma Major contusion without duct injury or tissue loss 2
Laceration Major laceration without duct injury or tissue loss 3
III Laceration Distal transection or parenchymal injury with duct injury 3
IV Laceration Proximal transection or parenchymal injury involving ampulla 4
V Laceration Massive disruption of pancreatic head 5
*Advance one grade for multiple injuries up to grade III. From Moore et al. 101
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non-trauma, that consists of studies that offer an extensive, multi-faceted view on the 
bacterium Clostridium difficile, and in particular on fulminant CDC.
In chapter 2 the search for a clinical prediction rule of fCDC is described. There are 
certain variables that predict the transition from a ‘simple’ CDI to fCDC. We hypothesize 
that if we can identify those variables and design a system with predictive value, we 
would be able to recognize the patients at risk for fCDC at an earlier moment resulting 
in an improvement of the associated morbidity and mortality.
Chapter 3 describes a 2-year prospective study on the implementation of a hospital-
wide standardized protocol for early surgical consultation in patients with suspected 
fCDC. Since previous studies have shown that early involvement of the surgical service 
can improve outcomes, we designed the so-called ‘consultation criteria’. The protocol 
requires referral of patients to the surgical service when they have suspected/confirmed 
(by toxin assay) CDI and reach the threshold of at least 2 out of 8 criteria. We will compare 
the 2-year ‘post-implementation’ cohort to an historic control group of fCDC patients, 
and hypothesize that outcomes, such as mortality, improve after implementation of this 
protocol.
The standard of care when patients with fCDC need surgical treatment is a total 
abdominal colectomy (TAC). In chapter 4 we look back, in a multicenter study, at a 
cohort of patients that underwent a TAC and focus on the optimal antibiotic treatment 
post-operatively. This study aims to determine if there exists a difference in outcomes 
in those treated with metronidazole alone or with a combination of metronidazole and 
vancomycin. 
The last chapter in part 1, chapter 5 discusses the influence of vitamin D levels on CDI 
severity. The hypothesis of this prospective study is that in patients with lower 25-hy-
droxyvitamin D levels, the CDI will be more severe. 
Continuing to Part 2; the abdominal challenges of traumatic origin. In chapter 6 the 
role of non-operative management in severe blunt renal injuries (BRI) is being discussed. 
The objectives of this study are to determine the rate and predictors of failure of NOM 
in patients with grade IV and V BRI. We hypothesize that such high grade injuries can 
be safely managed without an operation, but that the rate of complications, following 
operative and non-operative management of BRI, and the need for subsequent inter-
ventions is high. 
Chapter 7 discusses the rates and predictors of failure of NOM in patients with grade 
IV and V blunt liver injuries (BLI), with the hypothesis being that such high-grade injuries 
can be safely managed without needing an operation. 
Both studies (chapter 6 and 7) are a collaboration between level I and II, verified by 
the American College of Surgeons (ACS), trauma centers in the northeast of the United 
States, known as the REsearch COnsortium of New England Centers for Trauma (RECO-








that would be difficult to analyze for each one center alone. So far, five studies have been 
conducted and this dissertation contains two of them. 
Chapter 8 describes the management of severe pancreatoduodenal injuries, and spe-
cifically the trauma Whipple (pancreatoduodenectomy for traumatic injuries), using the 
largest national trauma database in the United States, the NTDB (National Trauma Data 
Bank).111 The reasoning behind this study was that this specific procedure, the trauma 
Whipple, is of such low incidence that there is basically no evidence in the literature 
that strongly favors or discourages this operation, neither are there strong and accurate 
indications for performing this rare, and difficult procedure. Our aim was to evaluate the 
outcomes of patients that undergo a pancreatoduodenectomy for trauma (PDT) in com-
parison to patients with injuries of similar severity that received alternative operations. 
Chapter 9 provides a general discussion, presentation of future perspectives, and a 
final conclusion. In chapter 10 the overall summary can be found.
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ABSTRACT
Background: 2-8% of patients with a Clostridium difficile infection will progress to ful-
minant C. difficile colitis (fCDC) which carries high morbidity and mortality. No system 
exists to rapidly identify patients at risk of developing fCDC and possibly in need of 
surgical intervention. Our aim was to design a simple and accurate risk scoring system 
(RSS) for daily clinical practice.
Methods: We prospectively enrolled all patients diagnosed with a C. difficile infection 
and compared patients with and without fCDC. An expert panel, combined with data 
derived from prior studies, identified four risk factors and a multivariable logistic regres-
sion model was performed to determine their effect in predicting fCDC. The RSS was cre-
ated based on the predictive power of each factor and calibration, discrimination, and 
test characteristics were subsequently determined. Additionally, the RSS was compared 
to a previously proposed severity scoring system.
Results: 746 patients diagnosed with C. difficile infection were enrolled between No-
vember 2010 and October 2012. Based on the log (odds ratio) of each risk factor, age 
> 70 years was assigned 2 points, White Blood Cells ≥ 20.000/µL or ≤2.000/µL 1 point, 
cardiorespiratory failure 7 points, and diffuse abdominal tenderness on physical exam 
6 points. Using this system, the discriminatory value of the RSS (c-statistic) was 0.98 
(95% confidence interval [CI]: 0.96 – 1).The Hosmer and Lemeshow goodness-of-fit test 
showed a p-value of 0.78 and the Brier score was 0.019. A value of 6 points was deter-
mined to be the threshold for reliably dividing low-risk (<6) from high-risk (≥6) patients. 
Conclusions: The RSS is a valid and reliable tool to identify at the bedside patients 








Development of risk scoring system in fCDC
INTRODUCTION
Clostridium difficile (C. difficile) is the most common cause of hospital-acquired diarrhea, 
affecting 10% of all hospital admissions, resulting in 3 million new cases in the United 
States annually.1-4 Of those cases, 2-8% develop fulminant C. difficile colitis (fCDC).3,5-8 
fCDC carries a mortality rate ranging between 13% and 80%.3,5-23 Many studies on fCDC, 
including two of our own, have suggested that early surgical involvement in these 
cases may improve outcomes.7,9,13,16,22,23 However, it is difficult to expediently identify 
those patients at risk of developing fCDC, and therefore more likely to require surgical 
intervention. In 2011 a study by Neal et al from the University of Pittsburgh proposed a 
scoring system (based on 12 clinical, laboratory, and imaging criteria), to evaluate the 
severity of C. difficile colitis and identify patients at risk for fCDC (Table 1).24 The complex-
ity of a 12-factor system limits its use in daily clinical practice. Utilization by health care 
personnel is typically improved when clinical pathways are simple without sacrificing 
accuracy.25,26 The aim of this study was to design a simple and accurate risk scoring 
system (RSS) for patients who are at risk of developing fCDC. We hypothesized that such 
patients can be reliably identified based on the RSS.
Table 1. Proposed CDAD Severity Scoring System, Neal et al.*
1-3 points “mild-moderate disease,” 4-6 points “severe” disease,
7 or more points ‘severe complicated’ disease
Criteria Points
Immunosuppression and/or chronic medical condition 1
Abdominal pain and/or distention 1
Hypoalbuminemia (< 3 g/dL) 1
Fever > 38.5°C 1
Intensive care unit admission 1
CT scan with nonspecific findings of pancolitis, ascites, and/or bowel wall thickening 2
White blood cell count > 15,000 or < 1500 and/or band count > 10% 2
Creatinine 1.5 fold > baseline 2
Abdominal peritoneal signs 3
Vasopressors required 5
Mechanical ventilation required attributed to CDAD 5
Disorientation, confusion, or decreased consciousness 5
* This scoring system is for patients with a diagnosis of CDAD and is not yet validated. Neal MD, Alverdy 
JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative 
to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated 




All patients with C. difficile colitis admitted to the Massachusetts General Hospital 
(MGH) between November 1, 2010 and October 31, 2012 were prospectively enrolled 
in a specific database aiming to collect data on C. difficile infections. Until September 
1, 2012, the diagnosis was based on the toxin A/B enzyme immunoassay. For the final 
two months, this was changed to a membrane enzyme immunoassay that detects C. 
difficile glutamate dehydrogenase antigen (an essential enzyme produced by all C. dif-
ficile isolates) and toxins A/B. In specimens with discordant tests, an additional PCR test 
for toxigenic C. difficile was performed, and the diagnosis was confirmed if the PCR was 
positive. Per our previous reports7,13, patients with fCDC were identified by the presence 
of significant systemic toxic effects and shock, resulting in admission to the intensive 
care unit (ICU), need for urgent colectomy, or death. 
Data 
Data were collected through the prospective database and supplemented by the infec-
tion control registry and the electronic medical records. We recorded: age, gender, race, 
ethnicity, admitting service, previous hospitalization (within last 2 months before cur-
rent admission), previous antibiotic use (within the prior 2 months), use of proton-pump 
inhibitors, recurrent infection, ICU admission, presence of immunosuppression and/or 
a chronic medical condition, laboratory values, such as white blood cell count (WBC), 
bands, serum creatinine levels, serum albumin levels, fever (defined as temperature 
>101.3 Fahrenheit), abdominal CT scan results (focusing on findings such as pancolitis, 
ascites, bowel wall thickening, and dilation), the need for mechanical ventilation or va-
sopressor support, antibiotic use, and mental status change (disorientation, confusion, 
or decreased consciousness). Physiologic and laboratory parameters, where necessary, 
were dichotomized at clinically relevant values. Outcome measures such as mortality, 
surgical intervention (total abdominal colectomy), hospital length of stay (LOS), ICU LOS, 
and discharge disposition were also collected. 
Statistical analyses and development of the severity scoring system
Univariate analysis was performed to compare patients with and without fCDC. Con-
tinuous variables were summarized using mean ± standard deviation and compared by 
Student t-tests for variables with normal distributions or summarized using median with 
interquartile range (IQR) and compared by Wilcoxon rank sum tests for variables that 
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Four variables were included in our RSS: Age > 70 years, WBC ≥ 20.000/µL or ≤ 2,000 
/µL, cardiorespiratory failure (defined as CDC related vasopressor and/or mechanical 
ventilation requirement), and diffuse abdominal tenderness on physical exam. These 
variables were based on consensus among experts and identified as risk factors for a 
complicated course (development of fCDC or mortality) by various studies.7,9,11,13,16,18,22,27 
The experts consisted of experienced general and acute care surgeons, gastroenterolo-
gists, and intensivists, all practicing at the Massachusetts General Hospital. They used 
a modified Delphi technique to select the most pertinent risk factors among those de-
scribed in the literature. To determine the effects of these four predictors, we performed 
a multivariable logistic regression model. Calibration of our system was investigated 
by the Hosmer-Lemeshow goodness-of-fit test. Discrimination was summarized by 
the area under the receiver operating curve (AUC) and the Brier score. Each variable 
in the system was assigned a point, proportional to its parameter estimate from the 
multivariable logistic regression model.28 Subsequently, a risk score was calculated by 
adding up all the points. To compare the RSS to the only previously published scoring 
system24, we compared the c statistic from each scoring system. We also compared test 
characteristics (sensitivity, specificity, positive predictive value, and negative predictive 
value) based on dichotomized scores. We then divided the risk scores into three risk cat-
egories and calculated how many patients were re-classified, as well as how many were 
correctly re-classified when using the new (MGH) scoring system. Statistical significance 
was considered at a two-sided p<0.05. All statistical analyses were performed using SAS 




Of 821 patients with confirmed C. difficile colitis enrolled in our prospectively collected 
registry, 75 had incomplete records, were younger than 18 years of age, or were eventu-
ally not admitted to the hospital. The remaining 746 patients were included in this study. 
48 (6.4%) progressed to fCDC; Table 2 describes those with and without fCDC. Demo-
graphics were similar in the two groups. C. difficile colitis was more frequently recorded 
as the primary diagnosis in fCDC patients. As expected, all clinical parameters were 
worse in the fCDC group. Additionally, fCDC patients were treated more frequently with 
intravenous metronidazole and vancomycin, while non-fCDC patients more frequently 
received oral metronidazole. The mortality was significantly higher in the fCDC group, 
and the ICU LOS was longer; however the hospital stay was similar between the two 
groups. 
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Table 2. Clostridium difficile infection (CDI) versus fulminant Clostridium difficile colitis (fCDC)
Variable CDI (N=698) fCDC (N=48) P value
Demographics
Age, mean (SD), y 66 ± 17.9 70.6 ± 16.2 0.064
Age ≥ 70 years, No. (%) 323 (46.3) 27 (56.3) 0.18
Male, No. (%) 334 (47.9) 28 (58.3) 0.16
Race, No. (%) 0.84
Caucasian 601 (86.1) 42 (87.5)
African-American 32 (4.6) 1 (2.1)
Asian 8 (1.1) 1 (2.1)
Other 38 (5.4) 2 (4.2)
Unknown 19 (2.7) 2 (4.2)
Ethnicity, Hispanic, No. (%) 27 (3.9) 1 (2.1) 0.80
CDI as primary diagnosis, No. (%) 86 (12.3) 23 (47.9) <0.0001
Admission source, No. (%) 0.60
Home 434 (62.2) 25 (52.1)
Nursing home 44 (6.3) 5 (10.4)
OSH 125 (17.9) 11 (22.9)
Rehab 83 (11.9) 6 (12.5)
Other 6 (0.9) 1 (2.1)
Unknown 6 (0.9) 0
Admitting service, No. (%) 0.006
Surgery 144 (20.6) 20 (41.7)
Medicine 536 (76.79) 28 (58.33)
Ob/gyn 7 (1) 0
Other/unknown 11 (1.6) 0
Pre-medical history
Recurrent C. difficile colitis (within last 6 months), No. (%) 143 (20.5) 12 (25) 0.47
Recent hospitalization (within last 2 months), No. (%) 347 (49.7) 27 (56.3) 0.38
Recent antibiotic usage (within last 2 months), No. (%) 533 (76.4) 39 (81.3) 0.44
PPI usage, No. (%) 336 (48.1) 27 (56.3) 0.28
Immunosuppression and/or chronic medical condition, No. (%) 586 (84) 36 (75) 0.25
ICU admission, No. (%) 192 (27.5) 45 (93.8) <0.0001
Clinical features
WBC count, median (IQR), /µL 13.2 (9-19.3) 21.4 (15.6-33.8) <0.0001
WBC >20.000 or <2.000 /µL, No. (%) 162 (23.2) 29 (60.4) <0.0001
Neutrophil bands, median (IQR), % 8 (3-17) 18 (10.5-26) <0.0001
Neutrophil bands > 10%, No. (%) 125 (17.9) 30 (62.5) <0.0001
Albumin, mean (SD), mg/dL 2.8 ± 0.7 2.3 ± 0.6 <0.0001
Albumin < 3g/dL, No. (%) 310 (44.4) 40 (83.3) <0.0001







Development of risk scoring system in fCDC
Table 2. (Continued)
Variable CDI (N=698) fCDC (N=48) P value
Creatinine 1.5 fold > baseline, No. (%) 202 (28.9) 22 (45.8) 0.032
Fever, No. (%) 62 (8.9) 9 (18.8) 0.003
Abdominal pain or distention on physical exam, No. (%) 97 (13.9) 47 (97.9) <0.0001
Peritoneal signs on physical exam, No. (%) 1 (0.1) 31 (64.6) <0.0001
Diffuse abdominal tenderness on physical exam, No. (%) 80 (11.5) 47 (97.9) <0.0001
Abnormal abdominal CT scan, No. (%)a 161 (23.1) 38 (79.2) <0.0001
Vasopressors required (CDC related), No. (%) 1 (0.1) 27 (56.3) <0.0001
Mechanical ventilation required (CDC related), No. (%) 0 19 (39.6) <0.0001
Cardiorespiratory failure, No. (%)b 1 (0.1) 29 (60.4) <0.0001
Mental status change, No. (%)c 107 (15.3) 18 (37.5) 0.0003
Medical treatment
Metronidazole PO, No. (%) 374 (53.6) 18 (37.5) 0.041
Metronidazole IV, No. (%) 399 (57.2) 46 (95.8) <0.0001
Vancomycin PO, No. (%) 493 (70.6) 45 (93.8) 0.002
Vancomycin IV, No. (%) 255 (36.5) 28 (58.3) 0.009
Vancomycin PR, No. (%) 29 (4.2) 19 (39.6) <0.0001
Outcomes
Mortality, No. (%) 51 (7.3) 13 (27.1) <0.0001
Total abdominal colectomy, No. (%) 0 19 (39.6) <0.0001
HLOS, median (IQR), days 11 (6-23) 11.5 (6-20.5) 0.61
ICU admission related to CDC, No. (%) 11 (1.6) 45 (93.8) <0.0001
ICU LOS, median (IQR), days 0 (0-0) 4 (2-8.5) <0.0001
Discharge disposition, No. (%) <0.0001
Home 302 (43.3) 11 (22.9)
Deceased 51 (7.3) 13 (27.1)
Nursing home 89 (12.8) 8 (16.7)
Rehabilitation 226 (32.4) 16 (33.3)
Other 13 (1.9) 0
Unknown 17 (2.4) 0
Abbreviations: CDI, Clostridium Difficile Infection; CDC, Clostridium Difficile Colitis; PPI, Proton Pump 
Inhibitors; ICU, Intensive Care Unit; WBC, White Blood Cell count; CT, Computed Tomography; PO, per oral; 
IV, intravenous; PR, per rectum; HLOS, hospital length of stay; ICU LOS, intensive care unit length of stay. 
a Abnormal abdominal CT scan: positive for non-specific findings such as: pancolitis, ascites, bowel wall 
thickening, dilation
b Cardiorespiratory failure: the need for mechanical ventilation or vasopressor support
c Mental status change: disorientation, confusion, or decreased consciousness
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Development of RSS
The 4 risk factors which were included in the multivariable logistic regression model 
are shown in Table 3. Each risk factor was assigned a number of points, proportional to 
its parameter estimate obtained from the logistic regression model. Based on the log 
(odds ratio) of each risk factor, age > 70 years was assigned 2 points, WBC ≥ 20.000/
µL or ≤2.000/µL was assigned 1 point, cardiorespiratory failure 7 points, and diffuse 
abdominal tenderness on physical exam 6 points. Using this system, the discriminatory 
value of the MGH RSS was high with an area under the curve of the ROC curve (Figure 
1) of 0.98 (95% confidence interval [CI]: 0.96 – 1). Additionally, for the RSS, the Hosmer 
and Lemeshow goodness-of-fit test showed a p-value of 0.78, while the Brier score was 
0.019. Table 4 describes the incidence of fCDC in our population according to the RSS. 
Based on the incidence rate, we used a value of 6 points as the threshold to distinguish 
low risk (<6) from high risk (>6) patients. 
Comparison of the RSS and Previously Published Severity Scoring 
System
We applied the previously published severity scoring system in our population. The area 
under the curve was 0.96 (95% CI: 0.93 – 0.99). Comparing the C-statistics of the two 
systems, showed a p-value of 0.22. The previously published system used a value of 4 
points as the cut-off for low risk (<4) vs. high risk (≥4). The performance of both scor-
ing systems were tested. This analysis shows a similar sensitivity (97.9%), but a higher 
specificity (88.4% vs. 46.4%), positive predictive value (36.7% vs. 11.2%), and negative 
predictive value (99.8% vs. 99.7%) for the RSS. To compare the RSS to the risk categories 
of the previously published system, we divided the scores into three risk categories as 
well based on the incidence rate (low risk: 0-5, medium risk: 6, high risk: >7). A total 
of 382 (50.7%) patients were reclassified by the RSS risk categories, among them, 333 
(88.1%) were correctly reclassified by the RSS risk categories as is shown in Table 5.
Table 3. Predictors of fulminant Clostridium difficile colitis in the RSS development cohort
Variable Odds Ratio 95% Confidence Interval Points
Age > 70 years 3.80 1.14 – 13.68 2
WBC ≥ 20.000 or ≤ 2.000 / µL 1.81 0.54 – 6.05 1
Cardiorespiratory failure* 285 24 – 21,491 7
Diffuse abdominal tenderness 189 27 – 8,429 6
Abbreviations: RSS, Risk Scoring System; WBC, White Blood Cell count.
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Figure 1. Receiver operating characteristic curves for the risk scoring systems of fulminant CDC (both RSS 
and Previously Published Severity Scoring System included) 
Abbreviations: ROC, receiver operating characteristic curve; CDC, Clostridium Diffcile Colitis; MGH, 
Massachusetts General Hospital Risk Scoring System; PGH, previously published severity scoring system.29
Table 4. Risks of fCDC by the Risk Scoring System














Abbreviation: fCDC, fulminant Clostridium Difficile Colitis.
Patients with scores ≥ 6 points were classified as high risk
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DISCUSSION 
In this study we present a severity scoring system for the purpose of detecting patients 
at risk of developing fCDC. With the goal of using a simplified system that can be easily 
remembered by clinicians and used at the bedside, we included 4 risk factors selected by 
an expert panel and based on previous studies.7,12,29 The RSS successfully discriminates 
patients with C. difficile infection from those who have fCDC (AUC, 0.98). Calibration 
was low (Brier score of 0.019), indicating that the possibility of developing fCDC could 
be estimated accurately. A cut-off of 6 points was used to divide patients at high risk of 
developing fCDC; this classified 97.9% of patients correctly. In combination with a high 
specificity (88.4%) and excellent negative predictive value (99.8%) this scoring system 
proves it has the potential to be used at the bedside in order to safely rule out the pos-
sibility of fCDC. The positive predictive value of 36.7% is low, and should be considered 
against the background of its estimation in a low-prevalence setting (6.4% of total 
cohort was diagnosed with fCDC).30 
Since the beginning of the 21st century there have been many C. difficile outbreaks; the 
majority are caused by a newly discovered, hypervirulent strain, NAP1/BI/027.31,32 This 
strain is associated with increased severity of the C. difficile infection, resulting in a higher 
likelihood of fCDC (which carries significant morbidity and mortality).33,34 Prediction rules 
to detect patients that are at risk for developing CDI, and also predict recurrent CDI, are 
available.35-40 Commonly used risk factors, such as age > 65 years, antibiotic usage, and 
Table 5. Reclassification table Risk Scoring System vs. Previously Published Severity Scoring System
MGH score
PGH score Low Risk (0-5) Medium Risk (6) High Risk (≥7) Total
Low Risk (0-3), N 294 23 8 325
# without fCDC 294 22 8
# with fCDC 0 1 0
Medium Risk (4-6), N 184 18 19 221
# without fCDC 184 17 19
# with fCDC 0 1 0
High Risk (≥7), N 140 8 52 200
# without fCDC 139 6 9
# with fCDC 1 2 43
Total 618 49 79 746
Abbreviations: fCDC, fulminant Clostridium Diffcile Colitis; RSS, Risk Scoring System.
Reclassification:
· 184+139+6 patients without fCDC were correctly moved into lower risk categories 
· 1 patient with fCDC was correctly moved into a higher risk category
· 1+2 patients with fCDC were incorrectly moved into a lower risk category
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multiple comorbidities, populate these prediction rules. Although many studies in the 
fCDC population have been published, describing risk factors of mortality6,7,10,15,16,18,20,21 
and recommending early intervention to prevent unfavorable outcomes7,9,13,16,22,23, sys-
tems to score the severity of fCDC are not common. Only one group has proposed such 
a system for severe, complicated C. difficile colitis.24 Partially based on recommendations 
of the Society for Healthcare Epidemiology of America and the Infectious Diseases Soci-
ety of America1, they designed a system that weighs variables such as cardiorespiratory 
failure and mental status changes heavily, as well as an additional 10 variables. That 
system had never been tested or validated until now. The risk factors used in our RSS 
were based on the literature and derived by expert consensus. In a case-control study by 
Greenstein and colleagues12, risk factors for development of fCDC were determined to 
be: WBC >16.000/mm3 at therapy start, presence of inflammatory bowel disease, opera-
tive therapy in the last 30 days, and history of intravenous immunoglobulin therapy. In a 
similar, but more recent study by Girotra et al.29, ‘red flags’ for developing fCDC were: age 
> 70 years, abdominal pain, and profound leukocytosis (>18.000/mm3). 
Upon comparison of our 4-factor RSS with the 12-factor Severity Score System24, we 
found a non-significant difference in AUC and an equal sensitivity of 97.9%. The two 
systems are, therefore, similarly effective. However, the RSS has a higher specificity and 
positive predictive value despite its greater level of simplicity, and is more likely to be 
adhered to. Additionally, our analysis showed that when the two systems disagreed, 
88.1% of the patients were correctly reclassified by our risk categories. 
A limitation of our study relates to the low number of patients with fCDC (48 patients, 
6.4% of cohort). It is because of this number that we were unable to divide our cohort 
into a development and validation cohort; external validation is necessary. Furthermore, 
the RSS was based on 4 predictors, which were chosen by an expert panel and derived 
from previous data, instead of a statistical model. Again, the low number of cases 
prevented an exhaustive risk factor analysis by stepwise logistic regression. Even when 
using only four risk factors, the 95% confidence intervals are particularly wide, attesting 
to the limited sample size. Although fCDC is becoming more frequent than in the past, 
its frequency is still low and multicenter studies will be needed to accrue large sample 
sizes. An additional limitation pertains to the timing of RSS, which was only calculated 
at one time point. If the WBC or abdominal exam changes, the RSS predictability may 
change as well. Therefore, a low-probability score should not put the probability of 
future deterioration completely at rest. It is notable that our score does not include 
computed tomographic images. For most patients with suspected fCDC a computed 
tomographic scan will be ordered. However, in our analysis it was found that such im-
ages contributed only a very small margin to the accuracy of the RSS (data not shown 
here) and therefore, it was elected to exclude computed tomographic findings as a risk 
factor. This buttresses the usual teaching that the physiology rather than the radiology 
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is important for clinical decision-making, while it has the added benefits that imaging 
is not required when calculating the risk, thus lowering the threshold of using the RSS, 
whereas it also saves costs. 
In conclusion, we designed a valid and reliable severity scoring system for fCDC that 
can be used at the bedside to score the severity of disease and identify patients at risk of 
developing fCDC. The next step will be to externally validate our risk scoring system in 
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Background: Fulminant Clostridium difficile colitis (fCDC) occurs in 2-8% of patients with 
CDC, and carries a high mortality. Prompt surgery may reduce mortality. Our aim was to 
determine whether a standardized hospital-wide protocol for surgical referral in CDC 
would result in earlier surgical consultation, earlier identification of patients who could 
benefit from surgical therapy, and reduced mortality from fCDC.
Methods: A multidisciplinary team developed consensus criteria for surgical consulta-
tion. Compliance with the referral protocol was evaluated by prospective chart review 
of all inpatient C. difficile cases. Outcomes of the prospective cohort were compared to 
an historic control group, comprised of patients from an earlier study performed at our 
institution. 
Results: From November 1, 2010 – October 31, 2012, we identified 1106 inpatients with 
CDC; 339 patients matched the consultation criteria, of who 213 received a surgical con-
sultation, resulting in an overall compliance rate of 62.8%. Of 46 patients with fCDC, 11 
(23.9%) died. All fulminant cases received a surgical consultation, with a median time to 
surgical referral of 3 hours. The adjusted mortality was significantly lower in the prospec-
tive group compared to the historical group (18.3% vs. 34.8%, p=0.031). The mortality 
rate was 14.7% when excluding patients with limitations of care and those transferred to 
our institution in a fulminant state. 
Conclusions: A hospital-wide protocol with established criteria for surgical consultation 
resulted in a 31.5% relative reduction in mortality from fCDC compared to historical con-
trols. The overall mortality rate for fCDC patients without limitations of life-sustaining 
treatment who presented to our emergency department or developed fCDC while 







Consultation criteria for patients with fCDC
INTRODUCTION
Clostridium difficile infections afflict up to 10% of all hospitalized patients and up to 20% 
of such patients receiving antibiotics.1-8 A study using the Nationwide Inpatient Sample 
showed a 109% increase in incidence of C. difficile infections between 1993 and 2003.8 
More recent national data showed that the rate of C. difficile hospitalizations per 1,000 
non-maternal, adult discharges increased from about 5.6 in 2001 to 12.8 in 2012, with 
annual costs in the U.S. estimated in the billions of dollars.9, 10 Two to eight percent of 
patients with C. difficile infection will develop fulminant disease, defined as C. difficile 
colitis (CDC) with significant systemic toxic effects and shock, resulting in the need for 
intensive care unit (ICU) admission, colectomy or death.8, 11-17 Mortality rates for fulmi-
nant CDC (fCDC) range between 13.8% - 80%.11-13, 16-34 A retrospective study in our own 
institution identified a 35% mortality rate for fCDC.11 This study and others have sug-
gested that admission to a surgical service and prompt colectomy may reduce mortality 
in fCDC.11, 12, 16-19, 23, 27, 31, 32 In spite of these data suggesting an important role for surgical 
consultation and surgery in the management of patients with fCDC, and guidelines 
recommending that colectomy be considered before severe shock is established,1, 13, 18, 27, 
35 delays in surgical consultation are common. This may be due in part to a lack of clear 
criteria for surgical consultation. 
In order to address this gap, we developed a hospital-wide protocol based on 
consensus-driven criteria for surgical referral of patients with CDC. We hypothesized 
that this protocol would result in earlier surgical consultation, earlier identification and 
treatment of fCDC patients, and reduced mortality from fCDC.
METHODS
Design:
This study has a before-after design across the time of implementation of a hospital-
wide surgical referral protocol for patients with severe CDC. Data on fCDC patients after 
the protocol (POST group) was recorded prospectively. Data on fCDC patients before 
the protocol (PRE group) were extracted retrospectively from the database of a previous 
study from our institution.11 
Protocol development:
Based on our review of hospital data, the three main sources of fCDC patients were 
the general medical wards, the Emergency Department, and the medical intensive 
care unit. Between August and October 2010 we coordinated a series of meetings with 
representatives of these departments. Retrospective data from our hospital11 and other 
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sites were reviewed, and consensus was reached about appropriate criteria for surgical 
consultation. These criteria were based upon several predictors of mortality identified 
in previous studies from our institution,11, 12 as well as in studies from other institu-
tions.13, 18-20, 27, 30, 31, 33, 36 The resulting protocol called for immediate surgical consultation 
for patients with known or suspected CDC, and any of the additional criteria listed in 
Table 1 indicating possible severe CDC. The protocol initially called for consultation for 
every patient with a single criterion. At a four-month interim analysis we found that 
no patients with only one criterion had developed fCDC. Within the multidisciplinary 
study group, it was decided that the threshold for consultation should be increased to 
two criteria. The consensus criteria for surgical consultation were disseminated through 
departmental meetings and conferences, the Massachusetts General Hospital intranet, 
and emails to staff members, fellows, and residents throughout September and October 
2010. Starting November 1, 2010 the protocol was applied to all patients arriving to the 
Emergency Department or already hospitalized in any hospital unit. 
Compliance with the protocol:
To monitor compliance with the protocol, we prospectively identified all patients with 
positive C. difficile immunoassays from our Infection Control Registry, ascertained 
whether those patients reached the threshold of two criteria (or one criterion during the 
first 4 months of the study), and recorded whether a surgical consult was called. Compli-
ance to the protocol was promoted through departmental meetings and conferences, 
and the intranet throughout the complete study period. Additionally, the representa-
tives from each department included in the study were charged with ongoing educa-
tion to maintain compliance with the agreed upon management protocol. Individual 
cases of non-consultation or delayed consultation were reviewed and fed back to the 
responsible clinicians by their departmental representatives.
Table 1. Consensus criteria for surgical referral in patients with confirmed or suspected fulminant 
Clostridium difficile colitis (any two of the following):
1 ICU admission
2 Temperature > 101 F
3 WBC count > 15,000 cells/mm3 or < 4000, or bands > 10%
4 HR > 120 beats/min
5 Systolic BP < 90 mmHg and/or need for vasopressors
6 > 12 bowel movements/day
7 Peritonitis on exam or abdominal pain not improving within 24 hours
8 Evidence of shock (decreased mental status, new organ failure, lactate > 2.0)
Abbreviations: ICU, Intensive Care Unit; F, Fahrenheit; WBC, White Blood Cell; bands, bandemia; HR, heart 
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Definitions and measurements:
CDC was defined by the identification of C. difficile in symptomatic patients. During the 
first 22 months of the study, the type of diagnostic test that was used to detect C. difficile 
infection, was the toxin A/B enzyme immunoassay. This was changed in the last 2 months 
of the study (September and October 2012) to a membrane enzyme immunoassay that 
detects both C.difficile glutamate dehydrogenase antigen and toxins A and B. In specimens 
with discordant glutamate dehydrogenase antigen and toxin results by the new test, an 
additional PCR test for toxigenic C. difficile was performed. Fulminant CDC was defined by 
the presence of septic shock37, need for intubation and/or vasopressors, or admission to 
the ICU owing to CDC. Subtotal colectomy was performed in patients with fCDC who were 
determined to be too toxic for a trial of non-operative therapy or were treated medically, 
but deemed to have failed medical therapy. In patients undergoing subtotal colectomy, 
CDC was confirmed by histopathologic analysis of the surgical specimen. 
Data collection:
The following data were collected prospectively from November 1, 2010 until October 
31, 2012 for the POST group: demographics; important comorbidities, measured by 
the age-adjusted Charlson Comorbidity Index38 (CCI); history of hospitalization and 
antibiotic therapy during the 2 months before the current admission; prior CDC in the 
6 months before the current admission; vital signs; physiologic parameters; abdominal 
examination findings; mental status; radiographic and/or endoscopic findings; medical 
intervention (antibiotics, intubation, and vasopressors); surgical intervention (type of 
operation); time interval between diagnosis (defined as a confirmed/suspected CDI and 
2 positive criteria) and surgical consultation; time interval between diagnosis and surgi-
cal intervention; indication for surgical intervention; surgical findings; final pathology; 
intensive care unit (ICU) and hospital length of stay; mortality; admission source; admit-
ting service; referral source; primary department that provided care; and discharge dis-
position. We also recorded whether the patients had any limitations of care, defined as a 
refusal by the patient or legal representative to undergo surgery or other life-sustaining 
treatments. Patients who were transitioned to comfort measures after failure of an ag-
gressive course of treatment were not considered to have limitations of care. The exact 
same data were recorded for the PRE group (January 1, 1996 to December 31, 2007). 
Outcomes:
The primary outcome was in-hospital mortality and secondary outcomes included ICU 
and hospital length of stay, time to surgical consultation and to surgery. The time was 
measured from either arrival to the Emergency Department with severe CDC symptoms 
or the time from which patients met consultation criteria if they were already hospital-
ized for other reasons. 
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Statistical analysis:
We compared the PRE and POST group to identify differences in patient characteristics 
and outcomes. Subgroup analyses were performed based on surgery status (colectomy 
vs. no-colectomy) and admitting service (surgical vs. non-surgical). Continuous variables 
were summarized using mean ± standard deviation and compared by Student t-tests, 
when variables had normal-like distributions, or summarized using median (interquar-
tile range) and compared by Wilcoxon rank sum tests, when variables could not be 
assumed to be normally distributed. Categorical variables were compared by Fisher’s 
exact test. Statistical significance was considered at a two-sided p<0.05. All statistical 
analyses were performed using SAS version 9.3 (The SAS Institute, Cary, NC). This study 
was approved by our Institutional Review Board. 
RESULTS
Over a 2-year period of prospective data collection 1106 patients had a positive toxin 
assay for C. difficile in our tertiary care center. Of those patients, 339 met our criteria for 
surgical consultation. A total of 213 patients were referred per protocol to the surgical 
service, resulting in an overall compliance rate of 62.8%. During the first 4 months of the 
study, when the threshold for surgical consultation required one criterion, compliance 
with the protocol was 53.6%. This increased to 65.2% after we changed the threshold 
for consultation to at least 2 criteria. In total, 48 patients with fCDC were included in the 
POST group. The overall incidence of fCDC in the period following protocol implementa-
tion was 4.3% (48/1106). We excluded 2 patients from the analysis who were treated 
with an experimental procedure (loop ileostomy with colonic lavage) as part of another 
research study. All 46 patients included in the analysis underwent surgical consultation, 
resulting in a compliance rate of 100% for patients with fCDC. The median time from 
diagnosis to consultation was 3 hours (IQR, 1-7.75 hours). The majority of patients with 
fCDC met either 4 (34.8%) or 5 (26.1%) criteria upon surgical consultation (Figure 1). No 
patient had only 1 or all 8 criteria.
The overall mean age of the fCDC patients in the POST group was 69.3 ± 16.4 years. 
Fifty-nine percent were male with an average age-adjusted Charlson Comorbidity Index 
of 6.3 ± 2.7. Half of the patients were admitted directly to the surgical service and 63% 
had CDC as their primary diagnosis. The median hospital stay for our entire cohort was 
13.5 days (IQR: 7-22 days), and the median ICU stay was 4 days (IQR: 2-9 days). No sig-
nificant differences in the main outcomes (mortality, ICU length of stay, hospital length 
of stay) were found when comparing patients admitted to the surgical service to those 
admitted to a non-surgical service. Comparing the PRE- and POST groups, the POST-
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mean white blood cell (WBC) count and lower mean serum albumin (see Table 2). Addi-
tionally, patients in the POST group were treated more often with enteral vancomycin or 
received combination therapy with vancomycin and metronidazole. After our interven-
tion a higher percentage of patients were directly admitted to the surgical service (50% 
POST vs. 15.2% PRE, p=<0.0001), and there was a shorter time interval between hospital 
admission and surgical intervention in patients undergoing surgery (median 1.5 days 
(IQR, 0-3) vs. 3 days (IQR, 1-11), p=0.018).
Mortality, our primary outcome, was decreased by a relative 31.5% after implement-
ing the protocol (34.8% vs. 23.9%, PRE vs. POST, p=0.15). The difference in mortality 
was statistically significant when adjusting for the difference in CCI between the two 
groups (adjusted rate 34.8% vs. 18.3%, p=0.031). The mortality rate dropped even fur-
ther when excluding those with limitations of care (unadjusted rate 30.3% vs. 18.6%, 
p=0.13; adjusted rate 30.3% vs. 15.3%, p=0.047) and when excluding both patients with 
limitations of care and those that were transferred to our institution in a fulminant state 
(unadjusted rate 31% vs. 14.7%, p=0.055; adjusted rate 31% vs. 12.8%, p=0.033). There 
were no significant differences in median hospital LOS and median ICU LOS (Table 3). 
The percentage of patients undergoing subtotal colectomy with ileostomy did not differ 
significantly between the PRE and POST group (37.9% PRE vs. 41.3% POST). Limiting our 
analysis only to those patients that received a colectomy, we did not find any significant 
difference in mortality, ICU or hospital length of stay. However, we found that patients 
in the POST group were admitted to the ICU sooner after admission to the hospital than 
patients in the PRE group (median 0 vs. 1 day, p=0.034). There was also a shorter interval 
between admission and surgical intervention for those that required surgery in the POST 
group (median 1.5 vs. 3 days, p=0.018). Comparing patients admitted to the surgical 









Figure 1. Number of criteria met by fulminant Clostridium difficile colitis patients upon surgical 
consultation
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Table 2. Comparison of fulminant Clostridium difficile colitis patients before (PRE) and after (POST) 
implementation of the surgical referral protocol
Parameter PRE N=198 POST N=46 P value
Age, mean (SD), y 68.6 ± 14.9 69.3 ± 16.4 0.79
Age ≥ 70 years, No. (%) 117 (59.1) 25 (54.3) 0.56
Male, No. (%) 95 (48) 27 (58.7) 0.19
CCI, mean (SD) 5.1 ± 2.3 6.3 ± 2.7 0.008
Risk factors, No. (%)
 Diabetes mellitus 59 (29.8) 12 (26.1) 0.62
Renal disease 50 (25.3) 12 (26.1) 0.91
Immunosuppression 99 (50) 16 (34.8) 0.063
Recurrent C. difficile colitis (within last 6 months) 65 (32.8) 12 (26.1) 0.38
Recent hospitalization (within last 2 months) 173 (87.4) 36 (78.3) 0.11
Recent antibiotic usage (within last 2 months) 181 (91.4) 41 (89.1) 0.63
Clinical features, No. (%)
WBC count, mean (SD), /μL 31.9 ± 21 25.7 ± 14.7 0.02
Neutrophil bands, mean (SD), % 18 ± 15.2 18.7 ± 11.3 0.74
Albumin, mean (SD), mg/dL 2 ± 0.6 2.5 ± 0.6 0.0001
Creatinine, mean (SD), mg/dL 2.2 ± 1.6 1.8 ± 2.0 0.25
Intubation, No. (%) 85 (42.9) 16 (34.8) 0.31
Vasopressors, No. (%) 92 (46.5) 25 (54.3) 0.34
CT results*, No. (%)
Abnormal scan 140 (70.7) 36 (78.3) 0.75
Colonic wall thickening 126 (63.6) 33 (71.7) 0.66
Colonic dilation 34 (17.2) 7 (15.2) 0.57
Ascites 79 (39.9) 19 (41.3) 0.77
Perforation 6 (3) 0 0.21
Admission source, No. (%) 0.011
Home 82 (41.4) 20 (43.5)
Outside hospital 34 (17.2) 11 (23.9)
Nursing home 16 (8.1) 5 (10.9)
Rehabilitation facility 66 (33.3) 8 (17.4)
Other 0 2 (4.3)
Hospital transfer in fulminant state, No. (%) 18 (9.1) 9 (19.6) 0.041
Surgery as admitting service, No. (%) 30 (15.2) 23 (50) <0.0001
Admission with CDC as primary diagnosis, No. (%) 135 (68.2) 29 (63) 0.5
Operation (subtotal colectomy with ileostomy), No. (%) 75 (37.9) 19 (41.3) 0.67
Interval hospital admission - ICU admission, median (IQ1-3), d 0 (0-4) 0 (0-1) 0.098
Interval hospital admission - surgical intervention†, median (IQ1-3), d 3 (1-11) 1.5 (0-3) 0.018
Interval ICU admission - surgical intervention†, mdian (IQ1-3), d 0 (0-2) 1 (0-2) 0.35
Limitation of care, No. (%) 13 (6.6) 3 (6.5) 0.99
Metronidazole (both PO and IV), No. (%) 182 (91.9) 41 (89.1) 0.54
Oral vancomycin, No. (%) 86 (43.4) 41 (89.1) <0.0001
Combination of metronidazole and vancomycin, No. (%) 80 (40.4) 40 (87) <0.0001
* CT was not performed for 48 from the PRE group and 8 from the POST group
† Limited to the patients who received surgical intervention 
Abbreviations: SD, standard deviation; CCI, Charlson Comorbidity Index; WBC, white blood cell; CT, 
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between hospital admission and surgical intervention, and between ICU admission and 
surgical intervention (measured in days) were significantly shorter in patients admitted 
directly to the surgical service. In the POST-group, such differences were not found. The 
mortality rate dropped significantly on non-surgical services (37.5% PRE vs. 13% POST, 
p=0.02), but at the same time there was a trend towards higher mortality on the surgical 
service (20% PRE vs. 34.8% POST, p=0.23). 
DISCUSSION 
With 3 million new cases every year in the US, and rising prevalence, C. difficile is now the 
leading cause of nosocomial diarrhea in both North America and Europe. CDC is not only 
increasingly common, but has also become more severe with the emergence of multiple 
hypervirulent strains linked to increasing morbidity and mortality.1, 6, 8, 11, 16, 30, 39-43 As se-
vere infections have become more common, the role of surgery in their management 
has been refined. Current guidelines recommend surgery only for severe, complicated 
disease, but recommend performing it before severe shock or irreversible organ dam-
age has intervened.35 Studies by Sailhamer11, Hall12, Seder33, and Ali18 suggest improved 
outcomes, including mortality benefits, when surgical intervention is performed early 
in the course of fulminant disease. Still, a study from our own institution showed that 
surgical consultation was often undertaken relatively late, sometimes days after the 
occurrence of multisystem organ failure.11 Our current study shows that by implement-
ing a standardized protocol for surgical consultation in CDC the time from diagnosis to 
surgical consultation can be reduced – in this case to a median of 3 hours for patients 
with fCDC - and the adjusted mortality rate decreased.
Currently, there are no evidence-based guidelines for when to obtain surgical consul-
tation in cases of CDC, though a number of criteria have been suggested to be risk fac-
Table 3. Outcomes of fulminant Clostridium difficile colitis patients before (PRE) and after (POST) 
implementation of the surgical referral protocol
Outcomes PRE N=198 POST N=46 P value
Mortality, all subjects, No. (%) 69 (34.8) 11 (23.9) 0.17
After adjusting for CCI, % 34.8 18.3 0.031
Mortality, excluding limitations of care, No. (%) 56 (30.3) 8 (18.6) 0.14
After adjusting for CCI, % 30.3 15.3 0.047
Mortality, excluding limitations / transfers, No. (%) 52 (31) 5 (14.7) 0.062
After adjusting for CCI, % 31 12.8 0.033
Hospital length of stay, median (IQ1-3), days 16 (8-32) 13.5 (7-22) 0.089
ICU length of stay, median (IQ1-3), days 4 (2-10) 4 (2-9) 0.34
Abbreviations: CCI, Charlson Comorbidity Index; ICU, intensive care unit; IQ, interquartiles.
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tors for transition to fCDC. These include older age (>70 years), profound leukocytosis, 
comorbidities including immunosuppression, history of inflammatory bowel disease, 
and intravenous immunoglobulin treatment, surgery within 30 days of presentation 
with CDC, and evidence of peritoneal signs on physical exam.15, 16, 20, 44 Our consultation 
criteria were developed through multidisciplinary consensus, and based largely on our 
own retrospective data.11, 12 Our priority was to identify patients who would develop 
fulminant disease, early in their course. We consciously developed criteria that we be-
lieved would be highly sensitive for fCDC, at the cost of some specificity. Hospital-wide 
compliance to our protocol was almost 65% over the 24-month study period. As ex-
pected, some clinicians were reluctant to place surgical consultations in patients who, in 
spite of meeting consultation criteria, appeared clinically well or improving. However, all 
patients who developed the fulminant disease were caught early in their disease course, 
with a median time to surgical consultation of 3 hours, resulting in 100% compliance in 
that group, which was the primary goal of our initiative. Further work might attempt to 
identify the most important clinical factors predicting the development of fulminant 
disease to allow further refinement of the consultation criteria.
We found a statistically significant risk-adjusted relative mortality reduction of 31.5% 
when comparing our post-protocol study cohort to historic controls. Our POST cohort 
had more comorbid disease than the PRE group, as shown by the higher age-adjusted 
CCI score. Although the mean peak WBC counts were higher and the mean lowest re-
corded albumin levels were lower in the PRE group, these discrepancies can be explained 
by the fact that patients under our protocol were recognized and treated earlier in the 
course of disease, before their WBC counts rose or serum albumin levels fell further. The 
unadjusted mortality was 23.9% in the new cohort. This dropped to 18.6% when exclud-
ing patients with limitations of care (refusal of mechanical ventilation, vasopressors, or 
surgery), and fell to 14.7% when we, in addition to excluding patients with limitations 
of care, also excluded those that were transferred in a fulminant state to our center. We 
believe this latter exclusion is relevant in a study focusing on early surgical consultation, 
since patients transferred to our institution in a fulminant state that may have lasted 
for days could not be expected to benefit from an early referral protocol. The overall 
mortality for fCDC for patients presenting de novo to our institution, or contracting the 
disease while admitted to our hospital is 14.7%. This is among the lowest mortality rates 
reported in the literature, where, over the last decade, most studies report mortality 
rates between 35-55%.8, 11, 17-20, 23, 24, 26-28, 31-33
In patients who required a total abdominal colectomy, the time interval between 
hospital admission and surgical intervention was measured, since multiple studies have 
suggested improved outcomes with shortened intervals.13, 18, 19, 27 Compared to the PRE 
cohort, the time interval from admission to surgical intervention was cut in half (median 
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overall percentage of fCDC patients undergoing colectomy (37.9% PRE vs. 41.3% POST). 
The fact that approximately the same number of patients underwent colectomy, sug-
gests that the improved outcomes were a result of performing colectomies earlier in the 
course of disease rather than a result of performing colectomies more frequently, and 
that early surgical consultation does not necessarily lead to increased rates of colectomy.
There has also been debate in the literature about whether patient outcomes could 
be improved by direct admission to a surgical service in severe CDC cases.11, 13, 18, 19, 27 
Sailhamer et al.11 showed a lower mortality rate in patients admitted to a surgical vs. a 
non-surgical service (12.8% vs. 39.3%), both in all CDC patients, and in those undergoing 
colectomy. However, a study by Byrn and colleagues13 showed no difference in mortal-
ity based on admitting service. Our results showed a significantly higher percentage 
of fCDC patients directly admitted to the surgical service after implementation of the 
protocol (15.2% PRE vs. 50% POST, p=0.67), but no differences in outcomes between 
patients admitted to the medical or surgical services. When comparing PRE vs. POST 
implementation of the protocol, stratifying by admitting service, the mortality rate 
within the medical service significantly decreased, while there was a trend towards 
increasing mortality on the surgical service. This can be explained in two ways. First, 
due to our intervention, patients admitted to non-surgical services in the POST group 
were more likely to have early surgical consultation and all its associated benefits. Sec-
ond, it is probable that in the PRE cohort a highly selected subgroup of patients likely 
to benefit from surgery were the only ones admitted directly to the surgical service. 
This is in contrast with the POST cohort, where early surgical consultation resulted in 
more surgical admissions, even of patients who were less likely to undergo surgery. 
This second contention is further supported by the fact that in the PRE cohort 66.7% of 
patients admitted to the surgical service underwent colectomy, compared to only 52.2% 
of patients in the POST cohort. It is likely that patients with severe CDC can be managed 
equally effectively on either a surgical or medical service as long as appropriate medical 
therapy is administered, close communication is maintained, and the need for surgical 
intervention is constantly reevaluated. 
Our study has a number of limitations. Our primary intervention was only adhered to 
65% of the time. As discussed above, we accepted a lower specificity in the consultation 
criteria in the effort to capture all potential cases with severe CDC. We included all CDC 
patients in the analysis, not only those for whom surgical consultation was obtained, 
thus the entire prospective POST cohort can be considered on an intention-to-treat basis. 
Further studies could seek to identify the most important criteria or factors associated 
with the transition to fCDC, to further refine the consultation criteria. Although our POST 
cohort was identified prospectively, the mortality benefit we describe is in comparison 
to historical controls collected retrospectively over a number of years during which the 
epidemiology and treatment of CDC evolved considerably. The more frequent use of 
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enteral vancomycin and general advances in critical care in recent years would tend 
to bias the results in favor of our intervention, suggesting a benefit to early surgical 
consultation that may not exist. Conversely, the preponderance of more virulent C. dif-
ficile strains in recent years might bias the results against our intervention. We controlled 
for patient comorbidities, but given the lack of complete microbiologic data on specific 
C difficile strains and resistance patterns, we could not adequately control for all of these 
confounders. Additionally, our institution has generated publications advocating early 
surgical consultation in CDC from both our General Surgery and Trauma and Acute Care 
Surgery services.11, 12 Our previously published historical controls represent one of the 
better mortality rates in the published literature for fulminant CDC. The relatively low 
mortality before intervention and an institutional environment in which awareness of 
the importance of surgical consultation in CDC may have been higher than is typical 
even before our intervention, would both bias our results towards the null hypothesis. 
As the first prospective study of early surgical consultation for CDC, our study shows 
that a hospital-wide protocol with established criteria for surgical consultation lowers 
mortality from fCDC. The overall mortality rate for fCDC patients without limitations 
of life-sustaining treatment was 14.7%, one of the lowest reported. Further studies are 
needed to refine the referral criteria and to determine whether this type of intervention 
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Background: Fulminant Clostridium difficile colitis (fCDC) is a highly lethal disease with 
mortality rates ranging between 12% - 80%. Although often these patients require a 
total abdominal colectomy (TAC) with ileostomy, there is no established management 
protocol for post-operative antibiotics. In this study we aim to make some recommenda-
tions for post-operative antibiotic usage, while describing the practice across different 
institutions.
Methods: Multi-institutional retrospective case series including fCDC patients who un-
derwent a TAC between January 1, 2007 – June 30, 2012. We first analyzed the complete 
cohort and consecutively performed a survivor analysis, comparing different antibiotic 
regimens. Additionally we stratified by time interval (antibiotics for ≤7 days, or ≥8 days). 
Primary outcome was in-hospital mortality. Additional secondary outcomes included 
hospital length of stay (HLOS), ICU LOS, number of ventilator-free days, and occurrence 
of intra-abdominal complications (proctitis, abscess, sepsis, etc.). Finally, a multivariate 
logistic regression analysis was performed to identify predictors of mortality.
Results: A total of 100 fCDC patients that underwent a TAC were included across 5 insti-
tutions. Four different antibiotic regimens were compared; A (metronidazole IV + vanco 
PO), B (metronidazole IV), C (metronidazole IV + vanco PO and PR), and D (metronidazole 
IV + vanco PR). The combination of IV metronidazole with or without PO vancomycin 
showed superior outcomes in terms of a shorter ICU length of stay and more ventilator-
free days. However, when comparing metronidazole alone vs. metronidazole and any 
combination of vancomycin, no significant differences were found. The addition of 
neither vancomycin enema, nor the time interval changed outcomes. Requiring a va-
sopressor before the operation, and the total units of FFP transfused during hospital 
admission were found to be risk factors for mortality.
Conclusion: Patients, after a TAC for fCDC, may be placed on either IV metronidazole or 
PO vancomycin depending upon local antibiograms, and proctitis may be treated with 
the addition of a vancomycin enema (PR). There was no data to support routine use of 
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INTRODUCTION
Colonization with Clostridium difficile can result in a wide range of disease patterns 
from asymptomatic colonization, to a mild infection (CDI), and sometimes even a se-
vere, fulminant, colitis.1, 2 Fulminant C. difficile colitis (fCDC) is a disease of increasing 
incidence, with high morbidity and mortality.3-5 Often these patients require surgical 
treatment, namely a total abdominal colectomy (TAC). Although this procedure has 
been performed and described many times4-17, not much has been written about the 
post-operative antibiotic course of these patients. There is literature describing post-
operative complications such as enteritis and surgical site infections12, 13, 18, however 
there is no established antibiotic management protocol for patients with fCDC that 
underwent a TAC. For almost three decades now, vancomycin and metronidazole have 
been the two most frequently used antimicrobial agents for the treatment of CDI19, but 
no guidelines recommend one specific antibiotic regimen for patients after a TAC. In this 
study the practice across different institutions is described. Our aim is to make some 
recommendations for post-operative antibiotic usage. 
METHODS
Design
This is a multi-institutional retrospective case series including fCDC patients who under-
went a total abdominal colectomy (TAC) between January 1, 2007 and June 30, 2012. 
The primary outcome was in-hospital mortality. Secondary outcomes included hospital 
length of stay (HLOS), ICU LOS, number of ventilator-free days, and occurrence of intra-
abdominal complications (proctitis, abscess, sepsis, etc.).
Definitions and data collection
Fulminant CDC is defined as4 CDC with significant systemic toxic effects and shock, 
resulting in need for ICU admission, colectomy, or death. Normally, a TAC is performed 
in patients with fCDC who were determined to be too toxic for a trial of non-operative 
management or who failed medical therapy. In all patients undergoing a TAC, CDC was 
confirmed by histopathologic analysis of the surgical specimen. 
The focus was on the post-operative course of these patients, and initially we com-
pared patients that received antibiotics post-operatively for ≤7 days, or ≥8 days. The 
following variables from patient electronic records were collected: 1) age, gender, race, 
and ethnicity; 2) Charlson Comorbidity Index20, APACHE II score, vasopressor require-
ment, transfusion requirements, P/F ratio, and total fluid balance; 3) laboratory values: 
red blood cell count, white blood cell count, platelets, hemoglobin, hematocrit, sodium, 
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potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, and glucose; 4) hos-
pital length of stay, ICU length of stay, ventilator-free days, time to full enteral feeds, 
mortality, and discharge disposition; and 5) complications: proctitis, sepsis, abscess, 
breakdown of rectal staple line, and surgical site infection.
Statistical analysis:
Descriptive statistics were tabulated to give an overview of our study cohort. When com-
paring groups, continuous variables were summarized as mean ± standard deviation, and 
compared by t-tests when variables were normally distributed. Otherwise, data were sum-
marized as median (interquartile range [IQR]), and compared by Wilcoxon rank sum tests. 
Categorical variables were compared by Fisher’s exact test. To examine the outcomes in 
the post-operative course, we conducted an additional analysis limited to survivors. We 
compared outcomes between antibiotic regimen, length of treatment, and with and with-
out the addition of an enema. We also compared antibiotic groups stratified by length of 
treatment. Additionally we compared survivors vs. non-survivors, and variables significant 
at 0.1 level were considered as candidates for a multivariable logistic regression model to 
identify independent predictors of mortality. Due to the small number of events, the final 
model included the two predictors significant at 0.05 level and adjusted odds ratios (aOR) 
with 95% confidence intervals (CI) were reported. A two-tailed P <0.05 was considered 
to be significant for all analyses. All analyses were performed in SAS version 9.3 (The SAS 
Institute, Cary, NC). This study was approved by our Institutional Review Board. 
RESULTS
A total of 100 patients from five institutions were collected. All patients underwent a 
total abdominal colectomy (TAC) for fCDC. The mean (± standard deviation) age was 66 
± 15 years, and 58% were male. The average age-adjusted Charlson Comorbidity Index 
(CCI) was 4.4 ± 2.7. Pre-operatively, the mean APACHE score was 18 ± 9, 43% required 
a vasopressor, the mean P/F ratio was 332 ± 147 mmHg, and median total fluid bal-
ance (TFB) was 2.6 L positive (IQR 0.6-5.4 L). Our primary outcome, mortality, was 26% 
(26/100) overall. The median (IQR) hospital length of stay (LOS) was 19 days (11-37), with 
a median ICU LOS of 6.5 days (3-15), and a median ventilator-free days of 25 (0-27). All 
other variables, including the intra- and post-operative status, as well as the complica-
tions that occurred, can be found in Table 1.  
The antibiotics studied in the post-operative course of fCDC patients were metroni-
dazole (per oral , PO, and intravenous, IV) and vancomycin (PO and per rectum, PR). In 
total, 14 different combinations could be made (Table 2). There was a significant amount 
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Table 1. Overall cohort with fulminant Clostridium difficile colitis (fCDC), managed with a total 
abdominal colectomy (TAC)
Parameter Overall cohort (n=100)
Demographics
Age, mean (SD), y 66.3 ± 15.3
Age > 70 years, No. (%) 44 (44)






Hispanic, No. (%) 4 (4)
Charlson Comorbidity Index (CCI), mean (SD) 4.4 ± 2.7
Pre-operative status
APACHE score, mean (SD) 18.3 ± 8.6
Vasopressor requirement, No. (%) 43 (43)
PF ratio, mean (SD), mmHg 331.7 ± 146.7
TFB, median (IQR), mL 2584 (608-5384)
Intra-operative status
EBL, median (IQR), mL 250 (100-500)
Blood transfusions, median (IQR), units 0.5 (0-3.5)
Post-operative status
Vasopressor requirement, No. (%) 65 (65)
PF ratio 24 h post-op, mean (SD), mmHg 302.4 ± 126.8
TFB post-op day 1, median (IQR), mL 7438 (4771-11659)
TFB post-op day 2, median (IQR), mL 9181 (5221-13095)
TFB post-op day 3, median (IQR), mL 8245 (4610-14174)
Outcomes
Hospital length of stay, median (IQR), days 19 (11-37)
ICU length of stay, median (IQR), days 6.5 (3-15)
Ventilator free days, median (IQR), days 25 (0-27)
Time to full enteral feeds, median (IQR), days 4 (2-6)
Proctitis + Pouchitis, No. (%) 6 (6)
Sepsis, No. (%) 28 (28)
Abscess, No. (%) 7 (7)
Breakdown rectal staple line, No. (%) 3 (3)
Surgical Site Infection, No. (%) 8 (8)
Mortality, No. (%) 26 (26)




Nursing home 14 (14)
Abbreviations: SD, standard deviation; APACHE, Acute Physiology and Chronic Health Evaluation; PF ratio, 
PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen); mmHg, millimeters of mercury; TFB, 
total fluid balance; mL, milliliter; EBL, estimated blood loss; IQR, interquartile range; RBC, red blood cells; 
FFP, fresh frozen plasma; ICU, intensive care unit.
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of treatment. When dividing the length of treatment into two groups, ≤ 7 days and ≥ 8 
days, we found that a majority of the centers (57% of patients) preferred post-operative 
antibiotic treatment for ≥ 8 days. There was a significant difference in in-hospital mortal-
ity between patients that received antibiotics for ≤ 7 days vs. ≥ 8 days (41.7% vs. 17.5%, 
p=0.016). In the survivor analysis, there were no significant differences in outcomes 
between patients that received antibiotics for ≤ 7 days vs. ≥ 8 days. 
Due to low numbers in some of the subgroups, we decided to compare the four larg-
est groups; subgroup A (metronidazole IV + vancomycin PO), B (metronidazole IV), C 
(metronidazole IV + vancomycin PO and PR), and D (metronidazole IV + vancomycin 
PR). None of the combinations turned out to be superior in mortality. When comparing 
groups A and C, as well as A and D, a shorter ICU LOS and more ventilator free days 
were found in favor of group A. The same results were found when comparing ICU LOS 
between groups B and C, as well as B and D, with group B being superior. No significant 
differences were found between groups A and B or between groups C and D (Table 3). 
Additionally we compared patients per time interval (≤ 7 days vs. ≥ 8 days), stratified by 
antibiotic regimen (group A-D), with no significant differences found. Similarly, there were 
no significant differences when comparing metronidazole alone vs. metronidazole with any 
combination of vancomycin (with and without stratification by time interval). An extra focus 
was the addition of a rectal enema of vancomycin to the antibiotic regimen. Overall, patients 
that received an enema in addition to IV/PO vancomycin or metronidazole had a longer ICU 
LOS (median (IQR) of 11 days (6-19) vs. 5 days (2-11), p=0.001), and a higher incidence of 
Table 2. Different combinations of antibiotics and number of treatment days
Combination of antibiotics Total (n=100)
Treatment 1-7 
days (n)
Treatment > 8 
days (n)
Metronidazole IV and Vancomycin PO 26 12 14
Metronidazole IV 21 11 10
Metronidazole IV and Vancomycin PO + PR 12 1 11
Metronidazole IV and Vancomycin PR 12 4 8
Metronidazole PO + IV and Vancomycin PR 7 2 5
Metronidazole PO + IV 6 2 4
Metronidazole PO + IV and Vancomycin PO 3 1 2
Vancomycin PO 2 1 1
Metronidazole PO + IV and Vancomycin PO + PR 2 0 2
Metronidazole PO 1 0 1
Metronidazole PO and Vancomycin PO + PR 1 0 1
Vancomycin PR 1 1 0
Vancomycin PO + PR 1 1 0
No antibiotics at all or unknown 5 - -
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proctitis (13.9% vs. 0%, p=0.006). When stratified by time interval, adding an enema to any 
antibiotic regimen of ≤ 7 days was associated with a delay to full enteral feeds (median (IQR) 
of 6 days (5-7) vs. 3 days (2.5-4), p=0.047). Receiving antibiotics including an enema for ≥ 8 
days was associated with a longer ICU LOS (median (IQR) of 11.5 days (9-22) vs. 5 days (4-13), 
p=0.008), and a higher percentage of patients with proctitis (13.9% vs. 0%, p=0.019). Similar 
results were observed when the analyses were limited to survivors. 
In the multivariate logistic regression analysis for mortality, we identified two predic-
tors significant at 0.05 level: requiring a vasopressor before the operation increased the 
risk of mortality significantly (OR, 6.46), as well as the total units of FFP transfused during 
hospital admission; for every extra unit of FFP the odds of dying increased with 17% 
(Table 4). The final model had a c statistic of 0.81 with no evidence of lack of fit (Hosmer-
Lemeshow Goodness-of-Fit Test, p=0.21). The combination of antibiotics however, did 
not turn out to be a risk factor for mortality.
Table 3. Comparison of antibiotic regimen
A (n=26) B (n=21) C (n=12) D (n=12) P value
Mortality, No. (%) 10 (38) 7 (33) 3 (25) 4 (33) None
Hospital length of stay, median (IQR), days 17 (9-31) 21 (11-46) 19.5 (14.5-29.5) 16.5 (10-29) None
ICU length of stay, median (IQR), days 4.5 (1-15) 4.5 (2-10.5) 11.5 (9.5-29) 11.5 (4.5-17.5) A vs. C: 0.017
B vs. C: 0.009
Ventilator free days, median (IQR), days 24.5 (0-28) 25.5 (0-27) 16 (0-25.5) 12 (0-22) None
Limited to Survivors A (n=16) B (n=14) C (n=9) D (n=8)
Hospital length of stay, median (IQR), days 16.5 (11-28) 22.5 (13-46) 20 (19-33) 21 (11-29) None
ICU length of stay, median (IQR), days 4 (0-5.5) 5 (3-8) 11 (10-29) 13.5 (7-17.5) A vs. C: 0.007
A vs. D: 0.031
B vs. C: 0.01
B vs. D: 0.038
Ventilator free days, median (IQR), days 26.5 (25-28) 27 (25-27) 22 (12-26) 17.5 (8.5-25.5) A vs. C: 0.021
A vs. D: 0.021
Group A: Metronidazole IV + Vancomycin PO
Group B: Metronidazole IV
Group C: Metronidazole IV + Vancomycin PO + Vancomycin PR
Group D: Metronidazole IV + Vancomycin PR
Abbreviations: IV, intravenous; PO, per oral; PR, per rectum; N.S., not significant; IQR, interquartile range; 
ICU, intensive care unit; LOS, length of stay; SSI, surgical site infection.
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DISCUSSION
In this multicenter study of 100 fCDC patients that underwent a TAC, we looked at the 
differences in antibiotic regimen postoperatively. Four different combinations of met-
ronidazole and vancomycin were compared, and the combination of IV metronidazole 
with or without PO vancomycin showed superior outcomes in terms of a shorter ICU 
length of stay and more ventilator-free days. However, when comparing metronidazole 
alone vs. metronidazole and any combination of vancomycin, no significant differences 
were found. The majority of patients (57%) within our study were treated for ≥ 8days, 
but that did not result in any significant differences in outcomes. In addition we showed 
that adding an enema (PR) of vancomycin did not improve outcomes.
For the past 30 years, vancomycin and metronidazole have been the two drugs of choice 
for the treatment of CDI.21-23 Current guidelines recommend metronidazole for the treat-
ment of an initial episode of mild to moderate CDI, as well as for a first recurrence, while 
vancomycin (with or without the addition of metronidazole) is the antibiotic of choice for 
more severe and complicated episodes, and a second recurrence.19 These recommenda-
tions are supported by studies of Belmares and Zar that looked specifically into disease 
severity stratification and found superior results for vancomycin in more severe cases.24, 25 
Early studies have shown that metronidazole and vancomycin are equally efficient, and 
have similar relapse rates in regular CDI, with a side note that metronidazole is more eco-
nomical than vancomycin.22 The efficacy of metronidazole was more recently challenged 
by a study of Vardakis et al., who showed in a systematic review that metronidazole had 
a higher treatment failure rate than vancomycin.26 Additionally, Musher and colleagues 
also showed higher recurrence rates in patients treated with metronidazole.27 
However, vancomycin has been shown to have varying results as well; Pepin et al. 
reported that vancomycin lost its superiority over metronidazole, coinciding with the 
emergence of NAP1/027 in the early 2000s, implying that vancomycin would not work 
as well in severe cases.28 A Cochrane database review in 2011 concluded that when look-
ing at both symptomatic and bacteriologic cure, there was no overwhelming evidence 
that either metronidazole or vancomycin was superior in treating CDI. One explanation 
of discrepancies was small sample size. 
Regarding our study, there is no literature on the ideal post-operative antibiotic regi-
men. Although vancomycin might be recommended for severe disease, patients that 
Table 4. Independent predictors of mortality
Predictor Odds Ratio 95% CI P value
Vasopressor requirement pre-operative 6.46 1.96 – 21.24 0.0021
Total units of FFP transfused during hospital admission 1.17 1.06 – 1.3 0.0021
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have undergone a TAC are technically moving away from their complicated course, since 
the source of infection is removed. Given there is no difference in outcome measures 
when comparing metronidazole alone vs. metronidazole and any combination of van-
comycin, and considering that CDI is being caused by antibiotic usage in the first place1, 
2, for postoperative patients it is reasonable to place them on either IV metronidazole 
or PO vancomycin depending upon local antibiograms. Complications such as proctitis 
or pouchitis should be treated with the addition of an enema (PR) of vancomycin (500 
mg Q8). Regarding duration of postoperative antibiotic treatment, we found no data to 
support routine use of more than 7 days. 
We have to emphasize that our study has its limitations. First, this is a retrospective 
review of patients with a complicated disease course; although many variables were 
collected, certain causality cannot be ascertained. However, our goal was to create some 
guidelines since this matter normally is decided only based on physician discretion. The 
sample size was small and therefore we were unable to evaluate all antibiotic regimens. 
And lastly, new drugs such as fidaxomicin were not included in this study, since this drug 
was only approved in 2011. Although good results in two trials (fidaxomicin was found 
to be equally effective to vancomycin in achieving a clinical response at end of therapy 
but superior in preventing a recurrence), future studies are warranted to test the usage 
of fidaxomicin in the post-operative course after a TAC for fCDC.29, 30 
Despite these limitations this is the first study to show a detailed multi-institutional 
overview of fCDC patients after a TAC. We described the overall state of health of this 
complex population, and showed that these patients gradually improve in the first week 
after surgery. In conclusion, there is no justification for mandated use of vancomycin 
versus IV metronidazole in the postoperative period and routine duration of therapy 
should not exceed 7 days unless warranted by clinical status.
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Background: Clostridium difficile is the most common cause of nosocomial diarrhea, 
affecting up to 10% of hospitalized patients. Preliminary studies suggest an association 
between vitamin D status and Clostridium difficile infections (CDIs). Our goal was to 
investigate whether serum 25-hydroxyvitamin D [25(OH)D] levels are associated with 
CDI severity.
Methods: We prospectively enrolled patients diagnosed with CDI and divided them into 
two severity groups: group A (positive toxin A/B enzyme immunoassay only) and group 
B (positive toxin A/B enzyme immunoassay plus abdominal CT consistent with colitis). 
Serum 25(OH)D levels [D3, D2, and total 25(OH)D] were measured on all patients after 
diagnosis of CDI. We performed multivariable logistic regression analysis to examine 
the association between 25(OH)D levels and CDI severity, while adjusting for age, Deyo-
Charlson Comorbidity Index, recent hospitalization, and vitamin D supplementation.
Results: 100 patients were enrolled between July 2011 and February 2013. The mean 
(SD) cohort age and Deyo-Charlson comorbidity index was 62 (19) years and 4 (3), 
respectively; 54% of patients were male. Mean serum total 25(OH)D level was 22 (10) 
ng/ml; 43% of patients had 25(OH)D <20ng/mL. Mean 25(OH)D3 level was significantly 
higher in group A (n=71) than in group B (n=29): 21 (1) ng/mL versus 15 (2) ng/mL, 
respectively (P=0.005). Multivariable logistic regression showed that 25(OH)D3 levels 
were associated with CDI severity [aOR: 0.92; 95%CI: 0.87-0.98].
Conclusions: We found a significant inverse association between 25(OH)D3 levels and 
CDI severity. Further studies are needed to determine whether vitamin D supplementa-
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INTRODUCTION
Clostridium difficile is the leading cause of healthcare-associated diarrhea in North 
America. It affects up to 12.8 per 1000 hospitalized patients, and the infection incidence 
continues to increase.1, 2 Colonization with C. difficile can range from a simple asymptom-
atic intestinal colonization to diarrhea, and ultimately colitis. Excess annual healthcare 
expenditures attributable to nosocomial Clostridium difficile infections (CDIs) range from 
$1-3 billion, and the average hospital length of stay is prolonged by 3-6 days.3-6 In hospi-
talized patients, CDIs may result in mild, moderate, or fulminant colitis, which is typically 
associated with significant morbidity and mortality.7-9 While the overall mortality rate for 
CDIs is approximately 9%,1, 2, 10 with fulminant C. difficile colitis (fCDC), it may be as high 
as 30%-80%.10-13 
Clostridium difficile is an opportunistic pathogen, which typically leads to disease if the 
normal gastrointestinal flora is perturbed.8 Suboptimal host immune responses appear 
to play a critical role in symptomatic CDI.14 Recently, the role of vitamin D in regulating 
key elements of the immune system has become an area of intense scientific investiga-
tion.15, 16 Indeed, vitamin D status, as measured by serum 25-hydroxyvitamin D [25(OH)
D] levels, may play an important role in patient susceptibility to nosocomial infections 
such as CDIs.17, 18 Vitamin D status is typically determined by accounting for both 25(OH)
D3 and 25(OH)D2 (cholecalciferol and ergocalciferol, respectively); the majority of 25(OH)
D in humans is comprised from cholecalciferol. While emerging evidence suggests an 
association of vitamin D status with the risk of developing hospital-acquired CDI19, it 
remains unclear whether patients with lower 25(OH)D levels are at risk for developing 
more severe CDIs. Therefore, our goal was to investigate whether vitamin D status is 
associated with the severity of CDI in hospitalized patients.
METHODS
We prospectively enrolled patients with confirmed CDI at the Massachusetts 
General Hospital between July 2011 and February 2013. Potential subjects were identi-
fied through the hospital’s Infection Control Registry, which includes a daily audit of 
patients who test positive for Clostridium difficile. After obtaining informed consent, a 
blood sample was collected, and patients were followed until hospital discharge. Our 
primary focus was the association of 25(OH)D2, 25(OH)D3, and total 25(OH)D levels with 
CDI severity. Partners Human Research Committee approved the study. 
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Definitions and measurements:
Serum 25(OH)D levels were measured by liquid chromatography-tandem mass spec-
trometry (LC-MS). The method used was an isotope dilution, LC-MS assay optimized in 
the hospital’s clinical research laboratory based on published procedures.20 The limit of 
detection is 2 ng/mL for 25(OH)D2 and 3 ng/mL for 25(OH)D3; to convert from ng/mL to 
nmol/L multiply by 2.496. The intra- and inter-assay coefficients of variability for total 
25(OH)D were both <10%. We reported serum levels of 25(OH)D3, 25(OH)D2, and total 
25(OH)D (D3+D2) levels. Based on published guidelines
21, we categorized total 25(OH)D 
levels into 4 groups: <10 ng/mL, 10-19.9 ng/mL, 20-29.9 ng/mL, and ≥30 ng/mL. Fresh 
blood samples were sent immediately to the clinical research lab where vitamin D levels 
(D2, D3, and total vitamin D) were determined.
Between July 2011 and September 2012, diagnosis of CDI was based on toxin A/B 
enzyme immunoassay. From September 2012 onwards, the hospital changed to a mem-
brane enzyme immunoassay (EIA), which detects C. difficile glutamate dehydrogenase 
antigen (GDA) and the A/B toxins. In specimens with discordant GDA and toxin results 
by the new test, an additional PCR test for toxigenic C. difficile was performed. When 
the PCR test was positive, the diagnosis of CDI was officially confirmed. Only patients 
diagnosed with CDI by the GDA/toxins EIA from the latter cohort were included; those 
that were diagnosed by PCR were excluded to avoid a potential bias when compared to 
the original test (toxin A/B enzyme immunoassay). All measurements were performed 
in the hospital’s clinical core laboratory (for CDI testing) and research core laboratory 
(for vitamin D testing); both are Clinical Laboratory Improvement Amendments (CLIA)-
certified facilities and maintain rigorous quality control standards. 
Patients were divided into two CDI severity groups: group A was defined as patients 
with a mild CDI, confirmed by a positive toxin assay, and with a normal abdominal com-
puted tomography (CT) scan, while group B was defined as patients with a more severe 
CDI, confirmed by a positive toxin assay, and with an abnormal abdominal CT scan. An 
abnormal CT scan was defined as an image demonstrating abnormal findings of panco-
litis, ascites, colonic wall thickening, and/or dilation. Fulminant CDC was defined as CDC 
with significant systemic toxic effects and shock, resulting in need for ICU admission, 
requirement of colectomy, or death.13 Patients with fCDC were included in group B. 
Data collection:
We collected the following data from a combination of patient electronic records and 
personal interviews: 1) age, gender, race, ethnicity; 2) admission source, admitting 
service, hospitalization within 2 months of the current admission; prior CDI within 6 
months of the current admission; 3) antibiotic therapy within 2 months of the current 
admission, proton-pump inhibitor (PPI) use, vitamin D supplementation (type and dose 
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albumin levels, and creatinine levels; 5) physical exam findings: presence of abdominal 
pain or distention, diffuse abdominal tenderness, and peritoneal signs; 6) abdominal CT 
scan findings; and 7) hospital length of stay, 28-day mortality, and discharge disposition. 
Information contained within the electronic medical records was used to calculate a 
Deyo-Charlson Comorbidity Index score for each patient.22 
Statistical analysis:
Descriptive statistics were used to compare patients in group A versus group B. When 
normally distributed, continuous variables were reported as mean (standard deviation), 
and compared by t-tests. Otherwise, non-parametric data were reported as median (in-
terquartile range [IQR]), and compared by Wilcoxon rank sum tests. Categorical variables 
were compared by Fisher’s exact test. We examined the association of 25(OH)D levels 
with CDI severity using multivariable logistic regression. Biologically plausible covari-
ates entered into the model included: age, recent hospitalization, prior CDI, vitamin D 
supplementation, and Deyo-Charlson Comorbidity Index. Serum 25(OH)D levels were 
treated as continuous variables, while CDI severity was treated as a dichotomous vari-
able (either mild or severe). To test the robustness of the multivariable model, we then 
performed stepwise logistic regression using forward and backward selection methods. 
Variables considered for entry or removal in the stepwise approach included: age, recent 
hospitalization, prior CDI, recent antibiotic use, vitamin D supplementation, CDI as pri-
mary diagnosis, albumin, Deyo-Charlson comorbidity index, and type of assay used to 
confirm a diagnosis of CDI. Based on prior studies19, we assumed that the mean 25(OH)D 
level in CDI patients was 20 ng/mL. To detect a clinically meaningful difference in 25(OH)
D levels (20 ng/mL vs. 15 ng/mL), with a shared standard deviation of 5 ng/mL, alpha 
set at 0.05, and beta set at 0.8, would require a minimum of 16 patients in each CDI 
severity group. Results are reported as odds ratios (OR) with 95% confidence intervals 
(CI). All analyses were performed in STATA 11.2 (StataCorp LP, College Station, Texas). A 
two-tailed P <0.05 or 95% CI that did not span a value of 1 was considered to statistically 
significant. 
RESULTS
Over a period of 20 months, we enrolled 100 consecutive patients. The mean (SD) age 
of the patients in the study cohort was 62 (19) years and 54% were male. The average 
Deyo-Charlson Comorbidity Index was 4 (3). The majority of patients were admitted 
directly from home (65%). While CDI was the primary diagnosis for admission in 21% 
of the study cohort, for 20% of patients, this was a recurrent CDI and 61% had been 
hospitalized for various other reasons within 2 months of enrollment into the current 
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Table 1. Comparison of patients with a ‘simple’ Clostridium difficile infection (group A) vs. patients 
with a ‘severe’ Clostridium difficile infection (group B).
Group A (n=71) Group B (n=29) P value
Vitamin D status
≥ 30 ng/mL, No. (%) 19 (26.8) 5 (17.3) 0.31
20 – 29.9 ng/mL, No. (%) 24 (33.8) 9 (31) 0.79
10 – 19.9 ng/mL, No. (%) 22 (30.9) 12 (41.4) 0.32
< 10 ng/mL, No. (%) 6 (8.5) 3 (10.3) 0.76
Vitamin D levels
25(OH)D level, mean (SD), ng/ml 23 (1.2) 20 (2) 0.13
25(OH)D3 level, mean (SD), ng/ml 21.1 (1.1) 15.2 (1.5) 0.005
25(OH)D2 level, mean (SD), ng/ml 1.9 (0.5) 4.2 (1.4) 0.051
Vitamin D supplementation, No. (%) 19 (27) 11 (38) 0.27
International Units daily, mean (SD), IU 227 (109) 221 (83) 0.98
Age, mean (SD), y 63 (2.3) 60 (3.4) 0.55
Age ≥ 70 years, No. (%) 29 (41) 9 (31) 0.36
Male, No. (%) 42 (59) 12 (41) 0.11
CDI as primary diagnosis, No. (%) 11 (15) 10 (34) 0.03
Deyo Charlson Comorbidity Index (DCI), mean (SD) 3.9 (0.3) 3.8 (0.5) 0.87
Admission source, No. (%) 0.4
Home 43 (61) 22 (76)
Nursing home 3 (4.2) 1 (3.5)
External acute care facility 14 (20) 2 (6.9)
Rehabilitation 11 (15) 4 (14)
Hospital length of stay, mean (SD), days 20 (3.2) 25 (5.1) 0.38
Mortality, No. (%) 3 (4.2) 1 (3.5) 0.86
Recurrent C. difficile colitis (within last 6 months), No. (%) 14 (20) 6 (21) 0.91
Recent hospitalization (within last 2 months), No. (%) 40 (56) 21 (72) 0.14
Recent antibiotic usage (within last 2 months), No. (%) 54 (76) 23 (79) 0.73
Proton Pump Inhibitors (PPI), No. (%) 34 (48) 15 (52) 0.73
White blood cell (WBC) count, mean (SD), /µL 16 (1.9) 19 (2.3) 0.32
Neutrophil bands, mean (SD), % 8.4 (1.8) 14 (2.9) 0.11
Albumin, mean (SD), mg/dL 2.9 (0.1) 2.5 (0.1) 0.007
Creatinine, mean (SD), mg/dL 1.7 (0.2) 1.5 (0.3) 0.57
Abdominal pain or distention on physical exam, No. (%) 6 (8.5) 11 (38) -
Peritoneal signs on physical exam, No. (%) - 1 (3.5) 0.12
Diffuse abdominal tenderness on physical exam, No. (%) 5 (7) 11 (38) -
Abnormal abdominal CT scan, No. (%)* - 29 (100) -
* CT: Computed Tomography (only 46 scans made)
Definitions: Deficiency = D < 20 ng/mL; Insufficiency = D < 30 ng/ml; Severe deficiency = D < 10 ng/ml.
Abbreviations: SD, standard deviation; CDI, Clostridium difficile infection; fCDC, fulminant Clostridium 
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study. In addition, 77% of patients had used more than one antibiotic within 2 months 
of enrollment, and 49% of patients were using PPIs prior to hospital admission. 
Clinical features of our study cohort over the course of their hospitalization was 
notable for: 1) a mean highest white blood cell count of 17 (15) per µL with an average 
bandemia of 10 (11)%; 2) a mean lowest serum albumin level of 2.7 (0.6) mg/dL; and 
3) a mean highest creatinine level of 1.7 (1.8) mg/dL. Overall, 20% of the cohort had a 
physical exam positive for abdominal pain, distention, or diffuse abdominal tenderness, 
while peritoneal signs were detected in only one patient; three patients progressed to 
fCDC. Median hospital length of stay was 11 days [IQR: 7-22 days] and overall in-hospital 
mortality was 4%. Regarding 25(OH)D levels, in a majority of patients, the blood sample 
was collected between days 2 and 5 after confirmed diagnosis of CDI. Nine per cent of 
patients were <10 ng/ml, 34% were 10-19 ng/ml, 33% were 20-29 ng/ml, and 24% were 
30 ng/ml or higher. The mean total 25(OH)D level was 22 (10) ng/mL; mean 25(OH)D3 
level was 19 (10) while mean 25(OH)D2 was 2.6 (5.5) ng/mL. Almost one third of patients 
were on vitamin D supplementation, prior to hospitalization, and the majority of them 
continued therapy over the course of the study (median daily dose of 400 [IQR 400-800] 
IU). None of the patients were started on vitamin D supplementation during hospitaliza-
tion. All these results are presented relative to CDI severity in Table 1. When dividing the 
patients (n=100) into two groups according to CDI severity, 71% was diagnosed with a 
positive toxin assay for CDI, but with a normal abdominal CT-scan (group A), while 29% 
had an abnormal CT-scan and were assigned to group B. 
In the multivariable regression model, two factors were associated with CDI severity: 
25(OH)D3 levels (adjusted OR, 0.92; 95%CI: 0.87-0.98) and recent hospitalization (OR, 3.9; 
95%CI: 1.23-12.4) (Table 2). Stepwise regression analysis did not materially change the 
association of 25(OH)D3 with CDI severity (adjusted OR 0.93; 95%CI: 0.88-0.98). The final 
model had a power of 0.79, with an observed R2 of 0.12. We did not observe an associa-
tion of either 25(OH)D2 or total 25(OH)D with CDI severity. Further adjusting for the type 
of assay used to confirm the diagnosis of CDI did not materially change these results. 
Table 2. Multivariable regression analysis to investigate the association of 25-hydroxyvitamin D 
levels with the severity of Clostridium difficile infection.
Variable Odds Ratio 95% Confidence Interval P value
25(OH)D3 level (ng/mL) 0.92 0.87 - 0.98 0.008
Vitamin D Supplementation 1.73 0.63 – 4.79 0.29
Age 0.99 0.96 – 1.02 0.44
Deyo-Charlson Comorbidity Index 0.98 0.79 – 1.22 0.85
Recent hospitalization (within last 2 months) 3.9 1.23 - 12.4 0.02
Total n=100, 71 cases in group A (mild), vs. 29 cases in group B (severe)
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DISCUSSION
In this study, we investigated whether serum 25(OH)D levels were associated with CDI 
severity. While it has been hypothesized that vitamin D status may play an important 
role in the pathogenesis of various nosocomial infections (including C. difficile)23, 24, re-
cent evidence confirms that 25(OH)D levels may be a modifiable risk factor for CDI.19 Our 
study provides further novel information and suggests that every 1 ng/mL increase in 
25(OH)D3 was associated with an 8% decrease in risk of CDI severity. These findings sup-
port the idea that vitamin D supplementation may be an important adjuvant therapy in 
the care of patients with CDI. However, due to the observational nature of our study, our 
ability to draw causal inferences is limited. 
Over the last decade, due to multiple outbreaks and the emergence of more virulent 
C. difficile strains, there has been a renewed focus on treatment options for severe CDI.10, 
25-31 Though various factors influence virulence, the immune response to C. difficile toxins 
appears to play a major role in determining host susceptibility to CDIs.32, 33 As such, it 
has been postulated that the immunomodulatory effects of vitamin D may be an im-
portant consideration in the care of patients with CDIs.18, 24 Indeed, cells of the innate 
and adaptive immune system express the vitamin D receptor (VDR)34; higher levels of 
vitamin D have been shown to suppress adaptive immunity, but to potentiate the innate 
immune response, enabling the cells to combat infection.16, 18 Vitamin D interacts with 
macrophages and can affect the production of cytokines, as well as neutrophil motil-
ity and phagocytic function.16 The active form of vitamin D, 1,25-dihydroxyvitamin D 
[1,25(OH)2D] has been shown to activate macrophages through up-regulated expres-
sion of cathelicidin and B-defensin 2 in neutrophils, monocytes, natural killer cells, and 
epithelial cells. These antimicrobial peptides are effective against both gram-positive 
and gram-negative bacteria, fungi, and mycobacteria at a variety of sites, including the 
gastrointestinal system.15, 35 In addition, preliminary evidence suggests that vitamin 
D can interfere with the pathogenesis of CDI by attenuating the expression of NLRP3 
(which normally produces IL-1B). This helps to protect macrophages against death 
induced by C. difficile toxins A and B, and therefore may limit inflammation and colonic 
damage.36 
We focused on both 25(OH)D3 and 25(OH)D2, in addition to total 25(OH)D levels in the 
current study. Despite a significant difference in 25(OH)D2 levels between CDI severity 
groups in an unadjusted analysis (Table 1), this relationship did not persist in the final 
multivariable regression model (Table 2). Since the relationship between 25(OH)D2 and 
CDI severity is only seen when supplementation status is taken out of the model, it 
confirms that ergocalciferol (vitamin D2) supplementation is the primary driver behind 
the observed 25(OH)D2 levels. This is an important observation since recent evidence 
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vitamin D binding protein than 25(OH)D2, thereby suggesting that 25(OHD)2 may not 
be as biologically significant as 25(OH)D3. Moreover, the hydroxylation steps involved 
in processing dietary vitamin D yield distinct end-products, such that the metabolism 
of cholecalciferol (vitamin D3) results in a compound with significantly longer biological 
activity when compared to the metabolism of ergocalciferol.17, 37, 38 These are important 
considerations for future studies, especially in terms of the need to potentially measure 
both 25(OH)D2 and 25(OH)D3 in cohort studies and the choice of supplements for ran-
domized, placebo-controlled trials. 
Our study is not without potential limitations. The study was conducted at a single 
teaching hospital, where care is often provided to some of the sickest patients from 
around New England. As such, the generalizability of these patients to other hospitals 
is unclear. Since blood samples for vitamin D status assessments were drawn after the 
diagnosis of CDI, reverse causation cannot be ruled out. While vitamin D status may 
be affected by acute illness39, the majority of our samples were collected within 4 days 
after a diagnosis of CDI, which limits the degree of potential derangement from baseline 
levels. And finally, although we did attempt to control for the burden of chronic disease 
by adjusting for the Deyo-Charlson Comorbidity Index in our multivariable analysis, we 
were unable to control for other important confounders and covariates that may reflect 
the influence of overall state of health. All of these limitations will need to be addressed 
in future investigations to extend and build upon the current study. 
In summary, this study of 100 patients with a diagnosed C. difficile infection suggests 
that the 25(OH)D level is a modifiable risk factor for CDI severity. We hypothesize that 
vitamin D sufficiency is associated with optimal expression of endogenous antimicrobial 
peptides and may regulate cytokine expression to limit the inflammatory cascade as-
sociated CDIs. In turn, these may attenuate the effect of barrier site disruptions that are 
characteristic of CDIs. Further prospective studies are needed to replicate our findings, 
to assess the potential benefit of optimizing vitamin D status in patients with active 
infection or at high risk for CDIs, and to identify the mechanism by which vitamin D 
sufficiency may confer protection against CDI and other nosocomial infections. 
88 Chapter 5
REFERENCES:
 1. Lucado J GC, Elishauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. HCUP 
statistical brief no. 124. 2011.
 2. U.S. Department of Health and Human Services AfHRaQ. HCUP Projections; Clostridium Difficile 
Infection 2011 to 2012. 2012.
 3. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial 
diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346-53.
 4. Dubberke ER, Reske KA, Olsen MA, et al. Short- and long-term attributable costs of Clostridium 
difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 2008; 46(4):497-504.
 5. O’Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of clostridium difficile-
associated disease in Massachusetts hospitals: clinical and economic consequences. Infect 
Control Hosp Epidemiol 2007;28(11):1219-27.
 6. Wang L, Stewart DB. Increasing hospital costs for Clostridium difficile colitis: type of hospital mat-
ters. Surgery 2011;150(4):727-35.
 7. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infec-
tion in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the 
infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55.
 8. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330(4):257-62.
 9. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 
38(4):350-4.
 10. Ricciardi R, Rothenberger DA, Madoff RD, et al. Increasing prevalence and severity of Clostridium 
difficile colitis in hospitalized patients in the United States. Arch Surg. 2007; 142(7):624-31; discus-
sion 631.
 11. Bhangu A, Nepogodiev D, Gupta A, et al. Systematic review and meta-analysis of outcomes fol-
lowing emergency surgery for Clostridium difficile colitis. Br J Surg 2012;99(11):1501-13.
 12. Morris AM, Jobe BA, Stoney M, et al. Clostridium difficile colitis: an increasingly aggressive iatro-
genic disease? Arch Surg. 2002;137(10):1096-100.
 13. Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis: patterns of care and 
predictors of mortality. Arch Surg. 2009;144(5):433-9; discussion 439-40.
 14. Bradbury AW, Barrett S. Surgical aspects of Clostridium difficile colitis. Br J Surg 1997; 84(2):150-9.
 15. Bartley J. Vitamin D: emerging roles in infection and immunity. Expert Rev Anti Infect Ther 
2010;8(12):1359-69.
 16. Bikle DD. Vitamin D and the immune system: role in protection against bacterial infection. Curr 
Opin Nephrol Hypertens 2008;17(4):348-52.
 17. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357(3):266-81.
 18. Youssef DA, Ranasinghe T, Grant WB, et al. Vitamin D’s potential to reduce the risk of hospital-
acquired infections. Dermatoendocrinol 2012;4(2):167-75.
 19. Messinger-Rapport BJ, Morley JE, Thomas DR, et al. Intensive session: New approaches to medical 
issues in long-term care. J Am Med Dir Assoc 2007;8(7):421-33.
 20. Singh RJ, Taylor RL, Reddy GS, et al. C-3 epimers can account for a significant proportion of total 
circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpreta-
tion of vitamin D status. J Clin Endocrinol Metab 2006;91(8):3055-61.
 21. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of 








Vitamin D status and Clostridium difficile
 22. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. Journal Chronic Dis. 1987;40(5):373-83.
 23. Youssef D, Bailey B, El Abbassi A, et al. Healthcare costs of Staphylococcus aureus and Clostridium 
difficile infections in veterans: role of vitamin D deficiency. Epidemiol Infect 2010;138(9):1322-7.
 24. Youssef D, Grant WB, Peiris AN. Vitamin D deficiency: A potential risk factor for Clostridium difficile 
infection. Risk Manag Healthc Policy 2012;5:115-6.
 25. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of 
Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 
2005;353(23):2442-9.
 26. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clos-
tridium difficile. N Engl J Med. 2005;353(23):2433-41.
 27. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium dif-
ficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40(11):1591-7.
 28. Pepin J, Valiquette L, Cossette BCINCF, et al. Mortality attributable to nosocomial Clostridium 
difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 
2005; 173(9):1037-42.
 29. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium dif-
ficile associated with outbreaks of severe disease in North America and Europe. Lancet 
2005;366(9491):1079-84.
 30. Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med 2008; 359(18):1932-
40.
 31. Kuijper EJ, Coignard B, Tull P, et al. Emergence of Clostridium difficile-associated disease in North 
America and Europe. Clin Microbiol Infect 2006;12 Suppl 6:2-18.
 32. Kelly CP. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. 
difficile infection. JAMA 2009;301(9):954-62.
 33. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: new challenges from an 
established pathogen. Cleve Clin J Med 2006;73(2):187-97.
 34. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of 
innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 2008;4(2):80-90.
 35. Youssef DA, Miller CW, El-Abbassi AM, et al. Antimicrobial implications of vitamin D. Dermatoen-
docrinol 2011;3(4):220-9.
 36. Tulk S HS, MacDonald J, Beck P. Vitamin D downregulates NLRP3 and protects against Clostridium 
difficile toxin-induced cell death. CDDW Abstract 2012.
 37. Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation 
in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin 
Nutr 2012;95(6):1357-64.
 38. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J 
Clin Nutr 2006;84(4):694-7.







Successful non-operative management of the most 
severe blunt kidney injuries: a multicenter study of  
the Research Consortium Of New England Centers 
for Trauma
Gwendolyn M. van der Wilden1; George C. Velmahos1; D’Andrea K. Joseph2; Lenworth 
Jacobs2; M. George DeBusk3; Charles A. Adams3; Ronald Gross4; Barbara Burkott4; Suresh 
Agarwal5; Adrian A. Maung6; Dirk C. Johnson6; Jonathan Gates7; Edward Kelly7; Yvonne 
Michaud7; William E. Charash8; Robert J. Winchell9; Steven E. Desjardins9; Michael S. 
Rosenblatt10; Sanjay Gupta11; Miguel Gaeta12; Yuchiao Chang1; Marc A. de Moya1.
1 Massachusetts General Hospital and Harvard Medical School, Boston, MA
2 Hartford Hospital, University of Connecticut School of Medicine, Hartford, CT
3 Rhode Island Hospital and Brown University, Providence, RI
4 Baystate Medical Center, Springfield, MA
5 Boston Medical Center and Boston University, Boston, MA
6 Yale New Haven Hospital and Yale University School of Medicine, New Haven, CT
7 Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
8 University of Vermont College of Medicine, Burlington, VT
9 Maine Medical Center, Portland, ME
10 Lahey Clinic, Burlington, MA
11 Southern New Hampshire Medical Center, Nashua, NH
12 Elliot Hospital, Manchester, NH
JAMA Surg. 2013 Oct 1;148(10):924-31
94 Chapter 6
ABSTRACT
Objective: To determine the rate, causes, predictors, and consequences of failure of 
non-operative management (NOM) in grade IV and V blunt renal injuries (BRI).
Design: Retrospective case series.
Setting: Twelve Level I and II trauma centers in New England
Patients: 206 adult patients with a grade IV or V BRI who were admitted between Janu-
ary 1, 2000, and December 31, 2011. 
Main Outcome Measures: Failure of NOM, defined as the need for a delayed operation 
or death due to renal-related complications during NOM. 
Results: Fifty-two patients (25.2%) were operated on immediately and 154 (74.8%) 
were managed non-operatively (with the assistance of angiographic embolization in 25 
patients). NOM failed in 12 patients (7.8%) and was related to the kidney injury in 10 
(6.5%). None of these 10 patients suffered complications because of the delay in BRI 
management. The time from admission to failure was 17.6 ± 27.4 hours (median: 7.5; 
range 4.5-102 hours), and the cause was hemodynamic instability in 83.3% of the cases. 
Multivariate analysis identified 2 independent predictors of NOM failure: Age > 55 years 
and road traffic crash as the mechanism of injury. When both risk factors were present, 
NOM failure occurred in 27.3% of the patients; when both were absent, there were no 
NOM failures. Among patients successfully managed by NOM, 46 (32.4%) developed 
renal-related complications, including hematuria (24), urinoma (15), urinary tract infec-
tion (8), renal failure (7), and abscess (2). These were managed successfully with no loss 
of renal units. The renal salvage rate was 76.2% for the entire population, and 90.3% 
among patients selected for NOM. 
Conclusions: Hemodynamically stable patients with grade IV and V BRI were safely 
managed by NOM. Only 6.5% failed NOM due to renal-related injuries and three fourths 
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INTRODUCTION
Up to 10% of patients with blunt abdominal trauma have renal injuries.1 Over the last 
few decades non-operative management (NOM) has become increasingly popular, es-
pecially for low-grade (I-III) blunt renal injuries (BRI). The published evidence is unclear 
about the role of NOM for higher grades (IV and V). In short, grade IV injuries indicate 
lacerations which extend to the renal pelvis and grade V injuries indicate a shattered 
kidney or renal artery injuries with parenchymal devascularization. Santucci et al2 
showed in a meta-analysis of 16 studies that approximately 90% of grade IV BRI could 
be managed without an operation. Even for grade V injuries there is evidence that NOM 
can be successful.3-6 Because grade IV and V injuries are uncommon, most of these stud-
ies lack an appropriate sample size to uncover statistical significances and make valid 
recommendations. 
The Research Consortium of New England Centers for Trauma (ReCONECT) includes 
level 1 and 2 trauma centers in the region and has produced, so far, four studies.7-10 In 
particular it has evaluated injuries of low prevalence, which can only be analyzed by a 
multicenter collaboration. The objective of the current study is to determine the rate 
and predictors of failure of NOM in patients with severe blunt renal injuries. We hypoth-
esize that such injuries can be safely managed without an operation, but that the rate 
of complications, following operative and non-operative management of BRI, and the 
need for subsequent interventions is high.
METHODS
Patients
This is a retrospective case series including all adult patients with a grade IV or V BRI, 
who were admitted from January 1, 2000, to December 31, 2011, in twelve New Eng-
land trauma centers. Renal injuries were graded based on computed tomography (CT) 
findings and according to the American Association for the Surgery of Trauma Organ 
Injury Scale (Table 1).11 Ten centers were verified by the American College of Surgeons 
Committee on Trauma as Level I (9 centers) or II (1 center) trauma centers; two additional 
centers were accredited as Level II trauma centers by their state but not the American 
College of Surgeons. Exclusion criteria were: age < 15 years, an urgent operation in an 
outside hospital, and death before or on arrival at the receiving hospital.
Definitions
The patients were divided into those who received an immediate operation (IO) and 
those managed by NOM. Hemodynamic instability and peritonitis were indications for 
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IO. Patients were included in the NOM group if there was a clear note in the record to 
that effect or an operation was booked more than 3 hours after the diagnosis of BRI. 
The decision to use the cutoff point of 3 hours in order to define NOM has been used in 
previous ReCONECT studies.8,10 Because the decision-making about an operation versus 
NOM was not always clear from the review of the medical records, we were obliged to 
make some arbitrary assumptions. Based on the infrastructure of our trauma centers, we 
believe that longer than 3 hour-intervals, between the diagnosis of BRI and the booking 
of an operation, indicated that the patient was initially managed by NOM. It would be 
extremely unlikely that a decision for IO was made after 3 hours from diagnosis. On 
the other hand it is possible that shorter periods of NOM (e.g. 2 hours) were labeled 
as IO in this study. Failure of NOM (f-NOM) was defined as the need for surgery after a 
trial of NOM or as death due to renal-related complications during NOM; if none of this 
happened, NOM was considered successful (s-NOM).
Data and Outcomes
The following data were collected: demographics, mechanism of injury (road traffic 
crash, fall, assault, or other), associated injuries, admission hemodynamics, Injury Sever-
ity Score (ISS), computed tomography (CT) findings, renal injury grade (IV or V), presence 
of free abdominal blood on CT (recorded as diffuse or confined around the kidney), type 
of management (NOM or IO), indication for operative intervention, operative proce-
dures, operative findings, any other interventions required, intensive care unit (ICU) and 
hospital stay, morbidity, and mortality. 
Table 1. Grading of Kidney Injury According to the American Association for the Surgery of Trauma 
Organ Injury Scale11
Grade* Type of injury Description of injury AIS-90
I Contusion Microscopic or gross hematuria, urologic studies normal 2
Hematoma Subcapsular, nonexpanding without parenchymal laceration 2
II Hematoma Nonexpanding perirenal hematoma confirmed to renal 
retroperitoneum
2
Laceration <1.0 cm parenchymal depth of renal cortex without urinary 
extravasation
2
III Laceration <1.0 cm parenchymal depth of renal cortex without collecting 
system rupture or urinary extravasation
3
IV Laceration Parenchymal laceration extending through renal cortex, 
medulla, and collecting system
4
Vascular Main renal artery or vein injury with contained hemorrhage 4
V Laceration Completely shattered kidney 5
Vascular Avulsion of renal hilum which devascularizes kidney 5
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The primary outcome was f-NOM, classified as renal-specific and non-renal-specific 
according to the reason for which the patient failed NOM. The secondary outcome was 
complications of NOM and the interventions required to treat those complications. 
Statistical Analysis
Patients with IO were compared to those with NOM. Additionally; f-NOM and s-NOM 
patients were compared. We dichotomized certain continuous variables across clini-
cally meaningful values: Age was dichotomized at 55 years; Injury Severity Score at 25; 
systolic blood pressure at 100 mmHg; heart rate at 100 beats per minute; and hematocrit 
level at 30%. Continuous variables were summarized using mean values with standard 
deviations (SD) and compared using two-sample t-tests, or summarized using median 
values with interquartiles and compared using Wilcoxon rank sum tests. Categorical 
variables (reported as counts and proportions) were compared using chi-square test or 
Fisher’s exact test. Logistic regression was performed to identify independent predictors 
of f-NOM. Odds ratios and 95% confidence intervals were reported for each predictor. 
The incidence of f-NOM based on different combinations of independent predictors 
of f-NOM was examined. P ≤ .05 indicated statistical significance. SAS version 9.2 (SAS 
Institute, Cary NC) was used for the entire analysis. The study was approved by the Insti-
tutional Review Boards of all participating hospitals.
RESULTS
In total, 206 patients were identified, 154 (74.8%) with grade IV and 52 (25.2%) with 
grade V BRI. Of those, 52 (25.2%) were managed by IO and 154 (74.8%) by NOM. 
The mean age of the population was 36.2 + 18.3 years (median: 30 years; range: 15-90), 
with 84% being under the age of 55. Seventy-five percent were male, with a mean Injury 
Severity Score of 25.7 + 13.1 (median: 24; range 4-75). Sixty-four percent of all injuries 
were caused by road traffic crashes. Other injuries besides the BRI were found in 164 
(79.6%) patients, including splenic injuries in 62 (30.1%), liver injuries in 57 (27.7%), and 
other abdominal injuries in 29 (14.1%). 
Among the 160 patients (77.7%) who required intensive care, the average ICU stay 
was 8 + 17.8 days (median: 2.5; range: 0-204 days). The average hospital stay for the 
entire population was 15.7 + 23.6 days (median: 8; range: 1-210 days). Overall, 17 pa-
tients (8.3%) died; 3 (1.4%) deaths were related to the kidney injury. The renal unit was 
preserved in 157 (76.2%) patients, including 18 of 52 IO patients (34.6%), 135 of 142 
s-NOM patients (95.1%), and 4 of 12 f-NOM patients (33.3%). 
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NOM vs. IO
Of the 52 IO patients, 34 renal units were lost. Thirty (57.7%) were subjected to nephrec-
tomy and one (1.9%) to a partial nephrectomy. Of the remaining four patients three died 
within 24 hours after admission and one patient had a non-perfused kidney for eight 
hours due to a prolonged transfer from another hospital; a damage control operation 
was performed and the kidney was left in situ.
Of the 154 NOM patients, 33 (21.4%) received angiography during the acute stage, 
25 (16.2%) proceeded to angiographic embolization for bleeding control, and 2 (1.2%) 
required repeat embolization. Additionally, 13 patients (8.4%) received a ureteral stent 
early after the injury. 
As expected, there were multiple differences in injury characteristics and physiologic 
stability between IO and NOM patients (Table 2). Morbidity and mortality were higher in 
IO patients and ICU and hospital stays were longer. There were 4 independent predictors 
of IO: ISS (OR: 1.06; 95% CI: 1.03-1.09), the presence of diffuse intra-peritoneal blood (OR: 
5.86; 95% CI: 2.38-14.41), active vascular extravasation on CT (OR: 3.45; 95% CI: 1.45-
8.15), and associated abdominal injuries (OR: 8.73; 95% CI: 2.97-25.67).
s-NOM vs. f-NOM
Failure of NOM was detected in 12 of 154 NOM patients (7.8%), without a difference in 
failure rates between grade IV (7.6%) and V (7.8%) patients. Ten of 12 f-NOM patients 
failed due to renal-related reasons (renal-related failure rate: 6.5%). The two remaining 
patients failed NOM due to their liver injuries. Operative intervention took place at 17.6 + 
27.4 hours after admission (median: 7.5; range: 4.5-102 hours). Hemodynamic instability 
was the indication for operation in 10 of 12 f-NOM patients (83.3%); one patient received 
an operation because of peritonitis and one more because of abdominal compartment 
syndrome. Eight patients were subjected to a nephrectomy, one to a partial nephrec-
tomy, and one to renal repair. The remaining 2 patients had no renal procedures; one 
had a decompressive laparotomy and the other received a liver resection and cholecys-
tectomy. One patient (8.3%) died 2 days after operative intervention due to multisystem 
organ failure. This patient failed NOM after 7 hours and received a nephrectomy and 
adrenalectomy.
Patients with f-NOM were older, had active extravasation on CT more frequently, and 
had a higher rate of general complications (Table 3). Their hospital and ICU stays were 
longer. Two independent predictors of f-NOM were identified: Age ≥ 55 years (OR: 5.99; 
95% CI: 1.58-22.61) and road traffic crash as the mechanism of injury (OR: 5.62; 95% 
CI: 1.09-28.86). When both risk factors were present, f-NOM occurred in 27.3% of the 
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Table 2.  Comparison between patients who received an Immediate Operation (IO) and those 
offered a trial of Non-operative Management (NOM)
Characteristic IO (n=52) NOM (n=154) P Value
Age, y, mean (SD) 36.3 (16.2) 36.2 (19.1) 0.97
Male sex, No. (%) 39 (75) 115 (74.7) 0.96
Type of injury, No. (%) 0.053
Motor vehicle crash 41 (78.9) 90 (58.4)
Fall 8 (15.4) 36 (23.4)
Assault 1 (1.9) 10 (6.5)
Other 2 (3.8) 18 (11.7)
Injury Severity Score, mean (SD) 34.3 (16.9) 22.8 (10.1) <0.0001
Systolic blood pressure on admission, mmHg, mean (SD) 105.1 (31.2) 120.8 (25.3) 0.002
Heart rate on admission, beats/min, mean (SD) 107.4 (24.7) 89 (21.5) <0.0001
Hematocrit on admission, %, mean (SD) 33.1 (7.4) 36.5 (6.3) 0.004
Hemoglobin on admission, gm/dl, mean (SD) 11.3 (2.3) 13 (3.6) 0.0003
Glasgow Coma Scale Score, mean (SD) 10.6 (5.4) 13.4 (3.6) 0.0009
Associated injuries, No. (%) 49 (94.2) 115 (74.7) 0.002
Liver injury, No. (%) 19 (36.5) 38 (24.7) 0.098
Splenic injury, No. (%) 26 (50) 36 (23.4) 0.0003
Other abdominal injuries, No. (%) 16 (30.8) 13 (8.4) <0.0001
CT grade of renal injury, No. (%) <0.0001
4 26 (50) 128 (83.1)
5 26 (50) 26 (16.9)
Presence of free abdominal blood on CT, No. (%) <0.0001
Diffuse 29 (55.8) 34 (22.1)
Confined around kidney 17 (32.7) 113 (73.4)
Unknown 6 (11.5) 7 (4.5)
Active extravasation, No. (%) 25 (48.1) 44 (28.6) <0.0001
Urinary extravasation, No. (%) 13 (25) 47 (30.5) 0.015
Morbidity, kidney-related, No. (%) 12 (23.1) 49 (31.8) 0.23
Morbidity, general, No. (%) 23 (44.2) 26 (16.9) <0.0001
Mortality, No. (%) 12 (23.1) 5 (3.2) <0.0001
Hospital length of stay, days, mean (SD) 23.4 (32.5) 13.1 (19.2) 0.004
Intensive Care Unit length of stay , days, mean (SD) 13.8 (17.2) 6.1 (17.6) 0.0004
Hospital length of stay in survivors, days, mean (SD) 28.2 (35.2) 11.9 (11.4) <0.0001
Intensive Care Unit length of stay, in survivors, days, mean (SD) 16.2 (18) 4.8 (7.3) <0.0001
Abbreviations: SD, standard deviation; CT, computed tomography.
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Table 3. Comparison between patients with successful (s-NOM) and failed non-operative 
management (f-NOM)
Characteristic s-NOM (n=142) f-NOM (n=12) P Value
Age, y, mean (SD) 35.2 (18.3) 47.6 (24.7) 0.11
Age ≥ 55 y, No. (%) 21 (14.8) 5 (41.7) 0.017
Male sex, No. (%) 107 (75.4) 8 (66.7) 0.51
Type of injury, No. (%) 0.26
Motor vehicle crash 80 (56.3) 10 (83.3)
Fall 34 (23.9) 2 (16.7)
Assault 10 (7) -
Other 18 (12.7) -
Injury Severity Score, mean (SD) 22.6 (10.3) 25.5 (7.8) 0.25
Injury Severity Score > 25, No. (%) 51 (35.9) 5 (41.7) 0.69
Systolic blood pressure on admission, mmHg, mean (SD) 121.4 (25.2) 114.3 (26.9) 0.39
Systolic blood pressure on admission, ≤ 100 mmHg, No. (%) 26 (18.3) 4 (33.3) 0.21
Heart rate on admission, beats/min, mean (SD) 89.3 (21.3) 84.9 (25.3) 0.57
Heart rate on admission > 100 beats/min, No. (%) 41 (28.9) 2 (16.7) 0.37
Hematocrit on admission, mean (SD) 36.6 (6.3) 35.4 (5.5) 0.51
Hematocrit level on admission ≤ 30%, No. (%) 22 (15.5) 1 (8.3) 0.5
Hemoglobin on admission, gm/dl, mean (SD) 13.1 (3.6) 11.8 (2.7) 0.36
Glascow Coma Scale Score, mean (SD) 13.5 (3.5) 12.3 (4.9) 0.39
Associated injuries, No. (%) 104 (73.2) 11 (91.7) 0.16
Liver injury, No. (%) 34 (23.9) 4 (33.3) 0.47
Splenic injury, No. (%) 32 (22.5) 4 (33.3) 0.4
Other abdominal injuries, No. (%) 11 (7.7) 2 (16.7) 0.29
CT grade of renal injury, No. (%) 0.98
4 118 (83.1) 10 (83.3)
5 24 (16.9) 2 (16.7)
Presence of free abdominal blood on CT, No. (%) 0.097
Diffuse 31 (21.8) 3 (25)
Confined around kidney 106 (74.6) 7 (58.3)
Unknown 5 (3.5) 2 (16.7)
Active extravasation, No. (%) 39 (27.5) 5 (41.7) 0.001
Urinary extravasation, No. (%) 44 (31) 3 (25) 0.078
Morbidity, kidney-related, No. (%) 46 (32.4) 3 (25) 0.6
Morbidity, general, No. (%) 20 (14.1) 6 (50) 0.001
Mortality, No. (%) 4 (2.8) 1 (8.3) 0.3
Hospital length of stay, days, mean (SD) 12.5 (19.4) 20.1 (15.4) 0.058
Intensive Care Unit length of stay , days, mean (SD) 5.8 (18.1) 10 (9.8) 0.008
Hospital length of stay in survivors, days, mean (SD) 11.1 (10.8) 21.6 (15.2) 0.014
Intensive Care Unit length of stay, in survivors, days, mean (SD) 4.4 (6.9) 10.6 (10) 0.007
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Complications
Renal-related complications developed in 12 IO patients (23.1%) compared to 49 NOM 
patients (31.8%, p = 0.23) (Table 2). Persistent or recurrent hematuria was the most com-
mon complication and occurred in 26 patients (12.6%), including 1 IO patient (1.9%) 
and 25 NOM (16.2%) patients (Table 4). In the majority of patients the hematuria was 
self-limited but 5 (19.2%) required angiographic embolization. The second most com-
mon complication was urinoma. It developed in 21 patients (10.2%) of who 5 received 
IO (9.6%) and 16 received NOM (10.3%). The IO patients were managed with a ureteral 
stent (3) or a percutaneous nephrostomy (2), whereas the NOM patients had a stent (8), 
percutaneous nephrostomy (2), or no intervention (6). Thirteen patients (6.3%) with a 
urinary tract infection were managed with antibiotics. A perirenal abscess was identified 
in 3 patients (1.4%) and drained percutaneously. Renal dialysis was required in 3 pa-
tients (1.4%); an additional 7 patients had transient serum creatinine elevations, which 
returned to normal in all patients. Of other general complications, pneumonia and deep 
venous thrombosis were the most frequent. 
Follow-up
Eighty-two (39.8%) patients returned for a clinic visit, 15 IO (28.8% of all IO) and 67 NOM 
(43.5% of all NOM) patients. Four NOM patients were reported with persistent hematuria 
upon follow-up, while one patient remained to have a poor function of the kidney due 
to hydronephrosis. An additional patient was hypertensive after a partial infarction of 
the kidney. None of the IO patients that were seen in the clinic had long-term sequelae. 
Of them 7 IO and 40 NOM patients had a repeat CT scan and only 2 (both NOM) had a 
small urinoma. No action was taken on any of these patients, based on the repeat CT 
scan.










Urinoma, No. (%) 5 (9.6) 16 (10.4) 15 (10.6) 1 (8.3)
Persistent hematuria, No. (%) 1 (1.9) 25 (16.2) 24 (16.9) 1 (8.3)
Local abscess, No. (%) 1 (1.9) 2 (1.3) 2 (1.4) 0
Urine tract infection, No. (%) 4 (7.7) 9 (5.8) 8 (5.6) 1 (8.3)
Renal failure, No. (%) 2 (3.8) 7 (4.5) 7 (4.9) 0
Other renal-related complications, No. (%) 3 (5.8) 5 (3.2) 5 (3.5) 0
General complications, No. (%) 23 (44.2) 26 (16.9) 20 (14.1) 6 (50)
Pneumonia 13 7 5 2
Deep venous thrombosis 4 6 5 1
Wound infection 3 0 0 0
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DISCUSSION
NOM has become the preferred way of managing BRI, even for high-grade injuries. 2, 3, 
12-24 Of 206 grade IV and V BRI patients, analyzed in our multicenter study, 74.8% were 
offered NOM, which was successful in over 92%. The failure related to the BRI was 6.5%. 
These findings agree in general with the existing literature evidence, consisting typically 
of limited cases series, often with disparate results. Altman et al3 managed 13 patients 
with grade V BRI, offering NOM successfully to six patients. All of them had functioning 
renal parenchyma upon repeat CT. Buckley and McAnninch25 reported successful NOM 
in one third of patients with grade IV blunt and penetrating renal injuries; none of them 
required a delayed nephrectomy. Shariat et al26 used NOM without failures in 80% of 
51 patients with grade IV BRI. In a systematic review of the literature Umbreit et al27 
examined 95 children with grade IV BRI. No intervention was possible in 72% and partial 
renal preservation in 95%. In contrast to that, Rogers et al28 reported on 10 children 
with grade IV and 10 with grade V BRI. While 80% of the grade IV injuries were managed 
successfully by NOM, all grade V injuries required IO and only 30% achieved long-term 
preservation of renal function. In our study, among patients who received an IO, 34.6% 
had a renal-salvage procedure (defined as a functioning renal unit of 50% or more25). Of 
NOM patients, 90.3% preserved the renal function of the injured kidney; the rate was 
95.1% among s-NOM patients.
Angiographic embolization has been a valuable adjunct of NOM and was used in 
16.2% of our NOM patients with a 92% initial success rate for bleeding control and 100% 
after a repeat attempt. Similarly, Hagiwara et al17 has shown excellent bleeding control 
in 7 of 8 patients with high-grade BRI and active extravasation. The effectiveness of an-
giographic embolization was lower in a study of 22 BRI patients by Menaker et al16, who 
experienced 7 failures (27%). Similarly, Hotaling et al31 analyzed the National Trauma 
Data Bank® and reported that 29% of patients with angiographic embolization required 
a repeat embolization. 
Multiple predictors of f-NOM have been identified in the literature, most of them ex-
pressing common sense. Toutouzas et al12 found ISS, fluid and blood requirements, and 
diagnostic findings to be predictive of f-NOM. Associated abdominal injuries, age, ISS, 
ongoing blood transfusions, and worsening acidosis are additional predictors of f-NOM 
in other studies.2, 5, 19, 25, 32 Age ≥ 55 years and road traffic crash as the mechanism of injury 
were the two independent predictors in our study and they both increased the odds of 
f-NOM by nearly 6-fold. Although an older age does not come as a surprise, the specific 
mechanism of injury requires further exploration. In a study by Kuan et al33, reporting on 
115 BRI patients from the Crash Injury Research and Engineering Network, 36 patients 
were found to have grade III-V injuries. In frontal collisions the seatbelt was deemed 
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causative factors in lateral collisions. It may, therefore, be true that road traffic crashes 
with or without seatbelts predispose patients to BRI more than other mechanisms of 
injury. 
The complications following high-grade BRI are significant34 even when the patients 
are managed by NOM. Starnes13 showed that the incidence of complications in severe 
BRI (Grades III-V) were similar between patients who underwent renal exploration (7.3%) 
or NOM (7.9%). Nephrorrhaphy was associated with the highest rate of complications. 
Similarly, Shariat et al26 showed non-significantly different rates of complications be-
tween NOM (28%) and IO patients (13%) with grade IV BRI. Obviously, these results may 
be misleading since renal-related complications are harder to develop after nephrec-
tomy, and one could argue that the ultimate complication is the loss of the kidney. In 
our study persistent hematuria and urinomas were the most frequent complications. An 
intervention was required in 19.2% of patients with persistent hematuria (angiographic 
embolization) and 71.4% of patients with urinoma (ureteral stenting, percutaneous 
nephrostomy, and percutaneous drainage of collection). 
Long-term follow-up is the Achilles heel of every trauma study. We only had data on 
39.8% of patients who returned to follow-up and on even fewer who had repeat CT 
scans. The study was not designed to address the speed of the healing process of high-
grade BRI nor the common questions of return to work or athletic activities. We could not 
comment on long-term sequelae in this population, such as nephrogenic hypertension. 
Other limitations of this retrospective review included the lack of standardized proto-
cols across all participating centers for the management of BRI, resulting in significantly 
different practices. Analyzing these differences made no statistical sense because the 
number per center became prohibitively low. Finally, as it happens in such unfunded, 
multicenter collaborations, we compromised certain fields in order to improve partici-
pation. Not all desirable details were requested because the primary intent was to allow 
centers to collect data without an unreasonable effort. 
Despite the above limitations, this study presents the highest number of grade IV and 
V BRI to date. NOM was safely applied without risking unnecessary renal unit loss or 
disastrous complications. Almost three fourths of the population was offered NOM, with 
an f-NOM rate of less than 8% and similar between grade IV and V injuries. Two indepen-
dent predictors of f-NOM were detected: an age greater than 55 years and road traffic 
crash; if both predictors were absent, there was a 100% success rate of NOM. Renal-
related complications were significant, primarily in the form of hematuria or urinoma, 
but successfully managed by additional interventions. At the end, 76.2% of patients with 
a grade IV or V BRI (and 90.3% of those treated by NOM) preserved renal function of the 
injured renal unit. Appropriate patients with these most severe kidney injuries can be 
confidently managed by NOM.
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ABSTRACT
Objective: To determine the rate and predictors of failure of non-operative manage-
ment (NOM) in grade IV and V blunt liver injury (BLI).
Design: Retrospective case series.
Setting: Eleven Level I and II trauma centers in New England.
Patients: Three hundred and ninety-three adult patients with a grade IV or V BLI who 
were admitted between January 1, 2000, and January 31, 2010. 
Main Outcome Measures: Failure of NOM (f-NOM), defined as the need for a delayed 
operation. 
Results: A total of 131 (33%) patients were operated on immediately, typically because 
of hemodynamic instability. Of the remaining 262 (67%) patients who were offered a 
trial of NOM, treatment failed in 23 patients (9%) but only in 17 (6%) because of the 
liver (ongoing bleeding in 7, biliary peritonitis in 10). Multivariate analysis identified 2 
independent predictors of f-NOM: Systolic blood pressure on admission ≤ 100 mmHg 
and other abdominal organ injury. f-NOM was observed in 23% of the patients with both 
independent predictors and in 4% of those with none of the two predictors. None of the 
f-NOM patients suffered life-threatening events because of f-NOM, and the mortality 
rate was similar between successful NOM (5%) and f-NOM patients (9%, p = 0.52). Of the 
patients with successful NOM, liver-specific complications developed in 10% and were 
managed definitively without major sequelae. 
Conclusions: NOM was offered safely in two thirds of grade IV and V BLI with a 91% suc-
cess rate. Only 6% of NOM patients required a delayed operation because of liver-related 
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INTRODUCTION
Over the last decades non-operative management (NOM) of blunt liver injuries (BLI) 
has become the standard of care for hemodynamically stable patients, who account for 
approximately 85% of all those with blunt hepatic trauma1-5. With increasing experience, 
even severe BLI have been managed by NOM. The splenic paradigm has shown that the 
literature offered an overenthusiastic picture about NOM success across all grades. Be-
cause the few high-grade splenic injuries were often diluted within the many low-grade 
injuries, the overall high success rates of NOM were misleadingly perceived as applicable 
to all grades6. A multi-center study from our ReCONECT (Research Consortium of New 
England Centers for Trauma) group in 2010 showed that 38% of non-operatively man-
aged grade IV and V splenic injuries eventually failed NOM. It also documented that 64% 
of all high-grade injuries required splenectomy either emergently or after failed NOM7. 
Anecdotal experience shows that severe BLI are more hemostatic than severe splenic 
injuries. In a study of 206 patients, the successful NOM to the liver was 17% higher than 
the successful NOM to the spleen2. The only study referring exclusively to high-grade 
liver injuries reports successful NOM in 41% of the patients but is limited by the low 
number of grade V injuries (only 10% of the entire population) 8. 
The ReCONECT group has combined the collective experience of multiple trauma 
centers in order to increase the sample size on injuries of low frequency 9,10. The objec-
tive of the current study is to determine the rate and predictors of failure of NOM in 




We retrospectively included all adult patients with a grade IV or V BLI, who were admitted 
from January 1, 2000, to January 31, 2010, in eleven New England trauma centers. Grad-
ing was based on computed tomographic (CT) findings and according to the American 
Association for the Surgery of Trauma Organ Injury Scale11 (Table 1). For patients who 
were taken to the operating room and given a different intraoperative grade than CT’s, we 
recorded the intraoperative grade. All centers are verified by the American College of Sur-
geons Committee on Trauma as level I (9 centers) or II (2 centers) trauma centers. Patients 
under the age of 15, patients who received an urgent operation in an outside hospital, 
and patients who were already dead at the scene or on arrival were excluded. Similarly, 
patients with a grade VI injury (liver avulsion) were not included, since such patients rarely 
arrive at the hospital alive, and if they do, they usually die within a few hours. 
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Definitions
Patients were categorized as receiving NOM or an immediate operation (IO). Hemody-
namic instability and signs of peritonitis were indications for IO. NOM was defined by 
either a clear note in the medical record committing the patient to NOM or by the fact 
that an operation was booked later than 3 hours from the diagnosis of BLI. The decision 
to use 3 hours as the threshold of NOM definition was selected by consensus, based on 
the infrastructure of the participating centers, which typically allowed for expeditious 
transfer to the operating room. We also wanted to account for patients with complex 
multiple trauma who spent an initial period of active resuscitation and diagnostic evalu-
ation before a final decision was made about IO versus NOM. 
Failure of NOM (f-NOM) was defined as the need for surgery after a trial of NOM or as 
death due to BLI while the patient was managed non-operatively. NOM was considered 
successful (s-NOM), if the patient did not receive an abdominal operation during the 
index hospital stay nor did he/she succumb to the liver injury. 
Data and Outcomes
We collected data on demographics, mechanism of blunt trauma (motor vehicle-related 
crash, fall, assault or other), associated injuries, admission hemodynamics, Injury Sever-
ity Score (ISS), liver injury grade (IV or V), CT findings, presence of free abdominal blood 
on CT (recorded as diffuse or only around the liver), type of management (NOM or IO), 
indication for operative intervention, operative procedure, operative findings, intensive 
Table 1. Grading of Liver Injury According to the American Association for the Surgery of Trauma 
Organ Injury Scale11 
Grade* Type of injury Description of injury AIS-90
I Hematoma Subcapsular, <10% surface area 2
Laceration Capsular tear, <1 cm parenchymal depth 2
II Hematoma Subcapsular, 10% to 50% surface area 2
Laceration Capsular tear, 1-3 cm parenchymal depth, <10 cm in length 2
III Hematoma Subcapsular, >50% surface area of ruptured subcapsular or 
parenchymal hematoma; intraparenchymal hematoma >10 cm 
or expanding
3
Laceration >3 cm parenchymal depth 3
IV Laceration Parenchymal disruption involving 25% to 75% hepatic lobe or 
1-3 Couinaud’s segments
4
V Laceration Parenchymal disruption involving >75% of hepatic lobe or >3 
Couinaud’s segments within a single lobe
5
Vascular Juxtahepatic venous injuries; ie, retrohepatic vena cava/central 
major hepatic veins
5
VI Vascular Hepatic avulsion 6
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care unit (ICU) and hospital stay, morbidity, and mortality. The outcome measure was 
f-NOM. It was further classified as liver-specific f-NOM, indicating that the operation was 
performed to treat bleeding, leak, or infection from the liver injury, or non-liver-specific 
f-NOM, indicating an operation for other intra-abdominal injuries (e.g. bleeding from 
the spleen).
Statistical Analysis
Patients who received NOM or IO were compared. Additionally, f-NOM patients were 
compared with s-NOM patients. Selected continuous variables were dichotomized 
across clinically meaningful values: Age was dichotomized at 55 years; Injury Severity 
Score at 25; systolic blood pressure at 100 mmHg; heart rate at 100 beats per minute; 
and hematocrit at 30%. Continuous variables were summarized using mean values with 
standard deviations (SD) and compared using two-sample t-tests, or summarized using 
median values with interquartiles and compared using Wilcoxon rank sum tests. Cat-
egorical variables (reported as counts and proportions) were compared using chi-square 
test or Fisher’s exact test. Logistic regression was performed to identify independent 
predictors of f-NOM significant at the .05 level. Odds ratios and 95% confidence intervals 
were reported for each predictor. The incidence of f-NOM based on different combina-
tions of independent predictors of f-NOM was examined. P ≤ .05 indicated statistical 
significance. SAS version 9.2 (SAS Institute, Cary NC) was used for the entire analysis. 
The study was approved by the institutional review boards of all participating hospitals.
RESULTS
During the study period of 10 years, 393 patients with grade IV and V BLI were included 
in the 11 ReCONECT hospitals that participated in this study. An immediate operation 
(IO) was performed in 131 (33%) patients, while 262 (67%) patients were managed non-
operatively. Of the 131 patients, 105 (80%) received damage control operations with 
packing of the liver.
The mean age of the population was 33 + 16 years (median: 28 years; range: 15-95 
years) and Injury Severity Score was 32 + 14 (median: 29; range: 4-75). Fifty-four percent 
were males, 44% had other intra-abdominal organ injuries, 14% had a brain injury, and 
32% had major fractures. The average ICU stay for the 324 patients who required critical 
care was 9 + 17 days (median: 3 days; range: 0-164 days) and average hospital stay of 
the total population was 16 + 22 days (median: 8 days; range: 1-204 days). Mortality was 
21% (84 patients), including 60 patients who died within 24 hours, 11 patients who died 
between the second and seventh day, and 13 patients who died later. 
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NOM vs. IO
Except for age, heart rate on admission, the presence of major fractures, and other extra-
abdominal injuries, all recorded variables were significantly different between IO and 
NOM patients. Not surprisingly, morbidity and mortality were higher in IO patients. ICU 
and hospital stays were similar between the two groups when all patients were evalu-
ated but were longer in IO patients when only survivors were analyzed (Table 2). 
s-NOM vs. f-NOM
NOM failed in 23 of 262 patients (9%) The rate of failure was 8% among grade IV and 
14% among grade V patients (p=0.28). Patients with f-NOM had a lower blood pressure 
on admission; higher rates of associated abdominal organ injuries, hepatic angiography, 
and morbidity; and a longer ICU and hospital length of stay (Table 3). Of the 23 f-NOM 
patients, 17 failed because of liver-related reasons (7 due to recurrent liver bleeding and 
10 due to biliary peritonitis). Of the 7 with recurrent bleeding, 5 received packing of the 
liver and 2 had non-anatomical resections. The remaining 6 f-NOM patients had non-
liver related issues (small bowel injury in 3 patients, colon injury in 1, duodenal injury in 
1, and gallbladder necrosis in 1). Therefore, the liver-related f-NOM was 6%. 
The 17 patients with liver-related f-NOM received their operations at an average of 6 
(7) days (range: 0-26 days) after admission, 2 (2) days (range 0-17 days) for those who 
had liver bleeding and 9 (8) days (range: 1-26 days) for those with biliary peritonitis. All 
but 2 of the 7 f-NOM patients who required an operation for liver bleeding, received an 
exploratory laparotomy within 24 hours of admission. No liver-related morbidity was 
recorded as a direct consequence of f-NOM and none of these patients died. 
Two independent predictors of failure of NOM were identified: systolic blood pres-
sure ≤ 100 mmHg on admission and the presence of associated abdominal organ injury 
(Table 4). If both independent risk factors were present, 23% had f-NOM, as opposed to 
11% if 1 factor was present, and 3.5% if none was present. The negative predictive value 
of the absence of both risk factors for f-NOM was 96%. 
Interventions
Of 262 NOM patients 94 patients (36%) received hepatic angiography and 65 (25%) were 
embolized. Among the 239 s-NOM patients, 79 (33%) received angiography and 55 were 
embolized (23%). Three of these 55 patients (5%) developed recurrent bleeding which 
was controlled by re-embolization in 2 and ceased spontaneously in 1. Of the 7 patients 
who failed NOM due to ongoing bleeding, 5 had angiography and 4 of were embolized 
before the operation. The success rate of embolization (including repeat embolization) 
was 93% (55 of 59).
Endoscopic retrograde cholangiopancreatography (ERCP) was performed in 16 NOM 
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ERCP after IO. Percutaneous drainage for abdominal collections was performed in 14 
NOM and 6 IO patients. 
In the end, 39% of the total study population (154 of 393) received an operation, in-
cluding 131 IO and 23 f-NOM patients. Of them 64% had grade IV and 36% had grade V 
BLI. Two f-NOM patients had laparoscopy, 1 for biliary peritonitis and 1 for a small bowel 
injury; all other patients received an exploratory laparotomy.
Table 2.  Comparison between patients who received an Immediate Operation (IO) and those 
offered a trial of Non-operative Management (NOM)
Characteristic IO (n=131) NOM (n=262) P Value
Age, y, mean (SD) 33 (15) 33 (17) 0.88
Male sex, No. (%) 86 (66) 125 (48) 0.003
Type of injury, No. (%) 0.021
Motor vehicle crash 108 (82) 213 (81)
Fall 6 (5) 26 (10)
Assault 7 (5) 2 (1)
Other 10 (8) 20 (8)
Injury Severity Score, mean (SD) 41 (15) 27 (11) < 0.0001
Systolic blood pressure on admission, mmHg, mean (SD) 102 (32) 122 (25) < 0.0001
Heart rate on admission, beats/min, mean (SD) 103 (33) 97 (21) 0.087
Hematocrit on admission, %, mean (SD) 31 (7) 37 (26) 0.0003
Glascow Coma Scale, mean (SD) 8 (6) 13 (4) < 0.0001
Brain injury, No. (%) 27 (21) 28 (11) 0.008
Major fracture, No. (%) 43 (33) 82 (31) 0.76
Other abdominal organ injury, No. (%) 45 (34) 127 (48) 0.008
Other extra-abdominal injury, No. (%) 103 (79) 216 (82) 0.36
CT grade of liver injury, No. (%) < 0.0001
4 79 (60) 234 (89)
5 52 (40) 28 (11)
Contrast extravasation on CT (n=228), No. (%) 28 (21) 70 (27) 0.0001
Free blood on CT, No. (%) < 0.0001
No Blood / Perihepatic 77 (59) 79 (30)
Diffuse 54 (41) 183 (70)
Morbidity, No. (%) 112 (85) 114 (44) < 0.0001
Mortality, No. (%) 69 (53) 15 (6) < 0.0001
Hospital stay, d, mean (SD) 17 (24) 16 (21) 0.62
ICU stay, d, mean (SD) 5 (9 24 (25) 0.30
Hospital stay in survivors, d, mean (SD) 33 (26) 14 (16) < 0.0001
ICU stay, in survivors, d, mean (SD) 20 (19) 7 (12) < 0.0001
Abbreviations: SD, standard deviation; CT, computed tomography; ICU, intensive care unit.
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Table 3. Comparison between patients with successful (s-NOM) and failed non-operative 
management failed (f-NOM)
Characteristic s-NOM (n=239) f-NOM (n=23) P Value
Age, y, mean (SD) 33 (17) 31 (13) 0.41
Age ≥ 55 y, No. (%) 26 (11) 1 (4) 0.32
Male sex, No. (%) 109 (46) 16 (70) 0.087
Type of injury, No. (%) 0.98
Motor vehicle crash 194 (81) 19 (83)
Fall 24 (10) 2 (9)
Assault 2 (1) -
Other 18 (8) 2 (9)
Injury Severity Score, mean (SD) 27 (11) 29 (7) 0.15
Injury Severity Score > 25, No. (%) 122 (51) 15 (65) 0.2
Systolic blood pressure on admission, mmHg, mean (SD) 124 (25) 110 (21) 0.007
Systolic blood pressure on admission, ≤ 100 mmHg, No. (%) 40 (17) 9 (39) 0.01
Heart rate on admission, beats/min, mean (SD) 97 (21) 97 (21) 0.95
Heart rate on admission > 100 beats/min 103 (43) 9 (39) 0.68
Hematocrit on admission, mean (SD) 37 (27) 36 (6) 0.51
Hematocrit level on admission ≤ 30%, No. (%) 43 (18) 3 (13) 0.53
Glascow Coma Scale, mean (SD) 13 (4) 14 (3) 0.5
Brain injury, No. (%) 26 (11) 2 (9) 0.75
Major fracture, No. (%) 75 (31) 7 (30) 0.93
Other abdominal organ injury, No. (%) 110 (46) 17 (74) 0.011
Other extra-abdominal injury, No. (%) 194 (81) 22 (96) 0.081
CT grade of liver injury, No. (%) 0.28
4 215 (90) 19 (83)
5 24 (10) 4 (17)
Contrast extravasation on CT (n=228), No. (%) 61 (26) 9 (39) 0.34
Free blood on CT, No. (%) 0.061
Perihepatic 76 (32) 3 (13)
Diffuse 163 (68) 20 (87)
Morbidity, No. (%) 91 (38) 23 (100) < 0.0001
Mortality, No. (%) 13 (5) 2 (9) 0.52
Hospital stay, d, mean (SD) 13 (15) 41 (46) 0.009
ICU stay, d, mean (SD) 6 (11) 29 (41) 0.015
Hospital stay in survivors, d, mean (SD) 13 (13) 32 (29) 0.008
ICU stay, in survivors, d, mean (SD) 6 (9) 21 (27) 0.023
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DISCUSSION
The shift towards NOM of BLI has been profound over the last few decades. From the early 
articles of near-mandatory operation for all liver injuries12,13 to recent recommendations 
of managing most BLI non-operatively14, there is clearly a major change in the standard 
of care. As it usually happens with new methods, the rapidly growing enthusiasm for 
NOM of solid visceral injuries allowed an overstatement of its scope and outcomes. For 
example, the unchecked optimism about the success of NOM on the injured spleen is 
balanced by recent evidence showing that over one third of severe splenic injuries fail 
NOM7.
The liver is known to respond well to NOM1,2,4,8,14-19. However, as it had happened with 
the spleen, the studies describing high non-operative success rates have included pri-
marily low-grade liver injuries. The severe injuries of the liver were typically treated with 
an operation. For example, among 128 patients with grade IV and 31 with grade V BLI, 
described by Kozar et al, only 40% with grade IV and 4% with grade V injury were offered 
NOM17. In 1996 a multicenter study from the Western Trauma Association revealed a 
very low number of NOM failures20. Of 404 BLI patients managed non-operatively 58 
had grade IV or V injuries. There were only 6 NOM failures (1.5%) and only 3 of them 
were related to the liver. The manuscript did not specify the grade of injury in these 6 
patients nor the number of patients with grade IV or V injuries managed with IO. In a 
study of 55 BLI patients managed by NOM at the Los Angeles County hospital, 8 patients 
failed NOM (14.5%) although none of them for liver-related reasons. Interestingly, 6 of 
the 8 failures were on patients with liver injury grade of III and higher14. Other groups 
have reported on high-grade injuries but focused either on operations only5 or did not 
distinguish between those who were operated on immediately and those who were 
operated on after NOM failed8. 
Our consortium of 11 New England Trauma Centers focused exclusively on the highest 
grades of injury, IV and V. One third of the patients were immediately taken for an opera-
tion and the remaining two thirds were offered NOM. Over 90% of the NOM patients 
left the hospital without a midline laparotomy. The liver was the cause of NOM failure 
only in 7% of the patients. Interestingly, 7 of the 17 liver-related f-NOM patients had 
ongoing bleeding and the remaining 10 had bile leaks. None of the 7 patients who bled 
experienced complications that could be attributed to f-NOM and none of them died. 
Table 4. Independent Predictors for Failure of Non-operative Management
Predictor OR (95% CI) P value
Systolic blood pressure on admission, ≤ 100 mmHg 2.70 (1.07 - 6.77) 0.03
Other abdominal organ injury 2.92 (1.10 – 7.76) 0.03
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The very high s-NOM rate was in part due to control of bleeding via angiographic 
embolization. One quarter of NOM patients were embolized with a 93% success rate for 
bleeding control. Multiple other studies have shown that liver embolization for trauma 
is safe and stops bleeding effectively21-23. In our population most angiographies were 
performed within the first 24 hours of admission, attesting to the fact that embolization 
was used as an important element of the NOM strategy. 
Additional interventions, such as ERCP, stenting, or percutaneous drainage of collec-
tions have been recommended as effective tools to control bile leaks following severe 
liver trauma24. Laparoscopic drainage of biliary collections has been used to ameliorate 
a severe inflammatory response in selected NOM patients, who remain tachycardic and 
febrile 3-5 days after injury25. In our study, we used ERCP and percutaneous drainage in 
6% and 5% of the population respectively.
Our multi-institutional collaboration enhances the sample size of a relatively uncom-
mon injury but affects the ability to collect important details, particularly in view of its 
retrospective design. Therefore, precise information about decision-making is missing. 
We accepted an arbitrary number of hours from admission, beyond which an operation 
was offered because of f-NOM. It is possible that some of these patients were never 
offered NOM but deteriorated during the period of evaluation. In this context, “failure” 
of NOM should not be attributed to the inability of trauma surgeons to triage patients 
appropriately but rather to the natural history of some injuries, which continue to bleed 
despite optimal management. We could not find patients who were clearly harmed 
by f-NOM. Although, undoubtedly, such patients exist, f-NOM does not seem to set 
up patients for an increased risk of complications and death. Close observation and 
monitoring is, of course, a prerequisite of subjecting such severe injuries to NOM. Finally, 
we could not make statements about issues which are widely debated and continue to 
remain without answers: How long should these patients remain in the hospital? When 
should they be allowed to return to strenuous activities? What is the role of routine 
repeat scanning? Our study was not designed to answer these questions.
In summary, grade IV and V liver injuries respond well to NOM. In contrast with splenic 
injuries of similar grade, many of which are destined to fail7, the majority of severe BLI 
can be managed without an operation. High-grade liver injuries seem to behave in a 
dichotomous way. They either bleed immediately and dramatically, and are in obvious 
need of surgical intervention or they do not bleed and can be managed reliably by NOM 
with a very low likelihood of subsequent bleeding. There is little reason to intervene 
surgically on those hemodynamically stable patients, no matter how awe-striking the 
CT scan may be. In this multicenter study 67% of patients with grade IV and V BLI were 
offered NOM, which was successful in 91% of them. Only 6% of the non-operatively 
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ABSTRACT
Background: Pancreatoduodenectomy for trauma (PDT) is a rare procedure, reserved 
for severe pancreatoduodenal injuries. Using the National Trauma Data Bank (NTDB),our 
aim was to compare outcomes of PDT patients to similarly injured patients who did not 
undergo a PDT.
Methods: Patients with pancreatic or duodenal injuries treated with PDT (ICD-9-CM 
52.7) were identified in the NTDB 2008-2010 Research Data Sets, excluding those receiv-
ing delayed PDT (> 4 days). The PDT group (n=39) was compared to patients with severe 
combined pancreatoduodenal injuries (grade 4 or 5) who did not receive a PDT (non-
PDT group, n=38). Patients who died in the emergency department or did not undergo 
a laparotomy were excluded. Our primary outcome was mortality; secondary outcomes 
were ICU length of stay, hospital length of stay and total ventilator days. A multivariate 
model was used to determine predictors of in-hospital mortality within each group, and 
in the overall cohort. 
Results: The non-PDT group had a significantly lower SBP and GCS at baseline, and more 
severe duodenal, pancreatic, and liver injuries. There were no significant differences in 
outcomes between the two groups. The Injury Severity Score (ISS) was the only inde-
pendent predictor of mortality among PDT patients (OR 1.12, 95% CI: 1.01-1.24) and in 
the entire cohort (OR 1.06, 95% CI: 1.01-1.12). The method of operation did not influence 
any of the outcomes. 
Conclusions: Compared to non-PDT, PDT did not result in improved outcomes despite 
a lower physiologic burden among PDT patients. More conservative procedures in high-
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INTRODUCTION
The pancreatoduodenectomy, as a single stage procedure, was first reported by Whipple 
in 1935 for the elective resection of periampullary carcinoma.1 While the operative 
mortality rate of this radical procedure has been improved to <5%, it is still associated 
with a 40% complication rate and a poor (<10%) 5-year survival when performed for 
adenocarcinoma of the pancreatic head.2,3 
Thirty years elapsed, before this procedure was first reported in trauma patients.4,5 
The frequency of duodenal and pancreatic injuries is low compared to other abdominal 
organ injury. Isolated duodenal injuries are very rare, and no adequate documentation 
of the exact incidence can be found. A review of Asensio on duodenal injuries6, esti-
mated the incidence at 4.3% of all patients with abdominal injuries (range 3.7-5.0%), 
while pancreatic trauma is present in only 3%.7 
Combined pancreatoduodenal injuries are equally uncommon. Eighty percent are 
caused by a penetrating mechanism, morbidity is high, and mortality ranges from 18-
30%.8-10 Pancreatoduodenectomy for trauma (PDT) therefore is a very rare procedure 
and is usually reserved for the most severe pancreatoduodenal injuries (grade 4 or 
5, according to the organ injury scale of the American Association for the Surgery of 
Trauma, Table 1)11. The largest study on PDT to date consists of only 18 patients from a 
single center.12 
In this study we examined this uncommon operation at a national level, using the Na-
tional Trauma Data Bank (NTDB). Our aim was to evaluate the outcomes of PDT patients 
in comparison to similarly injured patients without PDT.
Table 1. Grading of Pancreas and Duodenum Injury According to the American Association for the 
Surgery of Trauma Organ Injury Scale11 
Pancreas
Grade* Type of injury Description of injury AIS-90
I Hematoma Minor contusion without duct injury 2
Laceration Superficial laceration without duct injury 2
II Hematoma Major contusion without duct injury or tissue loss 2
Laceration Major laceration without duct injury or tissue loss 3
III Laceration Distal transection or parenchymal injury with duct injury 3
IV Laceration Proximal transection or parenchymal injury involving 
ampulla
4
V Laceration Massive disruption of pancreatic head 5
*Advance one grade for multiple injuries up to grade III. 
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METHODS
The NTDB is a database containing data on trauma patients, submitted on a voluntary 
basis by trauma centers in the United States. It was designed and is maintained by the 
American College of Surgeons, Committee on Trauma, and has been running since 1997. 
Currently, the data set includes over 5 million cases from over 900 trauma centers of all 
levels of designation. We used NTDB version 7.2, and focused on the Research Data Sets 
for 2008, 2009, and 2010, since 2008 was the year that a new and more complete dataset 
was introduced. 
Patients undergoing pancreatoduodenectomy for trauma (PDT) were identified, using 
the International Classification of Diseases, 9th Revision (ICD-9) procedure code 52.7 
(radical pancreatoduodenectomy). A total of 47 patients were found. Because the focus 
of this study is on outcomes of patients who received PDT acutely (either at the initial 
operation or within 4 days from admission), we excluded three patients who received 
delayed PDT beyond 4 days. Five additional patients were excluded because their ICD-9 
diagnosis codes did not include pancreatic or duodenal injuries. The final PDT sample 
comprised 39 patients (PDT group, Figure 1). This group was compared with patients 
who had severe combined pancreatoduodenal injuries (grade 4 or 5 in both organs, 
according to the organ injury scale (OIS) of the American Association for the Surgery of 
Trauma (AAST), Table 1)11 but did not receive PDT (non-PDT group, Figure 1). Patients 
who died in the emergency department (ED) or did not receive a laparotomy for their 
abdominal injuries were excluded in the non-PDT group. 
Data that were collected included: demographics, Injury Severity Score (ISS), Ab-
breviated Injury Scores (AIS), physiologic status upon arrival at the receiving hospital, 
associated injuries, and performed procedures. Our primary outcome was mortality, and 
Duodenum
Grade* Type of injury Description of injury AIS-90
I Hematoma Involving single portion of duodenum 2
Laceration Partial thickness, no perforation 3
II Hematoma Involving more than one portion 2
Laceration Disruption <50% of circumference 4
III Laceration Disruption 50-75% of circumference of D2;
Disruption 50-100% of circumference of D1,D3,D4
4
4
IV Laceration Disruption >75% of circumference of D2
Involving ampulla or distal common bile duct
5
5
V Laceration Massive disruption of duodenopancreatic complex 5
Vascular Devascularization of duodenum 5
*Advance one grade for multiple injuries up to grade III. D1-first position of duodenum; D2-second 
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additional secondary outcomes were hospital length of stay (HLOS), intensive care unit 
length of stay (ICU LOS), and ventilator days. 
Univariate analysis was performed to compare the two groups. We dichotomized certain 
continuous variables across clinically meaningful values: Injury Severity Score at 25; systolic 
blood pressure at 90 mmHg and 110 mmHg; and heart rate at 100 beats per minute. Con-
tinuous variables were summarized using mean values with standard deviations (SD) and 
compared using two-sample t-tests, or summarized using median with range and compared 
using Wilcoxon rank sum tests. Categorical variables (reported as counts and proportions) 
were compared using Fisher’s exact test. Logistic regression analysis was performed to iden-
tify independent predictors of mortality significant at a 0.05 level for each group, and in the 
overall cohort. Odds ratios and 95% confidence intervals were reported for each predictor 
and p ≤ .05 indicated statistical significance. SAS version 9.3 (SAS Institute, Cary NC) was used 
for the entire analysis. The study was approved by our institutional review board.
RESULTS
In three years (2008-2010) of NTDB data, a total of 39 patients were found to have re-
ceived a Trauma Whipple (PDT-group) in the acute phase for severe pancreatoduodenal 
injuries. Their mean age was 34 ± 18 years (median: 27 years; range 16-80), with only 
10.3% being over 55 years of age. Seventy-four percent were male, and 77% had a 
penetrating trauma as mechanism of injury. The mean Injury Severity Score (based on 
AIS) was 27 ± 13 (median 25; range 4-59). This group was compared to patients that had 
severe pancreatoduodenal injuries, but did not receive a PDT. As shown in Table 2, no 
significant differences were found in any demographical data.
Comparing physiologic status at baseline (Table 2), the non-PDT group had signifi-
cantly more patients with a lower systolic blood pressure, both when dichotomized at 
90mmHg (PDT vs. non-PDT, respectively 15% vs. 21%, p=0.028), and at 110 mmHg (28% 






















(ICD-9-CM procedure code 52.7)
44 patients
(with grade IV/V pancreatic AND
duodenal injury)
6 patients excluded:
- 3 died in the ED
- 3 did not receive laparotomy for abdominal injuries
38 non-PDT patients
8 patients excluded:
- 3 had PDT > 4 days after admission
- 5 without coding for pancreatic/duodenal injuries
39 PDT patients
Figure 1. PDT group vs. non-PDT group
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ference in Glasgow Coma Scale score (14 ± 3 vs. 10 ± 6, p=0.002). When comparing AIS 
scores though, no difference in head and neck AIS was found (p=0.85). 
Patients in the non-PDT group had significantly higher abdominal AIS, a higher per-
centage of patients with duodenal and pancreatic injuries, and more severe liver injuries. 
Surprisingly, of the patients that did receive a PDT, only 79% had either a severe (grade 
4 or 5) duodenal or severe pancreatic injury. In the non-PDT group this percentage was 
100%, since that was one of the inclusion criteria for this group (Table 2). 
There were no significant differences in outcomes. Mortality was 33% vs. 37%, respec-
tively, for the PDT and the non-PDT group (p=0.81). The hospital and ICU length of stay 
did not differ significantly between the two groups. Similarly, there was no significant 
difference in the number of minutes spent in the ED and the number of ventilator days 
(Table 3). No difference in the incidence of reported complications was found (PDT vs. 
non-PDT, respectively 51% vs. 55%, p=0.82). Looking at the time of death in both the 
PDT and non-PDT group, our results showed that patients that received a PDT died at a 
median of 7 days (range 1-180 days), while the patients in the non-PDT group died much 
earlier, at a median of 1 day (range 1-85 days).
Table 2. Descriptives of PDT group and non-PDT group
Parameter PDT (n=39) non-PDT (n=38) P value
Age (years) 34 ± 18 30 ± 14 0.26
Male, No. (%) 29 (74) 30 (79) 0.79
ISS (AIS based) 27 ± 13 30 ± 10 0.21
ISS >25, No. (%) 16 (41) 22 (58) 0.17
Penetrating trauma, No. (%) 30 (77) 26 (68) 0.45
Systolic Blood Pressure (mmHg) 118 ± 36 101 ± 47 0.22
SBP <90 mmHg, No. (%) 6 (15) 8 (21) 0.028
SBP <110 mmHg, No. (%) 11 (28) 20 (53) 0.01
Heart rate (beats/min) 96 ± 31 97 ± 42 0.90
HR >100 beats/min, No. (%) 16 (41) 19 (50) 0.19
GCS, mean (SD) 14 ± 3 10 ± 6 0.002
AIS head/neck, mean (SD) 0.2 ± 0.7 0.2 ± 0.7 0.85
AIS abdomen, mean (SD) 3.8 ± 0.8 4.7 ± 0.5 <0.0001
Severe duodenal and/or pancreatic injuries (IV-V), No. (%) 31 (79) 38 (100) 0.005
Severe duodenal injuries (IV-V), No. (%) 11 (28) 38 (100) <0.0001
Severe pancreatic injuries (IV-V), No. (%) 28 (72) 38 (100) 0.001
Severe splenic injuries (IV-V), No. (%) 0 4 (11) 0.12
Severe liver injuries (IV-V), No. (%) 7 (18) 16 (42) 0.006
Severe gallbladder injuries (IV-V), No. (%) 4 (10) 0 0.23
Abbreviations: ISS, Injury Severity Score; SBP, Systolic Blood Pressure; HR, Heart Rate; GCS, Glascow Coma 
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In PDT patients with available operative time data (n=33), the majority of procedures 
were performed within the first 6 hours after admission (21/33 patients = 64%). In the 
patients who underwent a PDT but did not have either a severe (grade 4 or 5) injury 
in the pancreas or duodenum, the majority (5/7 = 71%) also received this intervention 
during the index operation (Figure 2). There was no trend towards institutional bias in 
preference of one procedure over another (data not shown). Procedures in the non-PDT 
group are summarized in Table 4. 
Survivors and non-survivors in both groups were compared. As shown in univariate 
analysis, having received a PDT did not predict mortality (p=0.81). In the non-PDT group 
there were no predictors significant at 0.05 level in the univariate analysis. Among PDT 
patients, the SBP was significantly higher and the ISS was significantly lower among 
survivors, however only the ISS was found to be an independent predictor of mortality 
in our multivariable model. For every unit increase in ISS, the odds of mortality increased 
by 1.09 fold (95% CI: 1.01-1.18). For the overall cohort, the ISS remained the only in-
dependent predictor of mortality; for every unit increase in ISS, the odds of mortality 
increased by 1.07 fold (95% CI: 1.01-1.12). 
Table 3. Outcomes of comparison PDT group vs. non-PDT group
Outcomes PDT (n=39) non-PDT (n=38) P value
Hospital LOS, days, median (range) 18 (1-180) 12 (1-85) 0.32
ICU LOS, days, median (range) 8 (1-106) 10 (1-85) 0.96
Ventilator days, median (range) 7 (1-90) 8 (1-42) 0.73
ED stay in minutes, median (range) 25 (3-3850) 31 (2-13055) 0.55
Any complications, No. (%) 20 (51) 21 (55) 0.82
Mortality, No. (%) 13 (33) 14 (37) 0.81


























All PDT patients non-severe PD injuries
 
 Figure 2. Hours from admission to pancreatoduodenectomy
Abbreviations: PDT, pancreatoduodenectomy for Trauma; non-severe PD injuries = grade I-III.
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DISCUSSION
In 1964 Thal and Wilson first described the use of PDT in two trauma patients.5 Numerous 
subsequent reports have been published; however, they have all been limited by small 
sample sizes, ranging between 3-10 patients per study.4,13-17 The majority of patients 
sustained a penetrating injury, they were predominantly male, and mortality ranged 
from 20-100%. Our results are consistent with these prior studies. In a review of all PDTs 
described in the literature (245 cases)18 until 1999, the pooled mortality rate was 31%; in 
our study, mortality was found to be 33%. 
In the management of combined pancreatoduodenal injuries, there are several 
options available. Reviewing the existing published literature8-10,19, simple repair and 
drainage was used in 19-44% of patients, repair and exclusion in 34-53%, and a distal 
pancreatectomy in 3-16%. Trauma Whipple was employed in less than 8% of patients. 
In a review of pancreatic trauma by Glancy et al.20, the estimated frequency of PDT was 
0.07% in 1407 patients. The question remains, what are the ‘hard’ indications for per-
forming such a complex procedure? 
Subramanian et al21, in a review of pancreatic trauma, describe the indications for PDT 
as: extensive trauma to the head of the pancreas, severe combined pancreatoduodenal 
injury, or destruction of the ampulla of Vater. PDT is also described as a treatment op-
tion for isolated grade 5 pancreatic injury21,22 or isolated grade 5 duodenal injury.23 In 
the study by Asensio12, all 18 patients had injuries to both the pancreas (grade 5 in 17, 
grade 4 in 1) and duodenum (all grade 5). The indications for PDT in three-quarters of 
the patients were massive uncontrollable retropancreatic hemorrhage from associated 
Table 4. Type of abdominal procedures in non-PDT group
Type of abdominal procedures non-PDT
Other gastroenterostomy 10
Suture of laceration of duodenum 9
Other partial resection of small intestine 8
Open and other right hemicolectomy 8
Other repair of pancreas 7
Distal pancreatectomy 3
Total pancreatectomy 3
Anastomosis of pancreas 3
Other operations on pancreas 3
Other excision or destruction lesion/tissue of pancreas or pancreatic duct 2
Internal drainage of pancreatic cyst 2
Other partial pancreatectomy 2
Proximal pancreatectomy 1
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vascular injuries and massive unreconstructable injuries to both the pancreas and duo-
denum. In our study, 21% of patients receiving a PDT did not have a grade 4 or 5 injury 
in either the pancreas or the duodenum, nor did they have significant associated injuries 
in the abdomen. 
If we assume that PDT is being performed for the appropriate indication of severe 
injury to the pancreatoduodenal complex, it is likely that these patients usually have 
physiologic derangement or other intra-abdominal injuries requiring attention. Under 
elective conditions, several authors have recommended enlisting the assistance of an 
experienced hepatobiliary surgeon when attempting this operation23-26, and it is not 
unreasonable to assume that the higher experience-better outcomes relationship is also 
true in unstable trauma patients. Rather than attempt a rare and complex operation on 
a coagulopathic, hypothermic, and acidemic patient, it may be prudent to employ mod-
ern damage control principles (arrest hemorrhage, temporarily control contamination, 
restore physiologic balance) and defer a time-consuming and complex reconstruction 
to more favorable conditions.27 It is surprising, therefore, to discover that the majority 
of PDTs were performed within 6 hours of admission. This line of thinking is further sup-
ported by the difference in time of death. Patients that received a PDT died much later, 
while patients with a non-PDT died with a median of only 1 day. As we know, there is a 
tri-modal distribution of death in trauma, with neurologic and exsanguination deaths 
occurring immediately, hemorrhagic deaths occurring in the first 24 hours, and septic/
multi-organ failure deaths occurring days to weeks later. Reviewing the median time 
until death, we conclude that most of the non-PDT patients who died, probably died 
of hemorrhage and that PDT patients who died, likely died of progressive organ failure. 
This is consistent with the abovementioned finding that non-PDT patients had worse 
physiologic status upon arrival. We believe that this shows that the surgeon exercised 
good judgment in deciding not to perform a PDT in these patients, as they were prob-
ably very unstable. It is unlikely that performing a PDT would have saved the patient’s 
life. One remaining question is whether patients in the PDT group, dying presumably 
secondary to progressive organ failure, would have done better with a lesser operation 
(with presumably less of a physiologic insult), perhaps leading to a higher survival rate. 
This is a question that should be answered in a new study.
Having shown similar outcomes in patients that were equally injured but managed 
without a PDT, the question arises whether more conservative procedures are appropri-
ate. A study by Velmahos and colleagues28 in 2009 demonstrated a failure rate of 10.3% 
in 97 patients who were managed non-operatively for blunt pancreatic injury (BPI), 
blunt duodenal injury (BDI), or both. Of those patients, though, only 1 had a grade 4 BPI 
and the rest were all low grade, mostly grade 1 and 2. A study by Duchesne et al29 also 
confirmed that non-operative management (NOM) of patients with low-grade, blunt 
pancreatic injuries is successful in most patients, with only few complications and a 
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low mortality (5.7%). However, NOM in high grade injuries is highly unlikely to succeed. 
Nonetheless, more conservative procedures than PDT, such as primary repair, drainage, 
duodenal exclusion, or a partial pancreatectomy, are worth considering, since our study 
demonstrates that outcomes following these procedures are not significantly different 
compared to those after PDT. 
We acknowledge that due to its retrospective design, this study has some limitations. 
By using a large database we attempted to acquire the largest sample size for this pro-
cedure possible; however there are limitations with the NTDB that must be mentioned. 
The NTDB is a convenience sample that is not completely representative of all trauma 
centers in the United States. Submission of data is voluntary30, and this can result in 
selection bias. Additionally, there is the possibility of inaccurate diagnostic coding, as 
well as the limitation of included data variables. Regrettably, the NTDB does not include 
granular detail such as operative reports, intraoperative hemodynamic parameters, 
surgeon experience, institutional experience, etc. which may factor into the decision 
whether or not to perform a PDT. Furthermore complications are likely underreported 
in this database. Despite all these limitations, the NTDB is a very powerful tool and is 
especially useful in studying injuries of very low incidence. We were able to make an 
accurate comparison between patients that were managed with PDT versus those that 
were similarly injured, but were managed without PDT. 
CONCLUSIONS
In summary, the Trauma Whipple or PDT is a very uncommon procedure, and even when 
using the largest available trauma database, over the years 2008-2010 we could only 
identify 39 patients that received a PDT for severe pancreatoduodenal injuries during 
the acute phase. Twenty-one percent of PDT may have been performed for inappro-
priate indications, and in a majority of patients, PDT was performed during the index 
operation. This, however, did not result in an outcome benefit for patients managed 
with a PDT when compared to similarly injured patients who were managed without 
a PDT. More conservative procedures in high-grade injuries of the pancreatoduodenal 
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Major recent advances in research and patient care have produced enhanced outcomes 
in complex diseases. fCDC and trauma are not new diseases but continue to claim lives, 
on many occasions more than in the past. Our ongoing struggle lies not only in new 
therapeutic strategies but also in preventive methods, which will hopefully allow pa-
tients to avoid morbidity and mortality.
The infectious point of view
In this dissertation, the most severe, fulminant, version of C. difficile colitis (fCDC) is the 
hub of attention. Since the early 2000s, CDI is more often being caused by a hypervirulent 
strain, resulting in an increased incidence of fCDC, accompanied by a higher morbidity 
and mortality.1-6 Although appalling mortality rates have required surgeons to focus on 
this severe colitis, experimental treatment strategies typically target the earlier forms of 
disease, before it progresses to its fulminant stage. The only recent example of a new 
treatment option for fCDC is described in a pilot study of Neal et al.7; the creation of a di-
verting loop ileostomy, through which the colon is being lavaged, and post-operatively, 
is receiving vancomycin enema’s in an antegrade fashion (Figure 1). The randomized trial 
exploring this new option, is currently running, with Massachusetts General Hospital as 
the leading center in a multi-institutional collaboration. While this trial will provide us 
with evidence to which extent we can locally, and less invasive, manage this colitis, the 
question remains whether the answers should be looked for from a different scientific 
perspective.
Prevention is a key point in optimization of treatment. Looking back at Chapter 1, 
where SIRS was described as common ground between abdominal emergencies, we 
2 
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know that SIRS can result in secondary MODS, occurring in remote organs. That is 
the stage in which we would start calling the C. difficile colitis, fulminant. Patients can 
subsequently develop progressive organ failure, which can lead to death.8 Chapters 2 
and 3 describe interferences in the treatment of fCDC by using preventive measures; 
in this case, not prevention of the initial infection, but of disastrous outcomes from this 
severe colitis. While the first study focuses on a clinical prediction rule that will help us 
to identify patients at risk for developing fCDC, the second study describes an interven-
tion; a hospital-wide protocol that facilitates early surgical consultation. Both studies 
are focused on facilitating treatment at an earlier stage (optimization), which should 
prevent irreversible events such as mortality. 
Chapter 4 focuses on another, yet very important theme in CDI and fCDC; the usage 
of antibiotics. This study describes the different antibiotic regimen that are used after a 
total abdominal colectomy for fCDC, and aims to make recommendations about that us-
age, to optimize treatment and follow-up. This is leading us to an earlier moment in the 
disease course towards fCDC; the initial CDI. The usage of antibiotics is the biggest risk 
factor for developing CDI, since it is creating the optimal environment for latent spores 
to become active and toxic. Although it differs per antibiotic class whether the bacterium 
is resistant to it or not, the overall use should be reduced to the bare minimum of what 
is necessary; again, prevention is of the essence here. If we look at the mean incidence 
of CDI in both the United States (U.S.) and the Netherlands (NL), a huge difference can 
be detected: 12.5/1,000 admissions in the U.S. vs. 1.5/1,000 admissions in NL.6, 9-12 This 
is partially related to the differences in the administration of antibiotics13-15; in the U.S. 
there is a higher risk of prolonged courses, inappropriate use of broad spectrum agents, 
and lack of appropriate streamlining based on culture data. Although the appropriate 
use of antibiotics is being promoted by several antimicrobial stewardship programs with 
good results, there is still a lot that can be done. Antimicrobial stewardship refers to 
coordinated interventions designed to improve and measure the appropriate use of an-
tibiotics by promoting the selection of the optimal regimen, dose, duration of therapy, 
and route of administration. The most important goals are to achieve optimal clinical 
outcomes, minimize toxicity and other adverse events, and reduce the costs.16-18
Nevertheless, on certain occasions there is no choice but to prescribe antibiotics. In 
these cases, we need to make sure that our intestinal microbiota stays balanced, and 
when needed, to restore it. A technique called fecal transplantation (also known as 
intestinal microbiota transplantation [IMT]) seems to be the key in future attempts to 
do so. It has been described since the late fifties19 but was only recently approved by 
Medicare and Medicaid and is slowly being accepted as possible treatment by a broader 
audience. A literature review, including 317 patients across 27 case series and reports, 
showed that IMT was successful in disease resolution in 92% of cases. Death and other 
adverse events were both uncommon.20 The first randomized trial, published recently21, 
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confirmed that IMT is very effective in treating (recurrent) CDI; donor feces cured 94% of 
the patients. In particular patients with multiple relapses (recurrences) of CDI benefitted 
from this intervention. This treatment interacts with the normal physiology of the colon 
and its natural inhabitants. However, the question remains: what is the optimal balance 
of our intestinal microbiota, the ultimate composition of our colonic flora, that will 
protect us from infections like the one caused by Clostridium difficile? More important, 
once we know the answer to that question, how can we use that knowledge and turn it 
into a possible treatment for future threats or optimize it in such a way that it will help 
to also prevent other infections. In short, which germs are friends, and which ones are 
foes? The elaborate and inspiring article of Michael Pollan in the New York Times22 ad-
dresses that specific question and concluded that one of the keys to good health in this 
era may involve managing our internal fermentation, anticipating on how our external 
environment (with factors such as diet, medication, etc.) will interact with our internal 
environment, in this case, our gastrointestinal tract and its microbiota. 
In this same context of optimizing the components of our intestinal microbiota, the 
study in chapter 5 focuses on the association between vitamin D levels and severity of 
CDI. Our results show that lower levels of 25(OH)D3 are associated with a more severe 
course of CDI. The next step will be to test in a randomized controlled trial whether 
adding vitamin D supplementation to the regular treatment of CDI will prevent it from 
progressing towards a severe colitis. Another study would be to see if optimizing vitamin 
D levels will also completely prevent the CDI from occurring, something that was sug-
gested in preliminary data.23 While focusing in this thesis on vitamin D, there are various 
proteins, biomarkers, and other endogenous substances that might also be relevant in 
the search for the ultimate composition of the colonic flora. 
We are only at the start of discovering the effects of all those individual components 
within our intestinal microbiota, and although it will be important in future treatments, 
it will be essential in the prevention of new infections and diseases. To conclude the 
discussion regarding fCDC related results in this thesis, the ‘Holy Grail’ of optimization of 
treatment is closely related to improvement of the logistics of patient care; identifying 
those patients that are at risk of developing a fulminant colitis at an early stage, and 
assure that those patients are seen by a surgeon at the earliest moment possible. This 
may facilitate operative treatment at an earlier moment, when required, at which one 
can still speak of a life-saving procedure, rather than deteriorating the clinical status of 
the patient by a ‘second hit’ through surgical intervention. In addition to that, the focus 
of future research should include prevention, more specifically the modulation of the 
causal pathway to prevent a ‘simple’ CDI from turning into a life-threatening fCDC. Defin-
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From a different angle: optimization of surgical treatment in abdominal 
trauma
Trauma is globally the leading cause of death for people between the ages of 5 and 44 
years, and has a huge impact on healthcare systems worldwide. With 5.8 million people 
dying each year as a result of injuries, it accounts for 10% of the world’s mortality rate. 
In addition, many of those who survive acts of violence, accidents, or other causes of 
injury are left with temporary or sometimes permanent disabilities, both physical and 
mental (16% of all disabilities globally are caused by injury).24 Due to heterogeneity in 
demographics, infrastructure, but also culture, certain aspects of trauma-related injuries 
differ from country to country. More than 90% of injury-related deaths occur in low- and 
middle-income countries. But even between high-income countries there are huge 
differences, for example when comparing the United States, with a population of 316 
million, with the Netherlands (population of 17 million). A global overview is given in 
Table 1; the outcomes can mainly be explained by differences in (access to) healthcare 
systems, certain legislature (such as gun laws for example), and the impact of crime. 
This dissertation focuses on blunt abdominal trauma, an entity that affects up to 13% 
of trauma patients. Road traffic crashes and falls, as most important causes of blunt 
trauma, make up for 31% of injury-related mortality worldwide.24 Management of the, 
sometimes devastating, injuries is becoming more conservative, and less invasive. In 
chapter 6 we saw that the most devastating blunt renal injuries, those that are graded 
as a IV or V by the AAST organ injury scale25, can be managed safely and effectively with-
out an operation. The same applies to severe blunt liver injuries; outcomes described 
in chapter 7 show us that non-invasive treatment options should be considered in, 
again, grade IV and V injuries.26 Even in the most severe pancreatoduodenal injuries27, 
described in chapter 8, that potentially need a pancreatoduodenectomy, we have seen 
that they can equally effective be managed with more conservative procedures. The 
explanation for this more conservative trend is probably two-sided; on the one hand we 
have gained more knowledge over time on how the body responds to certain impacts. 
A major operation for managing the injuries imposes a significant extra insult on the 
body, due to often massive pre-operative resuscitation and intra-operative stress. In 






Patients treated for traumatic injuries in the 
Emergency Department annually
10,320 / 100.000 5,120 / 100.000
Trauma-related hospital admissions 790 / 100,000 710 / 100,000
Injury-related mortality 57 / 100,000 31 / 100,000
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these cases, the damage control surgery concept applies; delaying the operation to 
a later moment, or even dividing it into more but smaller procedures, may cause less 
secondary trauma. Relatively new treatment strategies, operative versus non-operative 
ones, run parallel to huge improvements in critical care monitoring over the past two 
decades, which provides us with the opportunity to follow the critically injured patients 
in detailed fashion, and enables us to identify those patients that need urgent surgical 
intervention at an early moment.28, 29
The question remains: How far can we go? To what extent can we rely on the patients’ 
own reserves to recover from those severe injuries without an invasive intervention? In 
the case of these abdominal events, we have shown that there will always be patients 
that require an operation. By the same token, some of these operations are unnecessary, 
and are offered only because practice is not evidence-based enough yet. The mentality 
change will be difficult to achieve, since it requires a paradigm shift in our ’mindset’, 
from immediate action and invasive treatments to a more observing role, often with our 
hands tied, although ready to act whenever necessary. Another part of the shift in surgi-
cal mentality is the delayed operation, or so-called damage control surgery, which we 
briefly touched upon before. The severely injured patients that do need that operation, 
need it urgently. It will however, only control the hemorrhage (with simultaneously vig-
orous resuscitation), prevent contamination and further injury, before metabolic failure 
(triad of acidosis, hypothermia, and coagulopathy) occurs. After that initial operation the 
patient will go to the ICU where hypothermia and acidosis will be corrected. The definite 
surgical procedure(s) will follow in the next couple of days (from 24-48 hours after the 
first procedure), in the window of opportunity between correction of metabolic failure 
and the onset of signs of SIRS, and possibly MODS. 
In conclusion to the second part of the discussion, we can safely limit invasive pro-
cedures for acute mesenchymal abdominal injuries and cover trauma patients with 
more conservative management, even when injuries, according to grading scales, seem 
devastating. It needs to be emphasized though that there will always be patients with 
an absolute indication for operation. The focus should be on recognizing those patients 
at an early moment. So optimization of surgical treatment in abdominal trauma is not 
only about choosing the right patient for the operation, but to also choose the right 
time to perform the right procedure. In order to do so, the infrastructure and logistics 
around these patients need to be optimal at all times, which can be a highly resource 
competitive endeavor, and requires investment of hospital resources. 
More into the future though, it will not only be about preventing those unnecessary 
procedures, but overall injury prevention will be key when focusing on lowering the 
current, unacceptably high burden that trauma is causing globally. Public health initia-
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drink-driving campaigns and speed limit rules, but also certain legislation mandating a 
higher standard of car safety, or bicycle helmet laws. 
Conclusions
Overall, two themes were dominating this discussion and were present in all studies of 
this thesis on the value of surgical management in abdominal emergencies; optimiza-
tion of treatment and prevention. Optimizing the treatment of both trauma patients 
and patients with fCDC refers to the identification of a possible progressive course at 
an early stage and improved logistics around this population. But although we have 
seen before that the systemic response to the insults are quite similar in both fCDC and 
trauma patients, the road leading to surgical intervention is quite different. In patients 
with fCDC, SIRS and then sepsis are present by definition, and the surgeon should in-
tervene before the patient enters into the phase of septic shock and MODS. In trauma, 
sepsis is not present at the early stage although SIRS is rampant. The surgeon’s goal 
is to control bleeding and contamination in order to ameliorate the progress of SIRS. 
However, a delicate decision making is needed because non-operative treatment may 
achieve these goals better than an operation in selected patients. 
Next to the surgical treatment described, it was shown that more adequate antibiotic 
usage and an optimal composition of intestinal microbiota will be important in pre-
venting a fulminant course of CDC, and potentially, in prevention of the initial CDI. In 
patients with blunt abdominal trauma we will need to focus on less invasive treatment, 
if the clinical situation permits. Public health initiatives can significantly contribute to 
improved outcomes by implementation of preventive measures.
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The studies that are part of this thesis focus on abdominal emergencies; fulminant 
Clostridium difficile colitis (Part I) and severe abdominal trauma (Part II). Several aspects 
of the optimization of treatment of these severe insults to the abdomen are described. 
An overall introduction is presented in chapter 1. 
I. Clostridium difficile colitis 
The bacterium Clostridium difficile causes an infection (CDI) which nowadays is the lead-
ing cause of hospital-acquired diarrhea, both in North America and Europe. While the in-
fection can range from asymptomatic colonization to a severe colitis, it puts pressure on 
the healthcare system by prolonged hospital stays, rising costs, and increased morbidity 
and mortality. The research in this thesis concentrates around the fulminant Clostridium 
difficile colitis (fCDC), which develops in 3-8% of patients with CDI. Chapter 2 describes 
the development of a risk scoring system (RSS), which enables the clinician to predict 
which patients are at risk to progress towards a fulminant state. An expert panel reached 
consensus, using a modified Delphi technique, about four risk factors which were used 
in the RSS. Based on the log (odds ratio) of each risk factor, the following factors were 
included and assigned points: age > 70 years (2 points), WBC ≥ 20.000/µL or ≤2.000/µL (1 
point), cardiorespiratory failure (7 points), and diffuse abdominal tenderness on physical 
exam (6 points). The discriminatory value of the MGH RSS (c statistic) was 0.98 (95% 
confidence interval [CI]: 0.96 – 1). Additionally, the Hosmer and Lemeshow goodness-of-
fit test showed a p-value of 0.78, while the Brier score was 0.019. A value of 6 points was 
determined to be the threshold for dividing low risk (<6) from high risk (≥6) patients. We 
concluded that the MGH RSS is a valid and reliable tool to identify patients who are at 
risk of developing fCDC at the bedside. External validation is still needed though, before 
widespread implementation can occur.
One of the reasons to focus on identification of patients that are at risk of develop-
ing fCDC, is the possibility of early intervention. Through a standardized hospital-wide 
protocol for surgical referral, described in chapter 3, we showed that by timely surgical 
consultation and early identification of patients requiring surgical therapy, we were able 
to reduce mortality. Criteria developed by a multidisciplinary team were used to trigger 
a surgical consult, and compliance to this protocol was tested during the 2-year study 
period. The overall compliance of the protocol was 62.8%. All patients who developed 
fCDC received a surgical consult, with a median time to consultation of 3 hours. When 
comparing our 46 fCDC patients after implementation of the protocol with an historic 
control group (before protocol implementation), the adjusted mortality decreased sig-
nificantly (18.3% vs. 34.8%, p=0.031). The mortality rate was even lower (14.7%) when 









ditionally, patients managed under the surgical consultation protocol were admitted 
to an intensive care unit faster, and the total time from hospital admission to surgical 
intervention (when required) was shortened.
When patients require an operation, the standard treatment is a total abdominal col-
ectomy (TAC) with ileostomy. Even if this procedure is considered life-saving, it results in 
high morbidity and a typically prolonged and complex post-operative course. In chapter 
4 that post-operative course is described, with a special focus on post-operative antibi-
otic usage. A total of 100 fCDC patients who underwent a TAC were included across 5 
institutions. Four different post-operative antibiotic regimen were compared: A (metro-
nidazole IV + vancomycin PO), B (metronidazole IV), C (metronidazole IV + vancomycin 
PO and PR), and D (metronidazole IV + vancomycin PR). Also, the length of treatment 
was examined (≤ 7 or >7 days). The recommendations, based on this study, are that IV 
metronidazole and PO vancomycin have similar effectiveness and that proctitis requires 
the addition of a vancomycin enema (PR). In addition, there is no data to support routine 
use of more than 7 days of antibiotics. Since prolonged antibiotic use is one of the classic 
risk factors for developing CDI, this last recommendation is especially important. A mul-
tivariate logistic regression was performed as well, and the requirement of a vasopressor 
before operation (Odds Ratio [OR]: 6.46; 95% CI: 1.96 – 21.24), and the total units of FFP 
transfused during hospital admission (OR: 1.17; 95%CI: 1.06 – 1.3) were found to be risk 
factors for mortality.
Chapter 5 extends our CDI research to the association between serum 25-hydroxyvi-
tamin D [25(OH)D] levels and the severity of CDI. Vitamin D has been shown to inter-
act with the immune system in various ways, and we hypothesized that lower levels 
of 25(OH)D could potentially worsen CDI. In a prospective study, patients diagnosed 
with CDI were enrolled and divided into two groups, according to severity: group A 
(positive toxin A/B enzyme immunoassay only) and group B (positive toxin A/B enzyme 
immunoassay plus abdominal computed tomography imaging consistent with colitis). 
Serum 25(OH)D levels were measured in 100 patients and showed that the mean 25(OH)
D3 level was significantly higher in group A (n=71) than in group B (n=29): 21 ± 1 ng/mL 
versus 15 ± 2 ng/mL, respectively (p=0.005). Even after adjusting for clinically relevant 
covariates, we found that 25(OH)D3 levels were associated with CDI severity (adjusted 
OR: 0.92; 95% CI: 0.87-0.98). This study shows that vitamin D interferes with the progress 
of CDI from a simple infection to a severe colitis and uncovers potential pathways for 
the origin of the disease. Further studies are warranted to see what the exact function of 
vitamin D in the pathophysiology of CDI is. 
II. Abdominal trauma
In Part II, the main focus is on new insights in the treatment of severe blunt abdominal 
trauma. Practice has shifted over the last decades from operative management to a less 
invasive approach. The first two studies described in this part are designed as large multi-
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institutional studies, including most of the trauma centers in New England (north-east 
of the United States). This New England collaborative was created to examine injuries, 
which have a low frequency and no single center can analyze adequately. The last study 
was conducted, utilizing the largest national trauma database in the United States, the 
National Trauma Data Bank (NTDB).
The focus in chapter 6 is on non-operative management (NOM) of grade IV and V 
blunt renal injuries, with emphasis on the rate, causes, predictors, and consequences of 
failure of treatment (f-NOM defined as the need for a delayed operation or death due 
to renal injury-related complications). In total 206 patients were enrolled across twelve 
centers between 2000 and 2011. One fourth of the patients was operated on immedi-
ately (IO), while the remaining 75% (154 patients) were managed without an operation 
(angiographic embolization in 25 patients). The overall failure rate of NOM was 7.8% (12 
out of 154 patients); in 10 patients related to their kidney injuries. Independent predic-
tors of failure were found to be an age > 55 years and road traffic crash as mechanism 
of injury. Even though when both factors were present, failure of NOM occurred in only 
27.3% of cases. In addition we looked at the occurrence of complications within this 
population. Around 10-15% of patients with blunt renal injuries will get a complication, 
most often persistent hematuria or the development of an urinoma. The majority of 
those complications do not require any operative intervention. Overall, the renal sal-
vage rate was 76.2% (both IO and NOM), and 90.3% among patients selected for NOM. 
While these results might have been expected due to the regenerating capacity of the 
kidney, no extensive evidence was available in the literature. This was the case as well 
for severe blunt liver injuries. Therefore, chapter 7 focuses on the rate and predictors of 
failure of NOM in grade IV and V blunt liver injuries. Our multi-institutional study group 
analyzed 393 patients admitted between 2000 and 2010 across eleven trauma centers. 
Thirty-three percent (131 patients) were operated on immediately, in most causes due 
to hemodynamic instability. Of the 262 patients that were managed without an opera-
tion, this failed in 23 of them (9%). In 17 out of those 23 patients (6% of total NOM group) 
non-operative management failed due to liver related reasons. In a multivariate logistic 
regression model we identified 2 independent predictors of f-NOM; systolic blood pres-
sure on admission ≤ 100 mmHg and other abdominal organ injury. Failure of treatment 
was observed in 23% of patients when both predictors were present. In patients who 
were managed successfully without an operation, liver-specific complications devel-
oped in 10% and were all managed without major sequelae. 
As mentioned above, due to a very low incidence of severe pancreatoduodenal 
injuries, the NTDB was utilized in chapter 8 to compare outcomes between patients 
who were managed with a pancreatoduodenectomy (PDT) for their traumatic injuries 
versus similarly injured patients (grade IV and V combined pancreatoduodenal injuries) 









gency Department), or received a PDT > 4 days after admission, or did not undergo 
a laparotomy at all (in non-PDT group) were excluded. We found that there were no 
significant differences in outcomes such as mortality, length of stay in ICU and hospital, 
and ventilator days, between the PDT group (n=39) and non-PDT group (n=38). SBP 
and GCS at baseline were significantly lower in the non-PDT group, indicating a worse 
clinical status at baseline. With regard to injury severity, we found that patients in the 
PDT-group did not always meet the ‘standard’ indication for a PDT, namely grade IV and 
V combined pancreatoduodenal injuries; 21% did not have a grade IV or V pancreatic or 
duodenal injury at all. Injury Severity Score (ISS) was found to be the only independent 
predictor of mortality in both the PDT group alone (OR: 1.09; 95% CI: 1.01 – 1.18) and 
in the entire cohort (OR: 1.06; 95% CI: 1.01 – 1.12), while the type of operation did not 
influence the outcomes. In conclusion, although patients who underwent a PDT had a 
lower physiologic burden, they were not associated with improved outcomes. Future 
studies should focus on whether implementation of more conservative procedures in 
these high-grade injuries of the pancreatoduodenal complex is appropriate. 
Finally, in the general discussion in chapter 9 I conclude that regarding fCDC, optimi-
zation of treatment is closely related to logistics of patient care. Identifying patients who 
are at risk of developing the fulminant disease and assuring that the surgical service is 
involved early on, may improve outcomes. When designing possible future treatments, 
prevention is definitely one of the key words; modulation of the causal pathway from 
‘simple’ CDI to fCDC, and defining the optimal balance of the intestinal microbiota. 
Regarding severe abdominal trauma, optimization of treatment also refers to improved 
logistics: focusing on more conservative management where possible, and early identi-




SUMMARY IN DUTCH (NEDERLANDSE SAMENVATTING)
De studies die deel uitmaken van dit proefschrift zijn gericht op abdominale spoed-
gevallen; de gecompliceerde, fulminante, Clostridium difficile colitis (Deel 1) en ernstig 
buiktrauma (Deel 2). Diverse aspecten met betrekking tot het optimaliseren van de 
behandeling van deze ernstige aandoeningen worden beschreven in dit proefschrift. 
Een algemene introductie van de onderwerpen is te vinden in hoofdstuk 1. 
I. Clostridium difficile colitis
De darminfectie veroorzaakt door de bacterie Clostridium difficile (CDI) is heden ten dage 
de meest voorkomende oorzaak van diarree tijdens ziekenhuisopname in zowel Noord-
Amerika als Europa. De infectie kan variëren van asymptomatische kolonisatie van de 
darmen tot zware colitis en vormt een ernstig probleem voor de gezondheidszorg, met 
lange ziekenhuisverblijven, hoge ziektekosten en verhoogde morbiditeit en mortali-
teit. Het in dit proefschrift beschreven onderzoek focust zich op de fulminante colitis 
(fCDC), die voorkomt bij ongeveer 3-8% van alle patiënten met een CDI. In hoofdstuk 2 
wordt beschreven hoe een model tot stand is gekomen dat helpt te voorspellen welke 
patiënten het hoogste risico hebben om een ernstige colitis te ontwikkelen; een risico 
scoringssysteem (RSS). Een expert panel koos vier risicofactoren, met behulp van een 
aangepaste Delphi methode, die in de RSS gebruikt werden. Op basis van de log (odds 
ratio) van elke factor, werden de volgende factoren meegenomen in de RSS en kregen de 
volgende punten toegewezen: leeftijd > 70 jaar (2 punten), leukocyten aantal ≥ 20.000/
µL of ≤2.000/µL (1 punt), cardiorespiratoir falen (7 punten) en verspreide abdominale 
gevoeligheid ten tijde van het lichamelijk onderzoek (6 punten). De discriminerende 
waarde van het MGH RSS (AUC) was 0.98 (95% betrouwbaarheidsinterval [BI]: 0.96 – 1). 
Daarnaast liet de Hosmer en Lemeshow goodness-of-fit test een p-waarde van 0.78 zien, 
terwijl de Brier score 0.019 was. Een waarde van 6 punten werd uiteindelijk gekozen als 
de grens om te kunnen onderscheiden tussen laag (<6) en hoog risico (≥6) patiënten. 
Concluderend, het MGH RSS is een geldig en betrouwbaar systeem om patiënten die het 
risico lopen om fCDC te ontwikkelen, tijdig te identificeren. Externe validatie is nog wel 
nodig voordat dit systeem dagelijks gebruikt kan gaan worden. 
De mogelijkheid van vroege interventie is één van de redenen om patiënten met 
een verhoogd risico op het ontwikkelen van fCDC te identificeren. Met behulp van 
een gestandaardiseerd, ziekenhuis-breed protocol voor chirurgische consultatie, dat 
wordt beschreven in hoofdstuk 3, laten we zien dat het verrichten van een chirurgisch 
consult op een eerder moment, met als gevolg vroege identificatie van patiënten die 
voordeel zouden kunnen hebben van een chirurgische behandeling, leidt tot daling 
van de mortaliteit. Criteria, ontwikkeld door een multidisciplinair team, zijn gebruikt om 
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twee jaar. Het protocol werd nageleefd bij 63% van de CDI patiënten. Alle patiënten 
die fCDC ontwikkelden ontvingen een chirurgisch consult, met een mediane tijd tot 
consultatie van 3 uur. Van de 46 patiënten die na implementatie van het protocol wer-
den geïncludeerd, bleek het mortaliteitscijfer na correctie van de comorbiditeits-index 
significant lager te liggen dan de historische controle groep (18.3% vs. 34.8%, p=0.031). 
De mortaliteit was 14.7% indien patiënten die palliatieve zorg kregen en patiënten die 
waren overgeplaatst uit andere ziekenhuizen werden uitgesloten. Bovendien werden 
patiënten onder het nieuwe protocol significant sneller opgenomen op de intensive 
care en werd de totale duur van ziekenhuisopname tot chirurgische interventie (indien 
nodig) significant bekort.
In het geval van chirurgische behandeling voor fCDC, wordt in de meeste gevallen een 
totale abdominale colectomie (TAC) verricht, waarna een ileostoma wordt aangelegd. 
Deze operatie, die dankzij verwijdering van de bron van infectie levensreddend kan zijn, 
resulteert dikwijls in verhoogde morbiditeit en gecompliceerd postoperatief beloop. In 
hoofdstuk 4 wordt dit postoperatieve beloop besproken, met speciale aandacht voor 
postoperatief antibiotica gebruik. In totaal werden, verdeeld over vijf ziekenhuizen, 100 
fCDC patiënten geïncludeerd die een TAC ondergingen. Vier verschillende postopera-
tieve antibioticabehandelingen werden vergeleken; A (metronidazol intraveneus [IV] + 
vancomycine oraal [PO]), B (metronidazol IV), C (metronidazol IV + vancomycine PO en 
rectaal [PR]) en D (metronidazol IV + vancomycine PR). Daarnaast werd ook de behan-
delingsduur geanalyseerd (≤ 7 en ≥ 8 dagen). De resultaten lieten zien dat geen enkele 
combinatie superieur was. Op basis hiervan bevelen wij aan dat patiënten dan wel met 
Metronidazol intraveneus, dan wel met Vancomycine oraal behandeld moeten worden, 
afhankelijk van het regionale ziekenhuisprotocol. Er werd geen bewijs gevonden dat 
behandeling langer dan zeven dagen ondersteunt. Aangezien antibiotica gebruik één 
van de voornaamste risicofactoren is voor het ontwikkelen van een CDI, is het van groot 
belang dat de duur van de antibiotica behandeling zo kort mogelijk wordt gehouden. 
Tot slot lieten de resultaten zien dat het gebruik van een bloeddruk verhogend medicijn 
preoperatief (Odds Ratio [OR]: 6.46; 95% BI: 1.96 - 21.24 ) en het totale aantal gegeven 
units fresh frozen plasma (FFP) tijdens de ziekenhuisopname (per extra unit, OR: 1.17; 
95% BI: 1.06 - 1.3 ) geassocieerd zijn met een hogere mortaliteit. 
In hoofdstuk 5 is gekeken naar de mogelijke associatie tussen serum-25-hydroxyvi-
tamine D [25(OH)D] spiegels en ernst van de CDI, om verder inzicht te vergaren in de 
etiologie van CDI. Eerdere studies hebben laten zien dat vitamine D op verschillende 
manieren invloed heeft op het immuun systeem en in deze studie hebben we de hypo-
these getest dat een lagere 25(OH)D spiegel geassocieerd is met een ernstigere versie 
van CDI. In een prospectieve studie werden patiënten, gediagnosticeerd met CDI, geïn-
cludeerd en vervolgens verdeeld in twee groepen, afhankelijk van de ernst van de CDI: 
groep A (positief voor toxines A/B op basis van ELISA techniek) en groep B (positief voor 
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toxines A/B op basis van ELISA techniek, met daarbij een abdominale CT-scan positief 
voor colitis). De serum 25(OH)D spiegels werden gemeten in 100 patiënten en lieten 
zien dat de gemiddelde 25(OH)D3 spiegel significant hoger was in groep A (n=71) dan 
in groep B (n=29): 21 ± 1 ng/mL versus 15 ± 2 ng/mL, respectievelijk (p=0.005). Na cor-
rectie voor klinisch relevante variabelen, bleven hogere 25(OH)D3 spiegels geassocieerd 
met minder ernstige CDI (gecorrigeerde OR: 0.92; 95% BI: 0.87-0.98). Concluderend laat 
deze studie zien dat er een associatie bestaat tussen vitamine D en de ernst van CDI. 
Aanvullende studies zijn nodig om de exacte functie van vitamine D te bepalen binnen 
de pathofysiologie van CDI. 
II. Abdominaal trauma
Deel II is gericht op nieuwe inzichten in de behandeling van ernstig (stomp) buiktrauma. 
De laatste decennia is deze behandeling veranderd van nagenoeg uitsluitend operatief 
ingrijpen naar een meer conservatieve behandeling. De eerste twee studies tonen 
resultaten van twee grote, multicenter studies waar het merendeel van de traumacentra 
in New England (Noordoosten van de Verenigde Staten) aan meededen. Voor de laatste 
studie is gebruik gemaakt van de grootste database op het gebied van trauma binnen 
de Verenigde Staten; de Nationale Trauma Data Bank (NTDB). 
In hoofdstuk 6 ligt de nadruk op het non-operatief behandelen (NOM) van graad IV 
en V stomp niertrauma. Wij hebben ons in het bijzonder gericht op de oorzaken, voor-
spellers en consequenties van het falen van een conservatieve behandeling (f-NOM; 
gedefinieerd als de noodzaak tot verlate operatie of mortaliteit ten gevolge van aan 
niertrauma gerelateerde complicaties). In totaal werden tussen 2000 en 2011 206 patiën-
ten geïncludeerd in 12 centra. Een vierde van de patiënten werd direct naar de operatie 
kamer gebracht (IO), terwijl de resterende 75% (154 patiënten) behandeld werd zonder 
operatie (met angio-embolisatie in 25 patiënten). In totaal faalde de conservatieve 
behandeling in 7.8% van de NOM populatie (12 van 154 patiënten); bij 10 patiënten 
was schade aan de nier de oorzaak. Onafhankelijke voorspellers van falen waren: leeftijd 
> 55 jaar en een verkeersongeluk als trauma mechanisme. Bij aanwezigheid van beide 
voorspellers was het percentage falen van NOM 27.3%. 10-15% van alle patiënten met 
stomp nier trauma ontwikkelden een complicatie, met aanhoudende hematurie en de 
ontwikkeling van een urinoom als belangrijkste complicaties. De meerderheid van deze 
complicaties behoefde geen operatieve behandeling. Concluderend kon 76.2% van de 
patiënten (IO + NOM) niersparend behandeld worden en 90.3% van de patiënten die ini-
tieel voor NOM geselecteerd waren. Deze resultaten konden wellicht worden verwacht 
gebaseerd op de regeneratieve kracht van de nieren, maar er waren tot op heden geen 
overtuigende studieresultaten beschikbaar om dit aan te tonen. Ditzelfde geldt voor 
stomp levertrauma; er bestond tot op heden geen studie die, met voldoende power, 
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hoofdstuk 7 ligt daarom op het falen van een conservatieve behandeling voor graad 
IV en V stomp levertrauma, en de risicofactoren hiervoor. Met de multi-institutionele 
groep, ditmaal bestaand uit 11 centra, werden 393 patiënten geïncludeerd tussen 2000 
en 2010. 131 patiënten (33%) werden direct operatief behandeld, voornamelijk van-
wege hemodynamische instabiliteit. Van de 262 patiënten die non-operatief behandeld 
werden, faalde dit beleid bij 23 patiënten (9%). In 17 van de 23 patiënten (6% van de 
totale NOM groep) lagen lever-gerelateerde oorzaken hieraan ten grondslag. Middels 
multivariabele logistische regressie werden twee onafhankelijke voorspellers voor het 
falen van conservatief beleid gevonden: een bloeddruk bij opname van ≤ 100 mmHg 
en de aanwezigheid van ander abdominaal orgaan letsel. Als beide voorspellers present 
waren, faalde de non-operatieve behandeling in 23% van de gevallen. Van de patiënten 
die succesvol behandeld werden zonder operatie, kreeg 10% een lever-gerelateerde 
complicatie. Deze complicaties konden in alle gevallen behandeld worden zonder 
blijvende problemen. 
De NTDB werd gebruikt in hoofdstuk 8 om de uitkomsten van letsel aan het pancrea-
ticoduodenaal complex te vergelijken tussen patiënten die behandeld werden met een 
pancreaticoduodenectomie (PDT) en patiënten die soortgelijke verwondingen hadden 
(graad IV en V gecombineerde pancreas- en duodenumletsels), maar geen PDT onder-
gingen. Patiënten die direct overleden, een PDT > 4 dagen na opname ondergingen, of 
helemaal geen laparotomie ondergingen (in de non-PDT groep) werden geëxcludeerd. 
Er werden geen significante verschillen in de uitkomsten gevonden tussen de PDT groep 
(n=39) en de non-PDT groep (n=38), inclusief mortaliteit, lengte van intensive care op-
name, lengte van ziekenhuisopname en het aantal dagen aan de mechanische ventilatie. 
Een interessante bevinding was het verschil in systolische bloeddruk en Glascow Coma 
Scale bij opname; beide waren significant lager in de non-PDT groep, hetgeen wijst op 
een slechtere klinische status bij opname. Verder is het opmerkelijk dat de ‘standaard’ 
indicatie voor een PDT, namelijk graad IV of V gecombineerd pancreaticoduodenaal 
letsel, bij 21% van de patiënten in de PDT groep niet aanwezig was. De Injury Severity 
Score (ISS) bleek de enige onafhankelijke voorspeller van mortaliteit te zijn in de PDT 
groep (OR: 1.09; 95% BI: 1.01 - 1.18) en in het totale cohort (OR: 1.07; 95% BI: 1.01 - 1.12), 
terwijl het type operatie niet van invloed was op de resultaten. Concluderend, alhoewel 
patiënten die een PDT ondergingen een betere uitgangspositie hadden, resulteerde 
dit niet in verbeterde uitkomsten. Toekomstige studies zullen moeten uitwijzen of het 
haalbaar is om deze ernstige letsels aan het pancreaticoduodenaal complex met een 
meer conservatief beleid te behandelen. 
Concluderend in de algemene discussie (hoofdstuk 9) moet de optimalisatie van 
behandeling in fCDC patiënten vooral gezocht worden in de logistiek rond de patiën-
tenzorg. Het identificeren van patiënten die risico lopen om de fulminante ziekte te 
ontwikkelen en ervoor zorgen dat deze patiënten vroegtijdig door de chirurg gezien 
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worden, kan de uitkomsten verbeteren. Toekomstige studies naar nieuwe behandelin-
gen zullen zich ook moeten focussen op preventie, zowel door middel van ingrijpen op 
het causale pad van ‘simpele’ CDI naar fCDC en definiëren wat de optimale balans is van 
de intestinale microbiota. Bij ernstig abdominaal trauma kunnen we concluderen dat 
optimalisatie van behandeling ook refereert naar verbeterde logistiek; focussen op een 
meer conservatieve behandeling wanneer mogelijk en het vroegtijdig identificeren van 
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